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SUMMARY 
XIII 
Summary 
Malaria is still one of the most important infectious diseases worldwide, responsible for 
more than 600 000 cases of death per year, most of them in young children. The infection 
is caused by apicomplexan parasites of the genus Plasmodium (amongst them 
P. falciparum) and transmitted by Anopheles mosquitoes. The emergence and spread of 
parasite resistance to previously effective drugs are a major threat to the control and 
elimination of the infection and raises an important need of new drug development 
strategies. Previously, the laboratory of medicinal chemistry (Dr. E. Davioud-Charvet) 
presented the chemical design of a series of very promising antimalarial agents, 3-
[substituted-benzyl]-menadiones (abbreviated as benzylMD), with potent in vitro and in 
vivo activities. The 3-[4-(triﬂuoromethyl)benzyl]-menadione 1c was selected as the lead 
compound for further studies. Ongoing studies on the mode of action evidenced that these 
agents disturb the redox balance of the parasitized erythrocyte by acting as redox-cyclers - 
a strategy that is broadly recognized for the development of new antimalarial agents.  
The presented work on the in vitro activity of benzylMD 1c represents an essential part of 
the lead optimization stage of the benzylMD drug development process. It could be shown 
that benzylMD 1c is a potent inhibitor of P. falciparum blood-stage parasites, which was 
unaffected by the most common resistance mechanisms to clinically used antimalarials. 
Lead 1c inhibited parasite development of all intra-erythrocytic stages with a preferential 
activity against early ring stages. The drug’s potent activity against all parasite stages is 
similarly reflected in its fast speed of action (i.e. killing speed), which is comparable to 
artemisinin, one of the fastest compounds described so far. In vitro resistance selection 
studies revealed a low intrinsic potential to induce stable drug resistance. In parallel, the in 
vitro antimalarial activity of several benzylMD derivatives was investigated to gain a better 
understanding about the structure-activity relationships. The second part of this work 
focused on the mode of action of benzylMD 1c. Most importantly, it could be shown that 
the lead benzylMD 1c is not an inhibitor of the mitochondrial electron transport chain, in 
contrast to the structurally related antimalarial atovaquone. Furthermore, in vitro drug 
interaction studies were chosen as a tool to explore key features of benzylMD 1c’s mode of 
action in a whole cell assay. Those studies provided insights into the roles of the 
glutathione reductase, NADPH, iron complexation and intracellular glutathione levels in 
drug activity. Overall, the findings of this work demonstrate the promising in vitro potency 
of lead benzylMD 1c and highly support the further development of benzylMD series as 
antimalarial drug candidates.  
RÉSUMÉ 
XIV 
Résumé 
Le paludisme reste une des maladies infectieuses les plus importantes à travers le monde 
causant plus de 600 000 cas de décès par an, pour la plupart chez les jeunes enfants. 
L'infection est causée par des parasites apicomplexes du genre Plasmodium (dont 
P. falciparum) et transmise par les moustiques Anophèles. L'émergence et la propagation 
de la résistance des parasites aux médicaments usuels, de faible coût et autrefois efficaces, 
est une menace majeure pour contrôler et éliminer l'infection. Elle souligne un important 
besoin de nouvelles stratégies de développement de médicaments. Dans le passé, le 
laboratoire de chimie médicinale (Dr E. Davioud-Charvet) a conçu une série de 3-benzyl-
ménadiones substituées (benzylMD) comme agents antipaludiques prometteurs avec une 
forte activité in vitro et in vivo. La 3-[4-(trifluorométhyl)-benzyl]-ménadione 1c a été 
choisie comme tête de série pour des études complémentaires. Les études en cours sur le 
mode d'action ont mis en évidence que cette benzylMD déstabilise l'équilibre redox des 
érythrocytes infectés en agissant comme agent catalytique redox (redox-cycler), une 
stratégie qui est actuellement reconnue pour le développement de nouveaux agents 
antipaludiques. Les travaux présentés dans cette thèse sur l'activité in vitro de la 
benzylMD 1c font partie de la phase principale d’optimisation du développement des 
benzylMDs. La benzylMD 1c est démontrée comme un puissant inhibiteur des stades 
sanguins du parasite P. falciparum. La tête de série 1c inhibe le développement du parasite 
à tous les stades intra-érythrocytaires, avec une activité préférentielle sur les stades 
précoces du cycle. La forte activité du composé contre tous les stades parasitaires est 
également reflétée par sa vitesse d'action, qui est comparable à celle de l'artémisinine, l'un 
des composés les plus rapides décrit jusqu'ici. Les études de sélection de résistance in vitro 
ont révélé un potentiel intrinsèque faible pour induire une résistance stable à la 
benzylMD 1c. En parallèle, l'activité antipaludique in vitro de nouveaux dérivés 
benzylMDs a été étudiée pour acquérir une meilleure compréhension des relations 
structure-activité. De plus, la benzylMD 1c n'est pas un inhibiteur de la chaîne de transport 
d'électrons mitochondriale, contrairement à l'atovaquone, un antipaludique structuralement 
apparenté. En outre, des études in vitro sur les interactions médicamenteuses ont été 
choisies comme outil pour explorer les principales caractéristiques du mode d'action de la 
benzylMD 1c dans un essai cellulaire. Ces études ont fourni des indications sur le rôle de 
la glutathion réductase, du NADPH, de la complexation au fer ou du taux de glutathion 
intracellulaire dans l'activité de cet agent. Dans l'ensemble, les résultats de ce travail 
démontrent l'activité in vitro très prometteuse de la benzylMD 1c et soutiennent 
l'amélioration de la série benzylMD comme nouveaux candidats-médicaments 
antipaludiques.
ZUSAMMENFASSUNG 
XV 
Zusammenfassung 
Malaria ist auch heute noch eine der wichtigsten Infektionskrankheiten weltweit, welche 
mehr als 600 000 Todesfälle pro Jahr verursacht, die meisten von ihnen bei jungen 
Kindern. Die Infektion wird durch Parasiten der Gattung Plasmodium (darunter 
P. falciparum) verursacht und von Anopheles-Mücken übertragen. Die Entstehung und 
Ausbreitung von Resistenzen der Parasiten gegen bisher wirksame Medikamente stellt eine 
große Bedrohung für die Kontrolle und Eliminierung der Infektion dar und begründet die 
dringende Notwendigkeit neue Wirkstoffe zu entwickeln. Kürzlich stellte das Labor für 
medizinische Chemie (Dr. E. Davioud-Charvet) eine vielversprechende Wirkstoffserie mit 
ausgeprägten in vitro und in vivo Aktivitäten vor, die 3-[substituierte-benzyl]-Menadione 
(abgekürzt als benzylMD). Das 3-[4-(Trifluoromethyl)benzyl]-Menadion 1c wurde als 
Leitsubstanz für weitere Studien ausgewählt. Laufende Untersuchungen belegen, dass 
benzylMD-Derivate das Redox-Gleichgewicht der infizierten Erythrozyten stören, indem 
sie als sogenannte Redox-Cycler agieren. Diese metabolische Wirkungsweise ist 
vielversprechend für die Entwicklung neuer Malariamedikamente 
Die vorliegende Arbeit über die in vitro Aktivität der Leitsubstanz benzylMD 1c stellt 
einen Teil der Evaluierungsphase im Laufe der Arzneimittelentwicklung dar. Es konnte 
gezeigt werden, dass benzylMD 1c ein wirksamer Inhibitor der Blutstadien des Parasiten 
P. falciparum ist, welcher zudem nicht negativ von den häufigsten Resistenzmechanismen 
der Parasiten beeinflusst wurde. Leitsubstanz 1c hemmte die Entwicklung aller intra-
erythrozytären Parasitenstadien und war besonders aktiv gegen frühe Ringstadien. Die 
hohe Aktivität des Wirkstoffes wurde ebenso durch seine Wirkungsgeschwindigkeit 
widergespiegelt, welche im Bereich von Artemisinin liegt, einer der schnellsten bisher 
beschriebenen Verbindungen. In vitro Resistenzstudien erwiesen ein geringes 
Eigenpotenzial der Leitverbindung eine stabile Medikamentenresistenz der Parasiten zu 
induzieren. Parallel zu diesen Studien wurde die in vitro Aktivität von benzylMD-
Derivaten gemessen, um ein besseres Verständnis über die Struktur-Aktivitäts-
Beziehungen zu gewinnen. Der zweite Teil der Arbeit konzentrierte sich auf die 
Wirkungsweise von benzylMD 1c. Vor allem konnte gezeigt werden, dass benzylMD 1c 
im Gegensatz zu dem strukturell verwandten Medikament Atovaquon nicht als Inhibitor 
der mitochondrialen Elektronentransportkette fungiert. Darüber hinaus wurden im Rahmen 
von Medikamenten-Interaktionsstudien Einblicke in die Rollen der Glutathionreduktase, 
des NADPH-Spiegels, der Komplexbildung mit Eisen oder des intrazelluläre Glutathion-
Spiegels für die Wirkstoffaktivität gewonnen. Insgesamt zeigen die Ergebnisse dieser 
Arbeit die vielversprechende in vitro Wirksamkeit der Leitsubstanz benzylMD 1c und 
unterstützen daher die weitere Entwicklung der benzylMD-Serie als Arzneimittel-
kandidaten gegen Malariaparasiten  
  
 
 
 
 
 1 
1 INTRODUCTION 
1.1  Malaria  
Even today malaria is one of the most important infectious diseases worldwide. The 
infection is caused by protozoan parasites of the genus Plasmodium and transmitted by 
female Anopheles mosquitoes. In the past, malaria was widespread throughout many 
regions of the world but was successfully eliminated from Europe, North America and 
Russia (White et al, 2014). Nowadays, malaria is mostly prevalent in tropical regions of 
sub-Saharan Africa, Asia, South and Central America with an estimated population of 3.4 
billion people at risk of infection in 2013 (Figure 1)(WHO, 2013). For the year 2012, the 
World Health Organization (WHO) estimated 207 million cases of malaria worldwide 
(80% in Africa) causing 627 000 cases of death (90% in Africa), most of them in children 
under the age of 5 (77%) (WHO, 2013). Malaria disproportionally affects the world’s 
poorest communities and poses on significant toll on the health and economic development 
of these populations. 
 
Figure 1  Trends in reported malaria incidence 2000 - 2012 (WHO, 2012)  
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1.1.1  Clinical manifestations  
Malaria is a general term for infections with protozoan Plasmodium parasites  
(i.e. P. falciparum, P. vivax, P. ovale, P. malariae or P. knowlesi). The clinical picture of 
the disease is generally very similar though infections vary in their global distribution, 
length of prepatency, severity of symptoms and mortality rate (Tuteja, 2007; White et al, 
2014). The development of clinical symptoms is highly dependent on age and immune 
status of the patient and ranges from asymptomatic infections to life-threatening cases. 
Individuals living in endemic regions with yearlong transmission of malaria (i.e. stable 
transmission) generally acquire a partial immunity to the clinical disease and to its severe 
manifestations during childhood (WHO, 2010). Young children (> 5 years) and pregnant 
women are particularly vulnerable to severe forms of malaria. The most severe forms and 
highest numbers of death are attributed to infections with P. falciparum (Malaria tropica) 
(WHO, 2013).  
Malaria is an acute febrile illness with rather unspecific symptoms, such as headaches, 
fatigue, muscle aches, nausea and vomiting (Grobusch & Kremsner, 2005). Primary 
symptoms are often mild and not necessarily attributed to malaria. A typical malaria fever 
episode is characterized by an initial “cold stage” (sensation of cold, shivering), a “hot 
stage” of fever over few hours (increased body temperature, flushes, fever, vomiting, 
headaches) that is followed by a sharp decrease of body temperature accompanied by 
excessive sweating (Grobusch & Kremsner, 2005). Fever episodes stem from a 
simultaneous rupture of infected erythrocytes and consequential activation of the immune 
system (Oakley et al, 2011). Upon synchronization of the parasitic life cycle in the host, 
fever occurs periodically: every 3
rd
 day for infections with P. vivax and P. ovale (Malaria 
tertiana) and P. falciparum (Malaria tropica), every 4
th
 day for infections with P. malariae 
(Malaria quartana) and every 24 hours for infections with P. knowlesi. Falciparum malaria 
is often marked by irregular or persistent fever episodes (Oakley et al, 2011). In non-
immune or untreated patients, high parasitemia causes clinical complications, including 
anemia, metabolic dysfunctions (acidosis, hypoglycemia) and organ impairment (renal 
injury, pulmonary edema) (Grobusch & Kremsner, 2005). The intensive sequestration of 
P. falciparum-infected erythrocytes to endothelia of small blood vessels causes 
microvascular obstruction, oxygen deprivation and provokes local inflammation of the 
capillaries, which may lead to severe symptoms and life-threatening forms of the disease, 
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such as multi-organ failure or neuronal complications (i.e. cerebral malaria) (White et al, 
2014). A P. falciparum infection during pregnancy might cause intense accumulation of 
infected erythrocytes in the placental microcirculation (i.e. placental malaria) and is 
associated to congenital malaria, low birth weight and premature delivery (White et al, 
2014). The other Plasmodium species only rarely cause life-threatening complications 
(Grobusch & Kremsner, 2005; White et al, 2014).   
 
1.1.2  Natural protections against severe forms of malaria 
Several genetic mutations of human erythrocytes are known for protecting carriers from 
the severe, life-threatening forms of malaria. Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency and hemoglobinopathies, for instance thalassemia and sickle cell disease, are 
important examples of such genetic polymorphisms. The similar geographic distribution of 
these genetic traits and past or present malaria infections support the so-called malaria 
protection hypothesis, which claims that co-evolution of humans and P. falciparum shaped 
the human genome in these regions (Cappellini & Fiorelli, 2008; Cyrklaff et al, 2012)  
The most widespread genetic defect of human erythrocytes is G6PD deficiency, which also 
represents the most common human enzyme defect (reviewed in Cappellini & Fiorelli, 
2008). G6PD is the first enzyme of the pentose phosphate pathway and the main producer 
of NADPH (nicotinamide adenine dinucleotide phosphate) in erythrocytes. Affected 
individuals are generally asymptomatic but more susceptible to oxidative insults in forms 
of oxidant drugs, chemicals or food components that may induce acute hemolytic anemia. 
Hemoglobinopathies result from unpaired globin chains in α- or β-thalassemia or from 
structurally altered β-globin in sickle-cell hemoglobin (HbS), hemoglobin C (HbC) or 
hemoglobin E (HbE) (reviewed in Cyrklaff et al, 2012; Taylor et al, 2013). Heterozygous 
carriers are generally asymptomatic but may suffer from mild anemia.  
The molecular mechanism(s) that protects affected individuals from the severe symptoms 
of malaria are complex and still not fully understood. Interestingly, in all cases, 
erythrocytes were shown to be more susceptible to oxidative stress, marked by a higher 
tendency of hemoglobin to oxidize and denature, caused either by structurally unstable 
mutant hemoglobin or decreased antioxidant capacity of the host cell (Ayi et al, 2004; 
Reeder, 2010; Cyrklaff et al, 2012). In support of this hypothesis, enhanced binding of 
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hemichrome 
1
 (i.e. denatured hemoglobin) to the erythrocyte membrane and enhanced 
phagocytosis of infected cells were observed for G6PD-deficient erythrocytes, 
heterozygous sickle cells (HbAS) and heterozygous thalassaemic cells (β-thalassemia and 
HbH) (see also section 1.2.2.3) (Cappadoro et al, 1998; Ayi et al, 2004). Furthermore, 
denatured and oxidized hemoglobin species were identified as candidates for preventing 
host actin re-organization in P. falciparum-infected homozygous HbCC and heterozygous 
HbSC erythrocytes (Cyrklaff et al, 2011). Remodeling of the host actin cytoskeleton was 
shown to be important to establish the parasite’s protein trafficking system and their 
inhibition might contribute to the protection against severe malaria infections (Cyrklaff et 
al, 2011; Cyrklaff et al, 2012).  
1.2  Causative agent of malaria - Plasmodium parasites 
The malaria causing protozoan parasite Plasmodium belongs to the phylum Apicomplexa 
(Lucius & Loos-Frank, 2008). Apicomplexa are obligate endoparasites that cause serious 
diseases in humans and animals (livestock, wild animals). Their name derived from the 
apical complex, a characteristic structure essential for host cell invasion that comprises the 
conoid, rhoptries, micronemes and dense granules. Most apicomplexan parasites harbor a 
unique organelle of bacterial origin that emerged from secondary endosymbiosis, the so-
called apicoplast (reviewed in detail in Lim & McFadden, 2010). The apicoplast retained a 
small genome and several metabolic functions and is therefore a potential target for 
chemotherapy, especially antibiotics (Botte et al, 2012).  
The genus Plasmodium comprises nearly 200 species that parasitize mammals, rodents, 
birds and reptiles (Lucius & Loos-Frank, 2008). Five species infect humans, P. falciparum, 
P. vivax, P. ovale, P. malariae and P. knowlesi. The latter one is of non-human primate 
origin but causes human infections in many regions of Southeast Asia. From a clinical 
perspective, P. falciparum and P. vivax are the most important species: P. falciparum 
causes the highest numbers of infections and most deaths and is widely endemic in Africa; 
P. vivax is widely spread over regions that are unaffected by P. falciparum since it 
develops in the mosquito vector at lower temperatures and survives transmission-free 
periods in the host by dormant liver stages (hypnozoites) (WHO, 2013).   
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1.2.1 Life cycle of Plasmodium falciparum 
The life cycle of the five human pathogenic Plasmodium species is exemplified by the life 
cycle of P. falciparum, but important species-specific differences are mentioned 
(summarized from Tuteja, 2007; Lucius & Loos-Frank, 2008; White et al, 2014). 
The life cycle of P. falciparum involves asexual replication in the human host and sexual 
reproduction in the invertebrate host, a female Anopheles mosquito that further acts as 
vector. Only few Anopheles species are efficient vectors for Plasmodium parasites, 
important ones in Africa are the A. gambiae and A. funestus complexes. 
Female Anopheles mosquitoes ingest sexually differentiated gametocytes (female 
macrogametocytes, male microgametocytes) during a blood meal on an infected individual. 
Inside the mosquito midgut, the gametocytes mature into gametes, fertilization occurs and 
the diploid zygote (ookinete) settles between the midgut epithelium and the basal lamina. 
The ookinete develops into an oocyst, inside which sporogony takes place, producing 
thousands of haploid sporozoites. After maturation, the oocyst ruptures and motile 
sporozoites migrate into the salivary glands of the mosquito to be further transmitted.  
Infective sporozoites are transmitted to humans by a bite of a female Anopheles mosquito. 
They are released into the skin, where they actively migrate to enter the circulatory system 
in order to be transported to the liver. Sporozoites invade hepatocytes and follow a first 
asexual replication cycle (exoerythrocytic schizogony). The liver stage is a phase of 
intensive multiplication, though clinically silent, and represents the bottle neck of the 
infection. Different to P. falciparum, P. vivax and P. ovale additionally form dormant liver 
stages (hypnozoites) that can reactivate the parasite’s life cycle and cause relapse of the 
disease still months after the primary infection (Wells et al, 2010). These dormant forms 
permit the parasite to survive periods without regular transmission by the mosquito vector. 
The hepatocytic schizogony releases thousands of merozoites into the blood stream, which 
rapidly infect erythrocytes and initiate the intraerythrocytic development (blood stage). 
Merozoite invasion of erythrocytes is a complex process that is yet not entirely understood 
but is an attractive target for drug or vaccine development (Boyle et al, 2013). In 
erythrocytes, the parasite develops inside a parasitophorous vacuole and follows another 
asexual replication cycle (intraerythrocytic schizogony) that is characterized by three 
morphological distinct stages, namely ring, trophozoite and schizont. Each mature schizont 
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contains up to 20 merozoites, which are released upon rupture of the host cell and rapidly 
invade new erythrocytes. The duration of schizogony is 48 hours for P. falciparum, 
P. vivax and P. ovale, 72 hours for P. malariae and 24 hours for P. knowlesi. The 
simultaneous rupture of infected erythrocytes and release of cell debris, hemozoin and 
parasite antigens into the circulation activates the immune system and induces the typical 
malaria symptom, fever (Oakley et al, 2011). A small proportion of intraerythrocytic stages 
differentiate to sexual stages, gametocytes, which are crucial for transmission to the 
mosquito vector.  
 
 
 
 
Figure 2  The life cycle of Plasmodium falciparum (Boddey & Cowman, 2013) 
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1.2.2 Intraerythrocytic development of Plasmodium falciparum 
The intraerythrocytic development is characterized by three morphological distinct stages, 
namely ring (0-24 hours), trophozoite (24-36 hours) and schizont (36-48 hours), the so-
called blood-stage parasites (Figure 3)(Maier et al, 2009).  
 
 
Figure 3  Development of Plasmodium falciparum in human erythrocytes (Maier et al, 2009) 
 
Parasite development is marked by a high metabolic activity by means of glycolysis and 
proteolysis of hemoglobin (Tuteja, 2007). The digestion of hemoglobin is described in 
more detail in the next section. The survival of the parasite depends on a profound 
reorganization of its host cell that is accompanied by expression and transport of parasite 
proteins beyond the parasitophorous vacuole, into the cytosol and to the membrane of 
erythrocytes (reviewed in Boddey & Cowman, 2013). Mature erythrocytes have lost their 
ability to synthesize proteins and the parasite must therefore establish an extraparasitic 
protein trafficking network in the host cell cytosol. Important examples of parasite induced 
remodeling include new permeability pathway, J-dots, Maurer’s clefts and knobs at the 
erythrocyte membrane. New permeability pathways enable the import of nutrients and 
exchange of waste products. Knob structures under the erythrocyte membrane contain 
knob-associated histidine-rich protein (KAHRP) and the P. falciparum erythrocyte 
membrane protein 1 (PfEMP1), which are responsible for cytoadhesion of infected 
erythrocytes to endothelia of small blood vessels. Cytoadhesion is a mechanism of immune 
evasion and moreover contributes to virulence and pathogenesis of malaria.  
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1.2.2.1  Hemoglobin digestion 
Hemoglobin of the host erythrocyte is a necessary source of amino acids for the parasite’s 
protein synthesis. Plasmodium digests the host’s hemoglobin not only for nutritional 
purposes, as original suggested, but also in order to provide sufficient space for its growth 
and additionally in order to maintain the host cell’s integrity and to prevent it from lysis 
(Krugliak et al, 2002; Lew et al, 2004).   
In order to protect the parasitic cytosol from redox-active byproducts of hemoglobin 
degradation (i.e. free heme 
2
, iron and reactive oxygen species), this process occurs inside a 
specialized lysosome-like compartment, the digestive vacuole, under acidic conditions 
(pH 5.0 - 5.4) (Klonis et al, 2007; Coronado et al, 2014). In these conditions, 
oxyhemoglobin 
2
 (Fe
2+
) is rapidly oxidized to methemoglobin 
2
 (Fe
3+
), a reaction that 
produces superoxide anions (O2
-•
). Superoxide anions dismutate spontaneously to 
hydrogen peroxide (H2O2) and oxygen (O2) under the acidic conditions of the digestive 
vacuole (Reeder, 2010). In the cytosol of the parasite, dismutation of superoxide anions is 
catalyzed by superoxide dismutases (SODs) (Becuwe et al, 1996; Sienkiewicz et al, 2004).  
Proteolysis of hemoglobin (i.e. methemoglobin) involves several well-characterized 
enzymes, for instance aspartic (plasmepsins I and II) and cysteine (falcipain) proteases 
(Goldberg et al, 1991; vander Jagt et al, 1992; Gluzman et al, 1994; Hogg et al, 2006). 
Further enzymes involved in hemoglobin digestion but also hemozoin 
2
 formation, as well 
as a recently identified protein complex, are in the focus of intense research (Jani et al, 
2008; Chugh et al, 2013). Proteolytic degradation of hemoglobin releases its prosthetic 
group, heme 
2
 (or: Fe
3+
-protoporphyrin-IX) in form of α-hematin 2 (i.e. hydroxylated 
heme), which is highly reactive and must be detoxified. Free heme is toxic to the parasite 
as it has been shown to inhibit enzymes, destabilize membranes by lipid peroxidation, 
cause osmotic changes and partake in Fenton reactions accompanied by the production of 
reactive oxygen species (Zhang et al, 1999) and (discussed in detail in Becker et al, 2004). 
Plasmodium parasites detoxify α-hematin by crystallization of it to hemozoin, the malaria 
pigment. The mechanism of hemozoin formation is not yet elucidated and is still under 
research. Different mechanisms have been proposed, such as a spontaneous autocatalytic 
process, an enzymatic process (e.g. histidine-rich proteins) and the involvement of lipids. 
The current theories about the mechanism of hemozoin formation are discussed in recent 
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 The definitions of hemoglobin species and heme-containing molecules are given in the Appendix, Table A1 
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reviews (Egan, 2008; Coronado et al, 2014). Their further understanding is of particular 
interest for the identification of new drug targets. In addition, there is increasing evidence 
that hemozoin is involved in the pathophysiology of malaria, for instance by regulating 
phagocyte activity and immune responses (reviewed in Coronado et al, 2014).  
1.2.2.2 Oxidative stress in Plasmodium falciparum-infected erythrocytes 
The intraerythrocytic-parasite stages have to cope with high fluxes of reactive oxygen 
species from endogenous but also exogenous sources, for example immune reactions 
(Becker et al, 2004). Reactive oxygen species are detoxified by the parasite’s first line 
defense (e.g. SOD, peroxiredoxins, see below) and further components of glutathione or 
thioredoxin-based redox systems. The glutathione and thioredoxin-based redox systems of 
P. falciparum are not only essential for the anti-oxidant defense but also to maintain a 
stable intracellular (redox) homeostasis. The redox systems of P. falciparum are described 
in more detail in section 1.2.3.  
Digestion of hemoglobin is the major endogenous source of oxidative stress for the 
parasite (see also section 1.2.2.1). This process is accompanied by the production of 
superoxide anions, hydrogen peroxide and the release of free redox-active heme. Another 
source of superoxide anions is the parasite’s mitochondrial electron transport chain. 
Superoxide anions are detoxified by dismutation to molecular oxygen and hydrogen 
peroxide. This reaction is catalyzed by ubiquitous metallo-proteins, superoxide dismutases 
(SODs), but can also occur spontaneously under acidic pH as in the parasite’s digestive 
vacuole (Reeder, 2010). Two iron-dependant SODs of P. falciparum were characterized so 
far, cytosolic PfSOD 1 and mitochondrial PfSOD 2, which might also be targeted to the 
apicoplast (Becuwe et al, 1996; Sienkiewicz et al, 2004). Hydrogen peroxide is readily 
participating in further redox reactions (e.g. Fenton reactions), thereby generating reactive 
hydroxyl radicals (OH
-•
), which can induce lipid peroxidation and DNA oxidation  
(Figure 4) (Jortzik & Becker, 2012). Plasmodium parasites rely mainly on peroxiredoxins 
for detoxification of hydrogen peroxides since they lack catalase or a classical glutathione 
peroxidase (further described in section 1.2.3).  
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Figure 4  Sources of oxidative stress in Plasmodium falciparum (Jortzik & Becker, 2012) 
Major sources of oxidative stress (e.g. O2
−
, OH
−
, H2O2) are the parasite’s food vacuole (Hb digestion) and 
mitochondria (mitochondrial electron transport chain). Means of detoxification are mitochondrial and 
cytosolic SOD and cytosolic thioredoxin (Trx)-dependent peroxiredoxins. See text for more details. 
Abbreviations: FPIX, ferriprotoporphyrin IX; H2O2, hydrogen peroxide; Hb, Hemoglobin; O2
−
, superoxide 
anion; OH
−
, hydroxyl radicals; SOD, superoxide dismutase; Trx, thioredoxin; TrxR, thioredoxin reductase. 
 
1.2.2.3 Phagocytosis of Plasmodium falciparum-infected erythrocytes  
The removal of aged or damaged erythrocytes from the circulation - a short outlook 
Under physiological conditions, hemoglobin is present in its ferrous oxidation state (Fe
2+
), 
which allows binding and transport of oxygen (for an extensive review about redox activity 
of hemoglobin, please refer to Reeder (2010)). Though, by auto-oxidation or in reaction 
with peroxide, the heme group can be oxidized to its ferric (Fe
3+
) oxidation state. 
Methemoglobin (Fe
3+
) is physiologically inactive and its formation is tightly controlled by 
an extensive antioxidant system (e.g. NADH–cytochrome b5–methemoglobin reductase, 
glutathione system) (Kanias & Acker, 2010; Reeder, 2010). During erythrocyte 
senescence, under pathological conditions or oxidative damage, hemoglobin oxidizes as 
marked by increased formation of methemoglobin and denaturation to hemichromes 
(Kanias & Acker, 2010; Reeder, 2010). Hemichromes were demonstrated to be a key 
determinant for the clearance of senescent or damaged erythrocytes from the blood stream. 
In more detail, hemichromes bind to the cytoplasmic tail of band 3 molecules that 
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subsequently cross-link to form aggregates. Anion transporter band 3 is the major integral 
protein spanning the erythrocyte membrane. Those band 3 clusters represent the age-
specific antigen on senescent erythrocytes for binding of autologous band 3-specific IgG 
antibodies, which initiate phagocytosis (Low et al, 1985).  
Of note, enhanced rates of erythrocyte phagocytosis were observed in patients suffering 
from hemoglobinopathies or G6PD-deficiency. This is reported to stem from unstable 
hemoglobin variants that are more prone to denature (e.g. sickle cells) or from high levels 
of oxidative stress generated in G6PD-deficient cells (Cappadoro et al, 1998; Ayi et al, 
2004).  
Phagocytosis of Plasmodium falciparum-infected erythrocytes  
The development of P. falciparum promotes important alterations in the host erythrocyte 
membrane, as marked by hemichromes binding and aggregation of band 3 molecules 
(Giribaldi et al, 2001; Turrini et al, 2003). Similar to senescent erythrocytes, those 
alterations were shown to attract the binding of autologous band 3-specific IgG antibodies, 
deposition of further opsonins (e.g. complement factor C3) and consequently phagocytosis 
in vitro (Turrini et al, 1992; Giribaldi et al, 2001; Turrini et al, 2003). The driving force 
behind those modifications is considered to be the oxidative stress in erythrocytes induced 
by the parasite and related denaturation of hemoglobin (Giribaldi et al, 2001 and further 
references cited herein). Supporting this hypothesis is the reported increase of erythrocyte 
membrane alterations and enhanced phagocytosis during parasite maturation. These events 
further correlate with the increase of oxidative stress exerted by the parasite to the host cell 
(Giribaldi et al, 2001).   
Enhanced phagocytosis of early parasite stages (i.e. ring stages) was observed in mutant 
erythrocytes, such as G6PD-deficient, heterozygous sickle cells (HbAS) and heterozygous 
thalassaemic (β-thalassemia and HbH) (Cappadoro et al, 1998; Ayi et al, 2004). Those 
cells are naturally more susceptible to oxidative insult and additional P. falciparum 
infection might cause an overload of oxidative stress already in early parasite stages. 
Consequently, enhanced immunological clearance of ring-stage infected erythrocytes by 
phagocytosis has been suggested as a common mechanism, but not the only one, for 
protection against severe forms of malaria (Ayi et al, 2004 and further references cited 
herein).  
INTRODUCTION 
12 
1.2.3  The redox system of Plasmodium falciparum  
P. falciparum possesses two closely interacting redox systems, based on either glutathione 
or thioredoxin, which fulfill important functions in the anti-oxidant defense and redox-
regulatory mechanisms (reviewed in Jortzik & Becker, 2012; Mohring et al, 2014). The 
majority of the redox system acts in the parasitic cytosol but single components could be 
further localized to subcellular compartments, as the mitochondrion, apicoplast, 
endoplasmic reticulum and also to the parasitophorous vacuole (Kehr et al, 2010). A stable 
redox homeostasis of the entire host-parasite unit is considered to be important and is 
evidenced by the protection of G6PD-deficient individuals against severe malaria. The 
interactions between the redox systems of the parasite and its host cell are complex but yet 
not fully understood (Patzewitz et al, 2012). 
The glutathione system of P. falciparum consists of glutathione, NADPH-dependent 
glutathione reductase, enzymes of glutathione de novo synthesis pathway, glutathione S-
transferase, glyoxalases, glutaredoxin and three glutaredoxin-like proteins (Figure 5) 
(reviewed in Jortzik & Becker, 2012; Mohring et al, 2014). 
The parasite relies highly on the tripeptide glutathione (γ-L-glutamyl-L-cysteinyl-glycine) 
in order to maintain the reducing environment of the cytosol. Furthermore, glutathione 
plays important roles in the anti-oxidant defense and the detoxification of metabolic 
byproducts (e.g. free heme) and xenobiotics (e.g. antimalarial compounds). The 
intracellular glutathione pool of the parasite must be maintained in its reduced form (GSH), 
since oxidized glutathione disulfide (GSSG) is toxic to the cell. GSSG is formed from 
oxidation of two GSH in numerous reactions, for instance reduction of reactive oxygen 
species and reactive nitrogen species, free radicals, dehydroascorbate or protein disulfides 
(Becker et al, 2003). GSSG might participate in uncontrolled S-glutathionylation of 
proteins and thereby disturb their regular functions. Protein S-glutathionylation is a 
common form of posttranslational modification of protein thiol groups and represents a 
redox-mediated regulatory mechanism of cellular functions (Kehr et al, 2011).  
High concentrations of reduced GSH (i.e. high GSH:GSSG ratio) are maintained by GSSG 
efflux to the host cell and regulation of GSH regeneration or de novo biosynthesis 
(Patzewitz et al, 2012). In contrast to other Plasmodium species, P. falciparum is unable to 
import GSH from its host cell (Patzewitz et al, 2012). De novo synthesis of GSH is 
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sustained by two cytosolic enzymes, namely γ-glutamyl-cysteine synthetase (γGCS) and 
glutathione synthetase (GS) (reviewed in Jortzik & Becker, 2012). GSH synthesis is likely 
to be essential in P. falciparum blood-stage parasites (Patzewitz et al, 2012). The 
flavoenzyme glutathione reductase (GR) is mainly responsible for regeneration of reduced 
GSH by reduction of GSSG in a FAD (flavin adenine dinucleotide) and NADPH-
dependant reaction (reviewed in Jortzik & Becker, 2012). The parasitic enzyme PfGR 
differs slightly from the human GR enzyme in several structural features and was 
discussed as a potential drug target in the past. Though, recent studies raised questions 
whether the PfGR might be indispensable for P. falciparum survival and identified further 
GSSG reducing proteins (e.g. Trx, Plrx), which might provide a backup system for 
regeneration of GSH in the parasite (discussed in Jortzik & Becker, 2012). Up to know, no 
clear conclusion could be drawn about the requirement of PfGR for the development of 
P. falciparum blood-stage parasites (Buchholz et al, 2010; Patzewitz et al, 2012). 
 
 
Figure 5  The glutathione system in Plasmodium falciparum (Jortzik & Becker, 2012) 
This scheme depicts the various functions of oxidized glutathione (GSH), reactions leading to formation 
of reduced glutathione disulfide (GSSG) and pathways of glutathione regeneration or de novo 
biosynthesis. See text for more details. Abbreviations: GR, glutathione reductase; Grx, glutaredoxin; 
GSH, glutathione; GSSG, glutathione disulfide; GST, glutathione S-transferase; protein-SSG, protein S-
glutathionylation; Trx, thioredoxin.  
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GSH serves as a coenzyme or reductant of several P. falciparum enzymes, which maintain 
the redox homeostasis and intracellular functions, such as glutathione S-transferase (GST), 
glyoxalases, glutaredoxin (Grx) and glutaredoxin-like proteins (GLP) (Mohring et al, 
2014). Glutathione S-transferase detoxifies electrophilic xenobiotics by forming GSH-
conjugates that are readily eliminated from the cell. The glyoxalase system detoxifies 
methylglyoxal, a toxic byproduct of glycolysis. Glutaredoxins are thiol-disulfide 
oxidoreductases that depend on a non-enzymatic reduction by GSH to further catalyze 
reduction of disulfide bridges in proteins (e.g. ribonucleotide reductase, plasmoredoxin). 
The physiological function of parasitic glutaredoxin-like proteins is yet unsolved but was 
proposed to be the deglutathionylation of proteins, which represents a mechanism of 
redox-related regulation of protein activity.  
In addition, GSH is considered to contribute to the degradation of free or bound heme by 
destruction of its tetrapyrrole ring via Fenton reaction products (e.g. hydroxyl radicals) 
(Atamna & Ginsburg, 1995). This mechanism is considered to contribute to parasite 
resistance against chloroquine (Ginsburg & Golenser, 2003; Patzewitz et al, 2013).  
The thioredoxin system of P. falciparum consists of three classical thioredoxins, two 
thioredoxin-like proteins, NADPH-dependent thioredoxin reductase, plasmoredoxin and 
five peroxiredoxins (Figure 6) (reviewed in Jortzik & Becker, 2012; Mohring et al, 2014). 
Thioredoxins are small redox active dithiol proteins with multiple functions in the 
antioxidant defense and as cellular redox messenger by regulating protein activities (e.g. 
protein S-glutathionylation). P. falciparum expresses three classical thioredoxins 
(i.e. PfTrx 1-3) and two additional thioredoxin-like proteins (i.e. PfTlp 1 and 2), that share 
sequence similarities with thioredoxins but are not substrates of the thioredoxin reductase. 
Cytosolic PfTrx1 contributes to the antioxidant defense by directly reducing oxidants (e.g. 
hydrogen peroxide, tert-butylhydroperoxide, cumene hydroperoxide and S-nitroso-
glutathione) and by reducing GSSG and the dithiol protein plasmoredoxin (Plrx). 
Plasmoredoxin is a unique member of Plasmodium’s thioredoxin family that shares similar 
functions with other members. Furthermore, PfTrx1 possibly reduces dehydroascorbate, 
lipoamide and lipoic acid and may thereby sustaining their antioxidant capacities.  
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In addition, thioredoxins serves as reducing equivalents (i.e. electron donor) for 
peroxiredoxins (Prx) that build the first-line defense against reactive oxygen and reactive 
nitrogen species. The peroxiredoxin protein family are ubiquitous peroxidases with 
additional function in the regulation of H2O2-mediated signal transduction. P. falciparum 
expresses five peroxiredoxins (i.e. Prx1a, Prx1b, Prx1m, Prx6, Prx5 or antioxidant protein 
(AOP) and nuclear peroxiredoxin nPrx), which differ in their subcellular localization (e.g. 
cytosol, mitochondria, apicoplast or nucleus) and substrate specificities (e.g. hydrogen 
peroxide, tert-butylhydroperoxide, cumene hydroperoxide and peroxynitrite). Plasmodium 
parasites do not encode catalase or a classical glutathione peroxidase and are therefore 
highly dependent on peroxiredoxins for the detoxification of peroxides. In support of the 
latter ones, the parasite imports the human peroxiredoxin 2 (hPrx2) in functional form into 
its cytosol (Koncarevic et al, 2009). The reduced forms of the classical thioredoxins 
(PfTrx 1-3) are maintained by a NADPH-dependent disulfide oxidoreductase, namely 
thioredoxin reductase (PfTrxR). Both isoforms of the thioredoxin reductase can further 
transfer electrons to other substrates than thioredoxins, such as low molecular weight 
compounds.  
 
 
Figure 6 The thioredoxin system in Plasmodium falciparum (Jortzik & Becker, 2012) 
This scheme illustrates reactions yielding reduced thioredoxin (Trx) and the various intracellular 
substrates of Trx reduction. See text for more details. Abbreviations: tBuOOH, tert-butylhydro-peroxide; 
CHP, cumene hydroperoxide; H2O2, hydrogen peroxide; Hb, Hemoglobin; O2
−
, superoxide anion; OH
−
, 
hydroxyl radicals; protein-SSG, protein S-glutathionylation; Prx, peroxiredoxins; SOD, superoxide 
dismutase; Trx, thioredoxin; TrxR, thioredoxin reductase.  
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NADPH is the essential electron donor for GR and TrxR and is therefore an important 
reducing equivalent of the parasite’s redox system. In P. falciparum and its hosting 
erythrocyte, NADPH is mainly generated in the pentose phosphate pathway (PPP) with the 
G6PD as key enzyme (Figure 7) (reviewed in Preuss et al, 2012b). Alternative sources for 
NADPH production in P. falciparum were previously suggested, for instance glutamate 
dehydrogenase and isocitrate dehydrogenase, but are not regarded to provide important 
amounts of NADPH.  
 
 
Figure 7  The pentose phosphate pathway of Plasmodium falciparum (Preuss et al, 2012b) 
The parasite’s pentose phosphate pathway produces NADPH for the glutathione and thioredoxin 
systems. Please refer to the text for more details. GSH, glutathione; GSSG, glutathione disulfide; GR, 
glutathione reductase; Grx, glutaredoxin; Trx, thioredoxin; TrxR, thioredoxin reductase; 6PGD, 6-
phosphogluconate dehydrogenase; G6PD, glucose-6-phosphate dehydrogenase; GluPho, glucose-6-
phosphate dehydrogenase 6-phosphogluconolactonase.  
Different to its host cell, the parasite expresses a bifunctional enzyme, designated 
PfGluPho, that combines G6PD and the second enzyme of the PPP, 6-
phosphogluconolactonase (6PGL) (GluPho stands for glucose-6-phosphate dehydrogenase 
6-phosphogluconolactonase) (Jortzik et al, 2011). PfGluPho is regarded to account for the 
majority of NADPH production of the parasite (Preuss et al, 2012b) and appears to be 
essential for its survival (personal communication Prof. K. Becker). The parasitic enzyme 
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differs substantially in structure and kinetic mechanism from the human homologues 
G6PD and 6PGL and is therefore a suitable drug target (Jortzik et al, 2011; Preuss et al, 
2012a). NADPH is formed by reduction of NADP
+
 in two reactions catalyzed by the 
PfGluPho and another enzyme of the PPP, 6-phosphogluconate dehydrogenase (6PGD) 
(Preuss et al, 2012b). The first reaction that produces NADPH converts glucose-6-
phosphate into 6-phosphoglucono-d-lactone, which is further transformed by the PfGluPho 
into 6-phosphogluconate. The second reaction converts 6-phosphogluconate into ribulose-
5-phosphate and thereby produces NADPH.  
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1.3 Malaria prevention, treatment and control 
The WHO recommends a multifaceted strategy to control and eliminate malaria by 
combining preventive measures, diagnostic testing, effective treatment and strong malaria 
surveillance (WHO, 2010; WHO, 2013). Preventive measures include vector control (i.e. 
insecticide treated nets, indoor residual spraying and larval control) and preventive 
chemotherapy for the most vulnerable patient groups (i.e. young children, pregnant 
women). Malaria diagnosis based on clinical symptoms should be confirmed by light 
microscopy or rapid diagnostic tests to avoid over-treatment.  
The main goal of symptomatic treatment is obviously to cure patients (i.e. rapid, complete 
cure of infections), thereby preventing chronic infections and progression of 
uncomplicated malaria to severe forms. From a public health perspective, effective 
treatment is furthermore important to limit parasite transmission by reducing the parasite 
reservoir of infected individuals and to prevent the emergence and spread of drug-resistant 
parasites (WHO, 2010; WHO, 2013).   
A crucial tool for control and important for elimination and eradication of malaria would 
be an effective vaccine. Despite enormous efforts of the scientific community, there is no 
licensed malaria vaccine to date (WHO, 2013). The most advanced vaccine candidate is 
RTS,S/AS01 that targets the P. falciparum circumsporozoite (CS) protein (Goldstein & 
Shapiro, 1997). Although this candidate already proved to be less efficient than expected in 
current clinical trials (Phase 3), the WHO will further guide the implementation of this 
vaccine after completion of the clinical studies (WHO, 2013). Several other vaccine 
candidates following different strategies are currently in early clinical trials (Phase 1, 2) 
and their development is expected to take another 5-10 years from now (reviewed in 
WHO, 2013; Arama & Troye-Blomberg, 2014).  
Due to the lack of an effective vaccine, chemotherapy represents the solely frontline 
strategy for the control and future elimination of malaria. The emergence and spread of 
parasite resistance to currently effective drugs is a major obstacle to the control of the 
infection and highlights the need of new drug development strategies.  
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1.3.1 Emergence of drug resistance and the rational for combination therapy 
The WHO defines drug resistance as “the ability of a parasite strain to survive and / or 
multiply despite the proper administration and absorption of an antimalarial drug in the 
dose normally recommended” (WHO, 2010). Emergence of drug resistance is considered 
as a two-step process: first, the genetic event raising mutants and secondly, the preferential 
transmission of resistant mutants in the presence of the drug (White & Pongtavornpinyo, 
2003; Petersen et al, 2011). The probability of the first event depends on multiple factors, 
such as the frequency of genetic mutation, the fitness cost of resistant parasites, the number 
of drug-exposed parasites but also the selection pressure in terms of drug concentration. 
Transmission of drug-resistant mutants is mainly determined by the intensity of 
transmission and the fitness cost related to resistance. Resistant parasites must be able to 
produce fertile gametocytes and to complete their development in the mosquito in 
competition with sensitive parasites.  
The resistance mechanisms described so far originate from mutations in genes or 
amplifications of gene copy numbers. Affected genes are either encoding the drug target 
(e.g. cytochrome bc1 complex, targeted by atovaquone) or transporters that affect the 
intracellular drug concentrations (e.g. PFCRT, PfMDR1, conferring resistance to 
chloroquine and others) (White & Pongtavornpinyo, 2003). Identified drug resistance 
genes and mechanisms of drug resistance are discussed in details in the review of Petersen 
and colleagues (2011). Drug resistance has been reported for all currently used 
antimalarials, including the latest cases of artemisinin resistance in Southeast Asia (WHO, 
2010). The emergence and spread of drug resistance is a major threat not only for sufficient 
patient’s treatment but also for the control and elimination of malaria.  
Currently, the only efficient tool to prevent or delay resistance development is the use of 
antimalarial combination therapy (White & Olliaro, 1996; WHO, 2010). The combined use 
of two or more drugs with independent mechanisms of action ensures that a resistant 
parasite arising de novo during treatment will be killed by the other compound of the drug 
combination.  
 
  
INTRODUCTION 
20 
1.3.2 The need of novel antimalarial medicines  
In the perspective of a future emphasis on malaria elimination and eradication, the 
scientific malaria community (e.g. represented by the Malaria Research Agenda initiative 
(malERA)), together with the WHO, has defined a research agenda for the development of 
the next generation of antimalarial medicines (for instance Alonso et al, 2011; mal, 2011; 
Burrows et al, 2013). The ideal medicine for malaria elimination has been described as so-
called Single Exposure Radical Cure and Prophylaxis (SERCaP), an agent that combines 
elimination of all parasite stages in the patient (i.e. radical cure), including gametocytes 
and hypnozoites, as well as prevention of reinfection for a defined time period (i.e. 
chemoprophylaxis). Up to now, no antimalarial drug or drug combination fulfills this 
ambitious ideal.   
The need of new antimalarial medicines for control and elimination of the infection can be 
classified as follows (summarized from mal, 2011; Anthony et al, 2012; Burrows et al, 
2013).  
 
 New combination partners for first-line treatment: 
One fast clearing agent to reduce the initial parasite load and a long-living 
partner for clearance of remaining parasites that are both active against 
multiple drug-resistant parasites. An example is the artemisinin-based 
combination therapy, which is endangered by parasite resistance.  
 Transmission-blocking agents:  
Compounds that kill or prevent the development of gametocytes or the 
development of parasite stages in the mosquito vector. Examples for 
gametocytocidal agents are artemisinin and primaquine, with the latter one 
being omitted in most African countries due to the risk of hemolysis in 
G6PD-deficient patients (WHO, 2010). 
 Prevention of malaria relapse caused by hypnozoites:  
Agents that kill dormant liver stages (hypnozoite) of P. vivax and P. ovale 
and thereby prevent related relapse of the disease. An example is primaquine 
(see before).  
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 Chemoprophylaxis:  
Protection from clinical manifestation can be achieved by compounds 
targeting sporozoites, liver stages or early blood stages. A prerequisite is a 
very good safety-profile and a long half-life suitable for monthly 
administration. Current examples are atovaquone-proguanil combination and 
mefloquine.  
 
The key criteria for these medicines were established by the Medicines for Malaria 
Venture (MMV) in form of so-called target candidate profiles (TCPs) (Burrows et al, 
2013). TCPs are providing detailed description about the characteristics of an ideal 
candidate molecule, for instance the required in vitro efficacy, pharmacokinetic and 
pharmacological properties.  
 
1.3.3 Antimalarial drugs targeting the parasite’s redox system  
A functional redox system is essential for the survival of Plasmodium parasites and 
especially intraerythrocytic parasite stages are particularly susceptible to oxidative stress 
(Becker et al, 2004). Disturbing the vulnerable redox homeostasis of the parasite-host unit 
has become a broadly recognized strategy for the development of new antimalarial drugs 
(Krauth-Siegel et al, 2005; Davioud-Charvet & Lanfranchi, 2011; Pal & Bandyopadhyay, 
2012; Belorgey et al, 2013; Nepveu & Turrini, 2013). Destabilization of the redox 
equilibrium can be achieved in different ways: by agents that (i) directly or (ii) indirectly 
generate reactive oxygen species, (iii) by inhibition of vital components of the redox 
system, or (iv) by subversive substrates or redox-cyclers (Davioud-Charvet & Lanfranchi, 
2011; Pal & Bandyopadhyay, 2012; Nepveu & Turrini, 2013). Selected examples of drugs 
targeting the parasite’s redox system are further discussed in the following section but this 
list is not exhaustive. For more comprehensive and detailed description of redox-active 
antimalarial compounds, please refer to reviews of Krauth-Siegel and colleagues (2005), 
Davioud-Charvet and Lanfranchi (2011), Pal and Bandyopadhyay (2012), Nepveu and 
Turrini (2013), such as Belorgey and colleagues (2013).  
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 (i)  Pro-oxidative agents generating directly reactive oxygen species  
Generation of reactive oxygen species by antimalarial drugs may ultimately cause an 
overload of oxidative stress in the parasite, cause important intracellular damage and 
inhibit further development. One important example is 4-aminoquinoline ferroquine 
(currently in clinical trials, Phase IIa in 2012) (Structure see Figure 8). Ferroquine acts as 
inhibitor of hemozoin formation likewise to its analogue chloroquine (Dubar et al, 2008). 
In addition, ferroquine contains a unique ferrocene core that allows reversible one-electron 
redox reactions under oxidizing conditions as present in the digestive vacuole (i.e. 
oxidation of ferrocene (Fe
2+
) to ferricinium (Fe
3+
)) (Chavain et al, 2008). Owing to this 
reactions, ferroquine generates lethal hydroxyl radicals that contribute considerably to its 
antiparasitic activity (Chavain et al, 2008).    
 
 
Figure 8  Structure of 4-aminoquinoline ferroquine 
The characteristic ferrocene core containts two cyclo- 
pentadienyl rings with a central iron (Fe
2+
) atom  
Other pro-oxidative antimalarials are primaquine and dapsone, that both generate 
hydroxyl-metabolites, which participate in electron-transfer reactions in complex with O2-
bound hemoglobin species and thereby leading to formation of methemoglobin and 
reactive oxygen species. The elevation of methemoglobin levels in non-infected 
erythrocytes is an undesirable side effect of those drugs that causes hemolytic anemia in 
patients with G6PD deficiency. Therefore, both drugs are currently of minor clinical 
importance for the treatment of malaria (discussed in Belorgey et al, 2013).   
 
(ii)  Antimalarial agents generating reactive oxygen species indirectly 
Quinolines and other clinically important antimalarials are acting as inhibitors of the vital 
hemozoin detoxification in the parasite’s digestive vacuole. It could be shown that 
inhibition of hemozoin formation by those drugs resulted in release of pro-oxidant free 
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heme (Fe
3+
) (Combrinck et al, 2013), which could consequently lead to generation of 
reactive oxygen species and oxidative stress. Though, these agents have no intrinsic redox 
potential and are unable to participate directly in electron-transfer reactions with 
hemoglobin species.   
 
(iii)  Enzymes of the antioxidant system as drug targets 
Several proteins and enzymes involved in the redox systems of P. falciparum are validated 
drug targets, for instance PfGR, PfGST, PfTrxR and PfGluPho (Krauth-Siegel et al, 2005; 
Jortzik et al, 2011; Pal & Bandyopadhyay, 2012). Since the antioxidant systems of the 
parasite and its host cell are tightly connected, analogues host cell enzymes are also in the 
focus of inhibitor development (Krauth-Siegel et al, 2005). Respectively, a broad selection 
of enzyme inhibitors or suicide substrates was synthesized and demonstrated to inhibit 
development of blood-stage parasites. Please refer to reviews of Krauth-Siegel and 
colleagues (2005), Pal and Bandyopadhyay (2012) such as Belorgey and colleagues (2013) 
for a detailed description of these inhibitors and their antimalarial activities. So far, only 
one enzyme inhibitor, methylene blue, could enter clinical studies (Zoungrana et al, 
2008).Some of those compounds were furthermore characterized as subversive substrates 
of PfGR, hGR and PfTrxR and are therefore proposed to act as redox-cyclers, such as 
methylene blue (Färber et al, 1998), aza-analogues of 1,4-naphthoquinones (Morin et al, 
2008) and benzylMDs (Müller et al, 2011).   
 
(iv) Antimalarial redox-cyclers 
A particular group of redox-active drugs are subversive-substrates that act as redox-
cyclers. The particular redox potential of those molecules allows them to take part in 
reversible one-electron or two-electron transfer reactions, for instance in a continuous 
reduction and oxidation cycle. Under physiological conditions, this would imply a 
NADPH-dependent transfer of electrons from disulfide reductases to intracellular key 
oxidant, for instance hemoglobin-associated or free heme species in infected erythrocytes, 
accompanied by formation of reactive oxygen species (previously discussed in detail for 
methylene blue and benzylMDs in Müller et al., 2011 and Ehrhardt et al., 2013). 
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Subversive substrates are also designated as turncoat inhibitors because they transform the 
antioxidant activity of disulfide reductases into a pro-oxidative activity, i.e. waste of the 
reductant NADPH and formation of reactive oxygen species (Morin et al, 2008).  
The dye methylene blue is not only the first characterized redox-cycler but was once the 
first synthetic drug used for the treatment of malaria, discovered at the end of the 19
th
 
century by Guttman and Ehrlich (Guttmannn & Ehrlich, 1891)(Structure see Figure 9).  
The drug was replaced by more effective or rapidly acting drugs, such as chloroquine, but 
regained attention with the appearance and spread of parasite resistance to those drugs. 
Previous studies explored methylene blue’s antimalarial activity and its mechanism of 
action in more detail and revealed its role as redox-cycler (reviewed in Schirmer et al, 
2003; Davioud-Charvet & Lanfranchi, 2011; Schirmer et al, 2011; Blank et al, 2012). 
Methylene blue is a subversive substrate of various NADPH-dependent disulfide 
reductases (e.g. hGR and PfGR, PfTrxR and others) that catalyze activation of the drug to 
its reduced form, leucomethylene blue (Färber et al, 1998; Buchholz et al, 2008a; Buchholz 
et al, 2008b; Blank et al, 2012). After activation, the drug can reduce hematin-containing 
targets such as methemoglobin and free heme, resulting in inhibition of hemozoin 
formation in the parasite (Atamna et al, 1996; Blank et al, 2012). Likewise, methylene blue 
is clinically applied for the treatment of methemoglobinemia, which can also occur during 
severe forms of malaria (Schirmer et al, 2011). Of particular interest for drug application is 
methylene blue’s activity against gametocytes that was explored in vitro and further 
confirmed in field studies (Akoachere et al, 2005; Coulibaly et al, 2009). Several 
methylene blue-based drug combinations are currently in clinical trials (Zoungrana et al, 
2008). 
 
 
Figure 9  Structures of antimalarial redox-cyclers  
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A more recent example for antimalarial redox-cyclers is illustrated with indolone-N-oxide 
derivatives (INODs) (Nepveu et al, 2010; Tahar et al, 2011) (Structure see Figure 9). 
INODs contain a redox pharmacophore that enables reversible oxidation-reduction 
reactions, a prerequisite for their activity as redox-cyclers. Intracellular bioactivation of 
INODs was proposed to be thiol- and / or enzyme-dependent and leads to formation of a 
reduced metabolite, the dihydro-INOD, which could be isolated from uninfected and 
P. falciparum-infected erythrocytes (Ibrahim et al, 2011). The subsequent cascade of 
INODs redox reactions is not fully explored so far but the current understanding is 
discussed in a recent review from Nepveu and Turrini (2013). Ultimately, drug action was 
shown to cause a strong destabilization of the cell membrane in P. falciparum-infected 
erythrocytes, which might stem from a direct activation of  redox signaling pathways 
INODs-generated radicals (Pantaleo et al, 2012; Nepveu & Turrini, 2013). It was 
considered that a stable erythrocyte membrane is vital for parasite maturation, a hypothesis 
that is supported by observations with erythrocytes that naturally present unstable 
membranes or mutations in critical structural proteins (discussed in Pantaleo et al, 2012). 
Next to P. falciparum, other unicellular parasites (Trypanosoma cruzi, Trypanosoma 
brucei, Leishmania donovani, Entamoeba histolytica and Trichomonas vaginalis) and also 
multicellular helminthes (e.g. Schistosoma mansoni) are susceptible to oxidative stress and 
might therefore be similarly targeted by redox active drugs (reviewed in Krauth-Siegel et 
al, 2005; Pal & Bandyopadhyay, 2012).   
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1.4 Redox-active benzylmenadiones as novel antimalarial compounds 
The natural protection of GR- and G6PD-deficiencies against severe forms of malaria was 
the inspiration for the development of new antimalarial compounds, which should act by 
disturbing the vulnerable redox homeostasis of the parasite-host unit. GR is a key enzyme 
in the antioxidant systems of Plasmodium parasites and its hosting erythrocytes and both 
enzymes are validated drug targets (Krauth-Siegel et al, 2005). The chemical class of  
1,4-naphthoquinones is a major natural product class that includes several anti-infective 
agents. Their significant biological activities originate from their ability to act as 
electron(s)-acceptor in redox processes (Hillard et al, 2008). From menadione as a starting 
point, different types of GR inhibitors were designed, for instance uncompetitive inhibitors 
(Biot et al, 2004; Bauer et al, 2006), fluorine-based suicide inhibitors (Bauer et al, 2006) or 
refined analogues of those compounds that are proposed to act as Trojan horse drugs (i.e. 
dual prodrugs) (Davioud-Charvet et al, 2001; Friebolin et al, 2008). 
Interestingly, the most potent antimalarial activity was observed for a group of 
benzylmenadiones (abbreviated benzylMD) that were proposed to act as prodrugs of 
subversive substrates of the GR (Müller et al, 2011). A subversive substrate is defined as 
an agent that “changes the physiological functions of the enzyme to the opposite” 
(Buchholz et al, 2008b). The enzymatic substrates, benzoylmenadions (abbreviated as 
benzoylMDs), are predicted to be formed intracellularly by oxidation at the benzylic chain 
(Müller et al, 2011). In order to act as subversive substrates, benzoylMDs are reduced by 
GR at the expense of NADPH (1 or 2 eletron(s)-transfer) (Figure 10). These reactions are 
occurring at the naphthoquinone core of the molecule. Under oxidizing conditions, 
oxidized benzoylMDs are regenerated, with the concomitant formation of reactive oxygen 
species, and can act again as substrate of the GR.  
 
 
Figure 10  Reactions of subversive substrates of NADPH-dependent disulfide reductases (Müller et al, 2011) 
GR, glutathione reductase; NQ, naphthoquinone core of the benzoylMD molecule.   
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The described redox reactions can be expected to continue until complete consumption of 
NADPH. Taking the formation of reactive oxygen species in account, benzylMDs reverse 
the antioxidative function of the GR into a pro-oxidative enzyme. The specific redox 
properties of benzoylMDs support the hypothesis that they act as continuous redox-cyclers 
and are therefore proposed to disturb the intracellular redox equilibrium of the infected 
erythrocyte (Müller et al, 2011; Johann et al, 2012) - a strategy that is broadly recognized 
for the development of new antimalarial agents (Pal & Bandyopadhyay, 2012; Belorgey et 
al, 2013; Nepveu & Turrini, 2013). Additionally, in respect to their pharmacokinetic 
properties, these benzylmenadiones are more drug-like and promise a better potential for 
lead optimization for drug development, than redox-cycler methylene blue. 
Further work led to the selection of a series of 3-[substituted-benzyl]-menadiones 
(abbreviated as benzylMD) that are active against drug-sensitive and chloroquine-resistant 
P. falciparum strains in culture and additionally showed moderate antiparasitic activity in 
P. berghei-infected mice (per os) (Müller et al, 2011). Based on its promising antimalarial 
activity, low cytotoxicity such as ease and low cost of synthesis, the (3-[4-(triﬂuoro-
methyl)benzyl]-menadione) 1c (benzylMD 1c, former also referred to as benzyl-
naphthoquinone 1c) was selected as the lead compound for further optimization studies 
(Structure see Figure 11). The synthesis of benzylMD 1c is achieved in only one step from 
commercially available starting menadione and phenylacetic acid derivatives, in a silver-
catalyzed radical decarboxylation reaction (Müller et al, 2011). 
 
 
Figure 11  Structures of benzylMD 1a (first hit) and benzylMD 1c (lead compound) 
 
In addition, selected benzylMD-derivatives were evaluated as potent compounds that 
inhibit the survival of helminths Schistosoma mansoni (Johann et al, 2012; Lanfranchi et 
al, 2012b).  
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1.4.1 Postulated mechanism of action of benzylMD redox-cyclers  
Based on a multidisciplinary approach, the lead benzylMD and its redox-active metabolites 
are postulated to (i) disturb the redox homeostasis of the parasite by cycling hemoglobin-
bound iron between three different oxidation states (+II, +III and +IV, influencing both 
spin state and axial ligation), (ii) enhance important NADPH-consuming processes that 
disrupt the antioxidant defense of infected erythrocytes, (iii) and lead to denaturation of 
hemoglobin, marked by binding of hemichromes to membranes of ring-infected 
erythrocytes which are known to enhance phagocytosis (Bielitza et al, submitted, 2014.).  
The generation and recycling of benzylMD 1c’s metabolites is proposed to occur in a 
continuous cascade of redox reactions, more precisely, by electron-transfer reactions in 
interaction with different intracellular components, such as NADPH-dependent disulfide 
reductases, iron or hemoglobin species (further detailed in the next section). Several 
predicted benzylMD-derived metabolites were synthesized (Müller et al, 2011; Cesar-Rodo 
et al, in preparation) and characterized in detail on their electrochemical, physicochemical 
and biochemical properties (Müller et al, 2011; Johann et al, 2012; Bielitza et al, 
submitted, 2014.). Of particular interest was thereby to evaluate their capacities to act as 
GR substrate, to interact with ferric targets (e.g. Fe
3+
 species, heme or methemoglobin) and 
to function as redox-cyclers. The structures of selected metabolites (i.e. benzoylMD 2c, 
reduced benzoylMD 3c, or benzoxanthone 4c) are depicted in Figure 12. Their 
electrochemical, physico- and biochemical properties and their antimalarial activities are 
presented in the Appendix (Table A2) (Müller et al, 2011; Johann et al, 2012; Bielitza et al, 
submitted, 2014.). The reduced metabolite benzoylMD 3c is not stable in open air and was 
therefore replaced by stabilized analogues 3c* (fluoro analogue) and 3c-MOM 
(methoxymethyl monoether of 3c) for further in vitro studies (Bielitza et al, submitted, 
2014.).  
 
 
Figure 12  Structures of postulated benzylMD 1c-derived metabolites 
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Formation of redox-active benzylMD metabolites 
The initial benzylMD 1c is considered to be a prodrug that is activated intracellularly by 
oxidation at the benzylic position (e.g. catalyzed by free or bound heme), generating the 
first metabolite, benzoylmenadione 2c (abbreviated as benzoylMD, step, Figure 13). In 
comparison to benzylMD 1c, metabolite benzoylMD 2c possesses a markedly more 
oxidant character, which significantly enhances its efficiency to accept electrons and 
therefore to act as substrate of NADPH-dependent disulfide reductases, as demonstrated 
with the GR. Previous studies evidenced that benzoylMD 2c and analogues are efficient 
substrates of both, the human and the P. falciparum GRs in infected erythrocytes. Of note, 
in all biochemical studies carried out with benzylMD 1c and predicted metabolites, the 
metabolite benzoylMD 2c was shown to be the key player in NADPH-dependent GR-
mediated redox-cycling and drug-induced hemoglobin catabolism.  
BenzoylMD 2c is consequently proposed to be reduced by GR (1 or 2 electron(s)-transfer) 
revealing the reduced benzoylMD 3c (step, Figure 13). Metabolite benzoylMD 3c was 
demonstrated to target relevant intracellular ferric iron Fe
3+
 species and to participate in 
electron exchange reactions. Numerous sources of iron (ferrous iron Fe
2+
, ferric iron Fe
3+
, 
labile iron pool) are present within the parasitized erythrocyte (oxyhemoglobin, 
methemoglobin, heme, hemozoin, hemichrome, labile iron pool) and play an important 
role in redox reactions (reviewed in Scholl et al, 2005). First, benzoylMD 3c was 
characterized as effective chelator of ferric iron (Fe
3+
), in contrast to benzoylMD 2c, which 
was not effective in binding to Fe
3+ 
species. Chelation of ferric iron (Fe
3+
) was proposed to 
assist in drug transport between different compartments of the infected erythrocyte 
(siderophore-like transport) and might cycle benzoylMD-species into the parasite’s acidic 
vesicles or digestive vacuole. Secondly, benzoylMD 3c was proposed to transfer electrons 
to key oxidants that are abundant inside P. falciparum-infected erythrocytes, such as the 
hemoglobin-catabolites methemoglobin and hematin. Recent biochemical studies 
evidenced the proposed reduction of methemoglobin under quasi-physiological conditions, 
using the stabilized benzoylMD 3c* (step, Figure 13). In line with the proposed redox-
cycling, reductions of methemoglobin and hematin were also fulfilled by oxidized 
benzoylMD 2c in the presence of GR and NADPH, which continuously regenerates the 
reduced benzoylMD 3c in vitro (designated as methemoglobin reduction assay). This UV-
Vis spectrophotometric assay was set up with the NADPH-based GR system and synthetic 
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methemoglobin and evidences methemoglobin reduction by a shift in the soret absorbance 
spectrum. The conditions of this assay are described in detail in (Johann et al, 2012). Once 
again benzylMD 1c was unable to directly reduce hemoglobin catabolites, irrespective of 
the presence of the GR / NADPH system.  
Reduction of hemoglobin catabolites is considered toxic for the parasite since they inhibit 
two essential processes of the parasite’s hemoglobin digestion. In detail, oxyhemoglobin 
(Fe
2+
) is a poor substrate of the hemoglobinase falcipain-2 (Hogg et al, 2006) and reduced 
heme (Fe
2+
-protoporphyrin-IX) was demonstrated to inhibit the crystallization of β-
hematin (i.e. synthetic hemozoin equivalent) in vitro (Monti et al, 1999). The generation of 
damaging Fe
2+
-species is additionally proposed to contribute to the production of harmful 
reactive oxygen species owing to Fenton chemistry.  
Re-oxidation of reduced benzoylMD 3c will regenerate metabolite benzoylMD 2c, which 
could then initiate another cycle of redox-reactions by acting as substrate of GR or another 
disulfide reductase. (steps  and , Figure 13) In theory, this redox-cycling can be 
expected to continue until depletion of the intracellular NADPH stock.  
In addition to this continuous redox-cycling, the formation of another metabolite was 
envisioned to occur by oxidative phenolic coupling reaction of the reduced benzoylMD 3c 
radical that could generate the benz[c]-xanthen-7-one derivative 4c (shortened as 
benzoxanthone 4c) (Figure 13, step). The generation of this metabolite represents a death 
end of benzylMD 1c’s redox-cycling but the benzoxanthone 4c itself showed a moderate 
antimalarial activity. Others xanthone derivatives were characterized as antimalarial agents 
that are postulated to act by inhibiting hemozoin formation (reviewed in Riscoe et al, 2005; 
Johann et al, 2012). Consistent with those studies, the benzoxanthone 4c was recently 
proved to be the most efficient inhibitor of β-hematin formation under quasi-physiological 
conditions among all benzylMD 1c-derived metabolites. In addition, the benzoxanthone 
was shown to reduce methemoglobin to oxyhemoglobin, although to a lower extent than 
benzoylMDs.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13  Cascade of redox reactions accounting for bioactivation of benzylMD 1c, formation of redox-active metabolites, formation of hemoglobin catabolites and antimalarial 
activity (modified after Bielitza et al, submitted, 2014.) 
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BenzylMD action is ultimately leading to generation of reactive oxygen species, 
denaturation of hemoglobin in vitro and binding of hemichromes to membranes of ring-
infected erythrocytes in culture  
As mentioned before, the proposed key feature of benzylMD 1c’s mechanism of action is 
the continuous NADPH-consuming redox cycling of naphthoquinones based on the 
interplay of drug metabolites with hemoglobin catabolites and free- or bound-iron species. 
These GR-catalyzed reactions are accompanied with the release of reactive oxygen species 
and are expected to disturb the redox homeostasis in infected erythrocytes. 
A prolonged methemoglobin reduction assay (benzoylMD 2c in the presence of the 
NADPH-based GR system and methemoglobin as described before) evidenced oxidation 
of hemoglobin catabolites and reactive oxygen species (e.g. H2O2, O2
-•
) in the presence of 
benzoylMD 2c, marked by the formation of ferrylhemoglobin 
3
 (Fe
4+
) and ultimately 
denaturation of hemoglobin to hemichrome, as evidenced by the formation of a greenish 
precipitate in the cuvette (Bielitza et al, submitted, 2014.). Evidence of ferrylhemoglobin 
formation in the 7h-long methemoglobin reduction assay was reached by using a 
derivatization reaction, i.e. the formation of the sulfhemoglobin (maximal absorbance at 
620 nm) following sodium sulfide addition to the reaction mixture. Indirect evidence of 
hemichrome formation at the end of the prolonged methemoglobin reduction assay was 
provided by conversion of hemichrome (Fe
3+
) to hemochrome (Fe
2+
) following dithionite 
addition to the cuvette. Hemochrome spectrum has a specific spectrum characterized by 
maximal absorbances at 530 and 558 nm (Bielitza et al, submitted, 2014.).  
Drug-induced hemoglobin denaturation is not solely mediated by direct interaction of 
benzylMD-metabolites with hemoglobin but also implies destruction of the heme structure 
via Fenton reactions triggered by reactive oxygen species. In such a way, after 
benzoylMD 3c-catalyzed reduction of methemoglobin to oxyhemoglobin, the latter one re-
oxidizes spontaneously to methemoglobin (Reeder, 2010). This reaction is accompanied by 
the formation of superoxide radical anions (O2
-•
), which dismutate spontaneously to 
hydrogen peroxide (H2O2) and oxygen (O2). Hydrogen peroxide is a reactive two-electron 
acceptor that further reduces ferrous or ferric iron to its ferryl (Fe
4+
) oxidation state 
(Reeder, 2010). Ferryl iron is reactive and unstable and readily returns to the ferric (Fe
3+
) 
oxidation state. Ferrylhemoglobin can further induce uncontrolled oxidation of 
                                                          
3
 For a definition of ferrylhemoglobin, please refer to Table A1 in the Appendix 
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macromolecules, such as lipids, DNA or proteins, including its own cross-linking. For 
instance, ferrylhemoglobin was reported to disturb actin dynamics during the parasite-
induced remodeling of the host’s cytoskeleton (Cyrklaff et al, 2011). In the process of 
uncontrolled reactions, the heme moiety may be irreversible damaged by a covalent 
binding to the protein or may be released from the protein structure, ultimately leading to 
denaturation of hemoglobin and formation of hemichrome (Kanias & Acker, 2010; Reeder, 
2010). Hemichromes are irreversible and insoluble denaturation products of hemoglobin 
and are marked by significant alterations in the tertiary structure of the protein.   
It is important to note, that NADPH was the limiting factor for the degradation of 
hemoglobin species  and consequent formation of ferrylhemoglobin in the methemoglobin 
reduction assay. This observation adds further support to the hypothesis, that benzylMD 
should highly consume intracellular NADPH and thereby contribute to the disbalance of 
redox homeostasis.  
In support of these in vitro observations, benzylMD-induced hemoglobin denaturation was 
furthermore proven to take place in P. falciparum-infected erythrocytes, as evidenced by 
membrane-bound hemichromes. Significantly increased amounts of hemichromes were 
observed in ring-stage infected cells treated with benzylMD 1c compared to untreated 
control cells, thereby providing a first proof of principle for the postulated mechanism of 
action. As discussed before in section 1.2.2.3, membrane binding of hemichromes was 
identified as a key determinant for phagocytosis of P. falciparum-infected erythrocytes 
(Turrini et al, 1992; Giribaldi et al, 2001; Turrini et al, 2003; Ayi et al, 2004). Given the 
high amount of membrane-bound hemichromes after benzylMD 1c treatment, one would 
expect that phagocytosis of benzylMD-treated infected erythrocytes might importantly 
contribute to parasite clearance in vivo. It is of particular interest to further investigate this 
possibility in adequate in vitro and in vivo studies. However, it is important to consider that 
hemoglobin denaturation and resulting hemichrome formation is not necessarily the 
mechanism by which parasites are killed upon benzylMD 1c treatment.   
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BenzylMD action is ultimately leading to perturbation of cytosolic GSH-dependent 
redox potential of trophozoite-infected erythrocytes in culture 
As stated before, the interplay of drug metabolites with hemoglobin catabolites in a 
continuous redox cycling is accompanied by the release of reactive oxygen species and is 
therefore expected to disturb the redox homeostasis in infected erythrocytes. The redox 
homeostasis in infected erythrocytes largely depends on the glutathione systems of both, 
host and parasite, with reduced thiol GSH as a major component of those systems. 
Genetically encoded redox-sensitive green fluorescent protein linked to human 
glutaredoxin-1 (hGrx1-roGFP2) is a real-time biosensor of the glutathione-dependent 
redox potential of living P. falciparum blood-stage parasites (developed by Kasozi et al, 
2013). Upon treatment with benzylMD 1c, microscopical analysis of the cytosolic 
expression of hGrx1-roGFP2 in trophozoites detected a change of the GSH:GSSG 
equilibrium towards GSSG, indicative of a shift towards a more oxidizing redox potential 
in the cytosol (Bielitza et al, submitted, 2014.). This finding is a first evidence for the 
perturbation of intracellular redox homeostasis upon treatment with benzylMD 1c and 
provides important support for the proposed mechanism of action.  
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1.5 Aim of the Study 
Previously, the Laboratory of Medicinal Chemistry (Dr. E. Davioud-Charvet) presented the 
chemical design of a series of very promising antimalarial agents, 3-[substituted-benzyl]-
menadiones (abbreviated as benzylMD), with potent in vitro and in vivo activities (Müller 
et al, 2011). Based on its antimalarial activity, low cytotoxicity as well as ease and low 
cost of synthesis, the benzylMD 1c was selected as the lead compound for further 
biological evaluation and chemical optimization studies. Ongoing work on the mode of 
action shows that benzylMDs disturb the redox balance of the parasitized erythrocyte by 
acting as redox-cyclers (Müller et al, 2011; Johann et al, 2012; Belorgey et al, 2013; 
Ehrhardt et al, 2013), a strategy that is broadly recognized for the development of new 
antimalarial agents (Blank et al, 2012; Belorgey et al, 2013; Nepveu & Turrini, 2013). 
Drug development for malaria treatment is a rather complex process that is not only 
challenged by the changing parasite landscape (i.e. emergence of drug resistance) but is 
also guided by strategies to control and eliminate malaria that are developed by the WHO 
and leading experts of the scientific community (e.g. represented by MMV or malERA 
initiative) (mal, 2011; Burrows et al, 2013). 
The aim of this doctoral project was to contribute to the evaluation and further 
development of the benzylMD series as antimalarial compounds. This work comprised:  
(I) a detailed characterisation of the in vitro activity profile of the lead compound 1c 
against cultured P. falciparum blood-stage parasites (i.e. lead evaluation studies) 
(II) studies for further understanding of the mechanism of action of these redox-cyclers 
(III) a screening of benzylMD derivatives for their in vitro antimalarial activity against 
cultured P. falciparum blood-stage parasites to guide further structural optimization of the 
lead compound by medicinal chemistry (i.e. lead optimization studies) 
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2 MATERIALS AND METHODS 
2.1 Materials  
2.1.1 Equipment  
Analytical scales  Sartorius, Göttingen Germany 
Autoclave  Tuttnauer Systec 2540, Wettenberg Germany 
Cell counter Beckman Coulter GmbH, Germany 
Centrifuges:  
Biofuge fresco  Heraeus Instruments, Hanau  Germany 
Microcentrifuge MC13  Amicon Bioseparatia/ Millipore, Germany 
Megafuge 2.0R  Heraeus Instruments, Hanau Germany 
Megafuge 1.0R  Heraeus Instruments, Hanau Germany 
Fluorescence plate reader  (FluoStar optima) BMG Labtech GmbH, Ortenberg Germany 
Freezer (-80 °C) UF85-300S Heraeus GmbH, Hanau  
Freezers (-20 °C) Liebherr, Biberach Germany 
Fridges (+4 °C) Liebherr, Biberach Germany 
Gas burner (gasprofi 1) micro WLD-TEC, Germany 
Heat block (Digi-block) JR Laboratory devices INC, USA  
Incubator for P. falciparum cultures Heraeus Instruments, Germany 
Liquid nitrogen tank  Air Liquide, Ludwigshafen  
Microscope: optical light microscope  Zeiss, Jena Germany;  Leica, Wetzlar Germany 
pH-meter (pH 537)  WTW, Weilheim Germany 
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Pipettes and pipette fillers: 
Single channel pipettes (Research,  
0-10 µl, 20-200 µl,  200-1000 µl) 
Eppendorf, Germany 
Multichannel pipette  
(Xplorer, 15-300 µl) 
Eppendorf, Germany 
Electric pipette filler 
(Pipetus® standard)  
Hirschmann Labortechnik, Eberstadt Germany 
Plate shaker (BioShake IQ) Analytica Jena, Germany 
Sterile work bench (Herasafe)  Heraeus Instruments, Hanau Germany 
Stop watch  Roth, Karlsruhe Germany 
Vortex (Genie 2) Roth, Karlsruhe Germany 
Water bath (Julabo 7A) Julabo, Seelbach Germany 
 
 
 
2.1.2 Disposables 
96-well plates, v-bottom Corning Costar 
96-well plates: black, clear  Greiner Bio-One, Kremsmünster Germany 
Aluminium foil  Roth, Karlsruhe Germany 
Cell culture plates  Greiner Bio-One, Kremsmünster Germany 
Centrifugation tubes Greiner Bio-one, Kremsmünster Germany 
Cryovials  Nalgene®, Wiesbaden Germany 
Culture flasks for cell culture Greiner Bio-One, Kremsmünster Germany 
Eppendorf tubes (dark or clear)  Sarstedt, Nümbrecht Germany Germany 
Falcon tubes (15 ml; 50 ml)  Corning incorporation, Bodenheim Germany 
Gloves  Hartmann, Heidenheim Germany 
Immersion oil  Zeiss, Jena Germany 
Kimwipes lite 200  Kimberly Clark  
Object slides  Marienfeld, Lauda-Königshofen Germany 
Parafilm  American International CanTM, USA  
Petri dishes for cell culture  Greiner Bio-one, Frickenhausen  
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(10 cm, 25 cm diameter) 
Pipette tips (0,2-20μl) Kisker, Steinfurt Germany 
Pipette tips  
(20-200μl, 200-1000μl) 
Corning incorporation, Bodenheim Germany; 
Eppendorf Germany; Biohit, Rosbach, 
Germany; 
Plastic pipettes  
(1 ml; 2 ml; 5 ml; 10 ml, 25 ml) 
Corning incorporation, Bodenheim Germany 
Sterile filters (0,2 μm)  Millipore GmbH, Ashburn  
Sterile filtration devices  Corning incorporation, Bodenheim  
 
2.1.3 Chemicals 
Chemicals were ordered from the following companies:  Amersham Pharmacia Biotech 
Europe GmbH, Boehringer JT Baker, Fluka, Gibco Invitrogen, Carl Roth GmbH, Sigma-
Aldrich, Serva, Grüssing, Merck, VWR International, Fresenius Medical Care and Ferax 
Berlin.  
 
2.1.4 Buffers, media, solution 
Albumax II  5% (w/v) Albumax II  
in RPMI 25 mM HEPES L-Glutamine (Gibco),  
filter sterilize  
Cell culture media  
Non-transfectants  10% human serum 
0.2 μg/ml Gentamycin  
0.2 mM Hypoxanthine 
in RPMI 25 mM HEPES L-Glutamine (Gibco) 
Transfectants  5% human serum  
5% Albumax II 
0.2 μg/ml Gentamycin 
0.2 mM Hypoxanthine 
in RPMI 25 mM HEPES L-Glutamine 
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Freezing Solution  6.2 M glycerol  
0.14 M Na-lactate 
0.5 mM KCL 
add ddH2O, adjust to pH 7.2 with 
0.5 M NAHCO3, pH 9, filter sterilize 
Lysis buffer for IC50 
determination  
20mM Tris base (2.423g) in 1l water  
adjust pH to 7.4 with concentrated HCl 
5mM EDTA (10ml 0.5M EDTA)  
0.008% w/v saponin (80mg saponin) 
0.08% w/v Triton X-100 (0.8ml) 
mix, vacuum filter, store at RT 
Sorbitol Solution  5% (w/v) D-sorbitol in ddH2O  
filter sterilize 
Thawing solution I  12% NaCl autoclave 
Thawing solution II  1.6% NaCl autoclave 
Thawing solution III  0.9% NaCl / 0.2% glucose  
filter sterilize 
 
2.1.5 Inhibitors 
The lead benzylMD 1c was prepared as previously described (Müller et al, 2011). The 
synthesis of other benzylMD derivatives will be described in future publications (Cesar-
Rodo et al, in preparation; Urgin et al, in preparation).  
The compounds allopurinol, amodiaquine (dihydrochloride, dihydrate), artemisinin, 
atovaquone, chloroquine (diphosphate salt), cycloguanil (HCl), 5-fluoroorotic acid hydrate 
(5-fluoroorotate), E64, fosmidomycin (sodium salt hydrate), methylene blue (trihydrate), 
proguanil (HCl) and pyrimethamine were purchased from Sigma-Aldrich. Quinine (HCl) 
was purchased from Serva (Heidelberg, Germany). Dihydroartemisinin was purchased 
from Euromedex (Souffelweyersheim, France). Cytochalasin D and ferroquine was a gift 
from Freddy Frischknecht (University Hospital Heidelberg, Germany) and Jacques Brocart 
(Lille University, France), respectively. Plasmion was purchased from Fresenius Kabi, 
France.  
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In general, stock solutions of compounds were prepared in DMSO, with the following 
exceptions. Methylene blue, chloroquine and fosmidomycin were prepared in pure water; 
quinine was dissolved in 70% ethanol and proguanil in 50% ethanol. All stock solutions 
were stored in aliquots at -20 °C. A fresh aliquot was used for each experiment in order to 
avoid drug degradation by repeated freezing and thawing.  
For some experiments it was necessary to use an identical drug solution over several days 
(e.g. stage specificity or killing speed experiment). In these cases, drug dilutions in culture 
medium (working solutions) were distributed into several eppendorf tubes in the volume 
required for one part of the experiment and stored at -20 °C or -80 °C. Aliquots were 
thawed immediately prior use and remaining drug solution was discarded. Any other 
storage of drug solution in aqueous solutions such as culture medium was strictly avoided.  
2.1.6 P. falciparum strains 
Two familiar P. falciparum laboratory strains were used for this study, the chloroquine-
sensitive (CQs) 3D7 strain and the chloroquine-resistant (CQr) Dd2 strain. Their 
chemosusceptibility to common antimalarials is given in the Appendix (Table A3). 
Transfectant P. falciparum strains 3D7attB and 3D7attB-yDHODH were kindly provided 
by Hangjun Ke and Akhil B. Vaidya (Department of Microbiology and Immunology, 
Drexel University College of Medicine, Philadelphia, U.S.A) (Ke et al, 2011).  
2.1.7 Computer software 
EndNote X6  Thomson Reuters, CA, USA  
FIJI/Image J version 1.47c available at http://fiji.sc/Downloads, 
(Schindelin et al, 2012) 
MS Powerpoint 2010  Microsoft Corporation, CA USA 
MS Word 2010  Microsoft Corporation, CA USA  
MS Excel 2010  Microsoft Corporation, CA USA  
SigmaPlot 12.5  Systat Software Inc., IL, USA  
GraphPad Prism 6 GraphPad Software Inc., USA 
Illustrator CS4 Adobe Systems Software Ireland Ltd. 
ChemBio Draw Ultra 13.0 PerkinElmer Informatics 
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2.2 Methods  
Experiments presented in this work were performed in two different Laboratories, at the 
Department of Parasitology, Heidelberg, Germany and the Museum National d’Histoire 
Naturelle, Paris, France (further designated as MNHN Paris). Cultures were maintained 
under the respective standard culture conditions of both laboratories and are described in 
detail in the following paragraphs. If not stated differently, the experiments are described 
as conducted at the Department of Parasitology, Heidelberg, Germany 
The drug concentrations chosen for several experiments were based on multiples of the 
drug’s IC50 values. Though, it is known that IC50 values of a given drug may differ 
between laboratories, depending on the respective assay and culture conditions. In order to 
exclude any experimental fluctuations, IC50 concentrations were determined prior to each 
experiment in the identical conditions of the experiment itself (e.g. parasitemia, 
hematocrit) and in the routine culture condition of the respective laboratory as described 
below.  
2.2.1 Cell culture of Plasmodium falciparum parasites 
2.2.1.1 Culture conditions 
Intraerythrocytic stages of P. falciparum were cultured according to standard protocols 
(Trager & Jensen, 1976). Cultures were maintained in an incubator with a fixed 
atmosphere of 5% O2, 3% CO2, 92% N2 and 95% humidity at 37 °C. Routine cultures were 
established at a hematocrit of 3% - 4% in final volumes of 14 ml or 35 ml in a 10 cm or 
25 cm diameter petri dish, respectively. The parasitemia varied between 0.5% - 5% 
according to need. The detailed composition of culture media is stated in section 2.1.4, 
Strains 3D7 and Dd2 were cultured in non-transfectant medium, containing 10% human 
serum. Strains 3D7attB and 3D7attB-yDHODH were cultured in transfectant medium, in 
which half of human serum was replaced by Albumax.  
At the MNHN Paris, routine cultures were established at a hematocrit of 1 - 2% in final 
volumes of 25 ml – 50 ml in culture flasks as previously described in detail (Fromentin et 
al, 2013). A prepared gas mix, containing 3% CO2, 6% O2, 91% N2, was directly injected 
into culture flasks with closed lids and those were maintained in an incubator at 37 °C. 
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Short time incubation of culture plates (e.g. growth-inhibition assay) were performed in a 
candle jar with an atmosphere of approximately 17% O2, 3% CO2 and 80% N2 at 37 °C. 
Cultures were grown in complete medium consisting of RPMI 1640 (Life Technologies 
Inc.) supplemented with 11 mM glucose, 27.5 mM NaHCO3, 100 UI/ml penicillin, 100 
μg/ml streptomycin, and 8-10% heat-inactivated human serum.  
Hematocrit and parasitemia were adjusted for individual experiments according to the 
respective protocol (see respective paragraph). Cultures were surveyed regularly (latest 
every 3
rd
 day) on Giemsa-stained thin blood smears (see next paragraph). According to 
need, solely the medium was exchanged in order to avoid accumulation of toxic parasite 
metabolites or cultures were diluted with fresh erythrocytes in order to decrease 
parasitemia. The detailed composition of culture media is stated in section 2.1.4.  
2.2.1.2 Morphological monitoring of parasites cultures and determination of 
parasitemia 
Parasite cultures were examined on Giemsa-stained thin blood smears that allowed 
determining developmental stages, morphological alterations and parasitemia. Thin blood 
smears were prepared from a small volume (few microliters) of concentrated erythrocytes 
on microscope slides and subsequently air dried, fixed in 100% methanol for several 
seconds, and stained in Giemsa solution for 10 - 30 min. After staining, slides were washed 
under running tap water and air dried. Smears were analyzed on a light microscope under 
oil immersion using a 100× objective. Parasitemia is defined as the percentage of infected 
erythrocytes and is established by counting a total of 1000 cells.  
2.2.1.3  Synchronization techniques 
Different techniques are available to synchronize, enrich or purify different stages of the 
parasite’s intraerythrocytic development (i.e. ring, trophozoites or schizonts).  
Synchronization of cultures to the ring stage was performed using the sorbitol method 
(Lambros & Vanderberg, 1979). Sorbitol destroys trophozoite and schizont-stage parasites, 
which possess the tubovesicular network, by osmotic shock. Ring-stage parasites are still 
lacking this induced transport system and therefore survive sorbitol treatment. Briefly, 
pelleted infected erythrocytes (0.5 - 1.5 ml) were resuspended in prewarmed 5% sorbitol 
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solution (8 - 10 ml) and incubated for 5 min in a closed falcon tube at 37 °C (e.g. water 
bath or incubator). After incubation, cells were centrifuged (1900 rpm, 2 min, room 
temperature (RT)) and the supernatant sorbitol solution was removed. An additional 
washing step in culture medium is optional but may increase lysis of mature parasites. 
Cells were resuspended in culture medium, adjusted to the desired hematocrit and returned 
to culture.  
Enrichment (and thereby synchronization) of mature schizonts was obtained using the 
plasmion method (Pasvol et al, 1978; Lelievre et al, 2005). Plasmion is a commercially 
available gelatin solution and the separation of schizont-infected erythrocytes from 
trophozoite or ring-infected erythrocytes and non-infected erythrocytes is based on their 
different sedimentation behavior in gelatin solutions.  Briefly, infected erythrocytes were 
pelleted by centrifugation (1900 rpm, 2 min, RT) and the majority of culture medium was 
removed, except for ca 0.5 ml culture medium per 0.5ml cell pellet. The cells were 
resuspended in the remaining culture medium, mixed with 4 ml prewarmed plasmion and 
incubated for 20 min in a closed falcon tube at 37 °C (e.g. water bath or incubator). The 
falcon tube should be maintained in a stable upright position. During the incubation period, 
non-infected and trophozoite or ring-infected erythrocytes sediment whereas segmenters 
are retained in the plasmion phase. The supernatant, containing schizonts and segmenters, 
was transferred to a fresh falcon tube and washed twice with prewarmed culture medium. 
Cells were resuspended in culture medium, adjusted to the desired hematocrit and returned 
to culture. If needed, the pelleted infected and non-infected erythrocytes were separately 
washed and further maintained in culture.  
2.2.1.4 Cryopreservation 
P. falciparum ring-stage parasites are suitable for cryopreservation in a designated freezing 
solution (composition see section 2.1.4). For freezing, a culture rich in ring-stage parasites 
(3 - 5% parasitemia) was pelleted and the supernatant completely discarded. The remaining 
pellet was mixed with approximately 1/3 volume freezing solution (e.g. 500 µl cell pellet + 
150 µl freezing solution) and incubated for 5 min at room temperature. Subsequently, 
another 4/3 volume of freezing solution was added (e.g. 600 µl) and the solution 
thoroughly mixed. The cell solution was transferred to specific cryovials (300 - 500 µl per 
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vial) and frozen at -80 °C. Short-term storage was maintained in a -80 °C freezer, while 
cryovials were transferred to liquid nitrogen tanks for long-term storage.  
For thawing of parasite cultures, frozen cryovials were shortly warmed up in a 37 °C water 
bath until cell solution was passably liquid. Then, 200 µl of thawing solution I was added 
dropwise and the resulting solution transferred to a fresh 15 ml falcon tube. Slowly, 9 ml of 
thawing solution II were added dropwise under steady rotation of the falcon tube. The 
solution was centrifuged (1900 rpm, 2 min, RT) and the supernatant removed. In a last 
step, the cell pellet was slowly resuspended in 7 ml of thawing solution III, which was 
added dropwise. The solution was centrifuged (1900 rpm, 2 min, RT), the supernatant 
removed and the pellet resuspended in few milliliters culture medium. The cell solution 
was then transferred to a petri dish and fresh erythrocytes such as more culture medium 
were added.  
2.2.1.5 Cloning of parasites by limiting dilution 
Clonal parasite populations were obtained by a limiting dilution approach. Therefore, a 
parasite culture was highly diluted and distributed in 96-well plates with an initial 
inoculum of 0.6 parasites per well to assure that parasite cultures in each well originate 
from only one single parasite (i.e. individual clones).  
A synchronised ring stage culture was adjusted to a fixed volume at 1.8% hematocrit. The 
total number of erythrocytes was determined using a cell counter. Parasitemia was counted 
on a freshly prepared blood smear and used to calculate the number of iRBC (infected red 
blood cell) per ml culture. The culture was diluted in serial steps to an initial number of 
3 parasites per ml (i.e. 0.6 parasites per well) and 20 ml volume per plate. If required, 
benzylMD 1c was added to the respective cultures. Parasite culture was distributed on a 
96-well plate, 200 l volume per well. Two plates were prepared per culture and condition. 
Weekly, culture medium (150 l) was changed with the addition of fresh erythrocytes  
(at 0.4% hematocrit). After three weeks, cultures were tested for the living parasites by 
DNA detection with SYBRgreen (as described in section 2.2.2).  
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2.2.2 Growth inhibition assay and determination of IC50 values 
The antimalarial activity of an agent is generally assessed by measuring the growth (i.e. 
multiplication) inhibition of P. falciparum blood-stage parasites under drug treatment and 
is expressed as 50% inhibitory concentration (short IC50 value). The IC50 value indicates 
the concentration needed to inhibit the parasite’s multiplication by 50% over a chosen time 
period. Growth inhibition assays were performed according to standard protocols based on 
detection of parasitic DNA by fluorescent SYBR
®
 green staining (Smilkstein et al, 2004; 
Beez et al, 2011). Briefly, a synchronous culture of P. falciparum blood-stage parasites 
was incubated for 72 h in the presence of decreasing drug concentrations in a 96-well 
microtiter plate. The final conditions of the tests were 100 µl volume per well, 
0.5% parasitemia and 1.5% final hematocrit (2% final hematocrit at the MNHN, Paris), 
72 h incubation time at 37 °C. Cultures were synchronized using the sorbitol method as 
described earlier.  
On the day of the assay, a culture of ring-stage parasites was established at 
0.5% parasitemia and 3% hematocrit (4% hematocrit at the MNHN, Paris), ca 6 ml were 
needed for one 96-well plate. A solution of niRBC at 3% hematocrit was used as negative 
control (ca 1 ml per 96-well plate).  
Drug solutions were prepared as working solutions (6×) in culture medium by diluting a 
freshly thawed stock solution (e.g. 5 - 6 mM in DMSO / water) to 6× starting concentration 
(i.e. highest drug concentration to be tested). Per drug, 50 µl of working solution is 
required to test the compound in duplicates. The starting concentration was chosen to allow 
the IC50 concentration to fall around the midpoint of a threefold serial dilution. This 
concentration was calculated based on IC50 values found in literature or was tested in 
preceding growth-inhibition assays. The range of drug concentrations should cover parasite 
viability from 0 - 100% with sufficient data points all over this range in order to assure 
correct IC50 value calculation by SigmaPlot (or any other appropriate software). Starting 
concentrations for the benzylMD derivatives tested in this work ranged from 1 - 30 µM but 
are dependent on parasitemia and hematocrit.  
Growth inhibition assays were performed on black 96-well plates according to the 
following plate scheme. The outer rows were omitted from use due to extensive 
evaporation and were filled with 100 µl culture medium. Firstly, 50 µl of culture medium 
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was filled in each well. For preparation of serial drug dilutions, 25 µl of drug working 
solution (6×) was added in the first well and thoroughly mixed. An 8-point 1:3 serial 
dilution was obtained by transferring 25 µl each from one row to the next row containing 
50 µl of culture medium. The 25 µl drug solution from the final row was discarded. One 
column of wells was reserved for non-infected erythrocytes (negative control) and another 
one for infected erythrocytes (positive control). Subsequently, 50 µl of prepared parasite 
culture was added to each well, 50 µl niRBC solution were added to respective wells. 
Plates were covered with clear lids and incubated for 72 h in the usual incubator. At the 
MNHN Paris, drug incubation on 96-well plates was performed in a candle jar. After the 
incubation period, plates were wrapped in aluminum foil and frozen at -80 °C until use in 
order to obtain complete lysis of erythrocytes (for 2 h at least).  
Plate scheme of growth-inhibition assay 
1 RBC iRBC Drug 1 Drug 1 Drug 2 Drug 2 Drug 3 Drug 3 Drug 4 Drug 4 X 
2 RBC iRBC Highest concentrations      X 
3 RBC iRBC         X 
4 RBC iRBC         X 
5 RBC iRBC  1:3 dilution      X 
6 RBC iRBC         X 
7 RBC iRBC         X 
8 RBC iRBC         X 
Abbreviations: RBC= non-infected red blood cells, iRBC = infected red blood cells. 
Parasite multiplication was assessed by fluorescent SYBR
®
 green staining of parasitic 
DNA. Measured fluorescence intensity stems from SYBR
®
 green binding to double-
stranded DNA and is associated to DNA replication by multiplying parasites. However, it 
had to be considered that benzylMD-derivatives and putative metabolites are 
autofluorescent to a certain extent. This autofluorescence was indeed observed at the 
emission wavelength used for SYBR
®
 green detection and could therefore be expected to 
increase the total fluorescence signal. An artificial increase of fluorescence intensity 
originating from autofluorescent compounds would be regarded as DNA content, therefore 
artificially increase IC50 value and the compound would seem less active. In order to 
circumvent this, the background fluorescence of the assay content (i.e. autofluorescence of 
compounds in lysed cell solution) was measured in a first step and deducted from the 
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fluorescence signals originating from SYBR
®
 green staining. The reliability of this 
approach was validated using chloroquine (non-fluorescent compound), methylene blue 
(highly fluorescent compound) and benzylMD 1c (weakly-fluorescent compound).  
On the day of the measurement, the plates were thawed for at least 1 h at room 
temperature. For the first step, 80 μl lysis buffer were added per well, the plate was shaken 
briefly to mix the suspension and incubated for 20 min in the dark. Afterwards, 
fluorescence was measured in a fluorescence plate reader at 520 nm emission wave length 
after excitation at 485 nm using specific program settings (gain 1380, 10 flashes/well, top 
optic). These results, representing the background (i.e. self-induced) fluorescence of tested 
compounds, were saved and the plates carefully removed from the plate reader. For the 
second step, 1.5 µl SYBR
®
 green were mixed into 2.5 ml lysis buffer (per 96-well plate) 
while avoiding exposure to bright light. Then, 20 µl of this solution was added per well, 
the plate was shaken briefly to mix the suspension and incubated for 40 min in the dark. 
After the incubation time, fluorescence was measured as in the first step and stored 
separately. For non-fluorescent compounds, one would mix 1.2 µl SYBR
®
 green into 
10 ml lysis buffer (per 96-well plate), distribute 100 µl per well, shake the plates briefly to 
mix the suspension and incubate the plate for 1 h in the dark. 
At the MNHN Paris, parasite multiplication was assessed using the 
3
H-hypoxanthine 
incorporation assay (Desjardins et al, 1979) as described recently (Fromentin et al, 2013). 
In brief, after 24 h incubation, 0.5 µCi 
3
H-hypoxanthine was added per well and the plates 
were returned to the candle jar to complete the incubation period. After the incubation 
period, plates were wrapped in aluminum foil and frozen at -20 °C until analysis. Thawed 
plates were harvested on filters and filtered dried at room temperature. Dried filters were 
moistened in scintillation liquid mixture (OptiScint, Hisafe). Radioactivity was counted in 
a 1450 Microbeta counter (Wallac, PerkinElmer). Radioactive signals originate from  
3
H-hypoxanthine uptake and incorporation into DNA by multiplying parasites 
IC50 values were calculated as follows. First, the background fluorescence values 
(measured in step 1) were deducted from the SYBR
®
 green fluorescence values (measured 
in step 2) for each individual well of the entire plate. The fluorescence intensity of non-
infected erythrocytes represents the background fluorescence of the cell solution, thus the 
calculated mean fluorescence intensity of non-infected erythrocytes (6 wells at least) was 
deducted from all infected erythrocytes measurements. The fluorescence intensity of 
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untreated infected erythrocytes represents 100% parasite multiplication. Thus, the 
multiplication of treated infected erythrocytes was calculated based on the calculated mean 
fluorescence intensity of infected erythrocytes and expressed as percentage. These values, 
together with the respective drug concentrations, were plotted in form of a dose-response 
curve in SigmaPlot (x-axis = drug concentration (M), y-axis = parasite multiplication (%); 
curve fit function, sigmoidal non-linear regression). The IC50 values were calculated by 
SigmaPlot according to the Hill function (four parameters).  
Growth inhibition assay and determination of IC50 values conducted at the Institut de 
Médecine Tropicale du Service de Santé des Armées, Marseille, France 
Dr. Bruno Pradines
4
 determined the in vitro antimalarial activity of lead benzylMD 1c and 
control antimalarials against multiple drug resistant P. falciparum strains originating from 
different countries. 
The following strains of P. falciparum (familiar laboratory strains or strains obtained from 
isolates after growth in culture for an extended period of time) were used in this study: Dd2 
(SE Asia), 3D7 (Africa), D6 (Sierra Leone), IMT 8425 (Senegal), IMT Vol (Djibouti), 
IMT L1 (Niger), PA (Uganda), IMT Bres (Brazil), FCR3 (the Gambia), W2 (Indochina), 
FCM29 (Cameroon), IMT K2 and IMT K14 (Cambodia). Strains “IMT” were isolated at 
the Institut de Recherche Biomédicale des Armées, Marseille. All strains are clonal and 
clonality was verified using PCR genotyping of polymorphic genetic markers, msp1, msp2 
and microsatellite loci (Bogreau et al, 2006; Henry et al, 2006). The chemosusceptibility 
profiles of these P. falciparum strains to common antimalarials in use and multidrug 
resistance (MDR) phenotypes of the strains are given in the Appendix (Table A3).  
Atovaquone was obtained from GlaxoSmithKline (Evreux, France), all other agents were 
purchased from Sigma-Aldrich. Stock solutions were prepared in DMSO with the 
following exceptions: Quinine, dihydroartemisinin and atovaquone were dissolved first in 
methanol and then diluted in water. 
Growth inhibition assays were performed as previously described in detail (Wenzel et al, 
2010) using the 
3
H-hypoxanthine incorporation assay (Desjardins et al, 1979). Briefly, 
synchronous parasitized red blood cells (final parasitemia, 0.5%; final hematocrit, 1.5%) 
                                                          
4 
Dr. Bruno Pradines, Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Recherche 
Biomédicale des Armées, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France 
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were incubated for 48 h in the presence of different drug concentrations in 96-well plates. 
All strains were synchronized twice with sorbitol before use. Inhibitors were analyzed in 
twofold serial dilutions in duplicates and in 3 - 5 independent repetitions. Parasite 
multiplication was assessed by adding 
3
H-hypoxanthine at time zero. 
Identification of cross-resistance to clinical antimalarials 
A possible in vitro cross-resistance of benzylMD 1c with clinical antimalarials was 
assessed by a correlation analysis as previously described (Briolant et al, 2010; Pradines et 
al, 2010). This analysis was conducted in GraphPad Prism by pairwise correlation of the 
IC50 values of benzylMD 1c and others antimalarial compounds using the Spearman 
nonparametric correlation. This nonparametric test was selected as the IC50 values for a 
given drug does not fit a normal distribution, as confirmed with the D’Agostino & Pearson 
omnibus and Shapiro-Wilk normality tests in GraphPad Prism. Results are presented as the 
coefficient of correlation (rs, Spearman nonparametric correlation coefficient) and the two-
tailed P value. The correlation coefficient quantifies the direction and strength of 
correlation and ranges from -1 (i.e. strong negative correlation) over 0 (i.e. no correlation) 
to +1 (i.e. strong positive correlation).  
2.2.3 In vitro stage specificity 
Stage specificity of drug action was assessed by exposing highly synchronous parasites for 
only short incubation times to benzylMD 1c or control antimalarial chloroquine and 
analysing subsequent parasite development. Briefly, highly synchronous P. falciparum 
3D7 parasites were transiently incubated with drug concentrations representing 1×IC50, 
5×IC50, 10×IC50 values for consecutive 8 hours periods (with the exception of a first, 
4 hours period). Subsequently, cells were washed, resuspended in drug-free medium and 
maintained until reinvasion was completed. The parasite development under drug 
treatment was assessed by counting parasitemia after reinvasion on Giemsa-stained blood 
smears. The experiments were performed at the MNHN under the respective routine 
conditions as described before. Drug incubation on 96-well plates was performed in a 
candle jar. The IC50 values of benzylMD 1c and chloroquine were determined before and 
moreover in parallel to the experiment under the respective conditions (see below).  
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To obtain 4 independent highly synchronous cultures, parasites were synchronized on a 4h-
time window by several successive plasmion and sorbitol treatments. Therefore mature 
schizonts (segmenters) were enriched using plasmion, as described before, and the culture 
was returned into the incubator to allow further development (i.e. reinvasion). With the 
first appearance of newly invaded ring-stage parasites (generally 4 - 5 hours later) the 
culture was synchronized again using sorbitol in order to destroy remaining trophozoite 
and schizont stages. This procedure was repeated over several life cycles in order to obtain 
a highly synchronous culture. Two days before the experiment, parasites were splitted into 
four culture flasks containing erythrocytes and plasma from different donors each and 
grown for 48 hours in normal culture conditions. On the day of the assay, another round of 
plasmion / sorbitol treatment was performed. Approximately 1 - 2 h after sorbitol 
treatment, the four independent highly synchronous cultures were adjusted to 
0.5% parasitemia and 2% hematocrit, distributed in small culture flasks (10 ml per flask 
per culture) and maintained at regular culture conditions for complete duration of the 
experiment. The experiment was started with parasites aged 0-4 hours. At different times 
of parasite development (i.e. every 8 h with the exception of an initial 4 h time point), the 
required amount of parasite culture was taken from the initial culture flask and distributed 
on 96-well plates (see below). Parasite development in the initial culture flask was 
followed over time by microscopic examination of Diff-Quick-stained smears. 
BenzylMD 1c and chloroquine effects on the whole parasite cycle were controlled by 
continuous incubation (48h) of the parasites with drugs. 
Drug treatment was performed on black 96-well plates according to the plate scheme 
depicted below. Drug solutions for the complete experiment were prepared as 4× working 
solutions in a mix of the 4 different culture media by diluting a freshly thawed stock 
solution. Different concentrations were prepared as serial dilutions. Drug solution was 
aliquoted for each experimental step and stored at -20 °C. One plate was used per 
incubation period and was prepared directly before use. The outer rows were omitted from 
use due to extensive evaporation and were filled with 100 µl culture medium. First, 25 µl 
of drug working solutions (4×) or culture media (for untreated controls) were added in the 
respective wells.  Subsequently, 75 µl of parasite solution from the initial stock culture was 
added to each well. Plates were covered with lids and incubated in a candle jar.  
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Plate scheme of stage specificity experiment 
X benzylMD 1c X chloroquine X 
X Culture 1 Culture 2 Culture 3 Culture 4 X Culture 1 Culture 2 Culture 3 Culture 4 X 
X 
untreated 
control 
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untreated 
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X 
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untreate
d control 
untreated 
control 
untreate
d control 
X 
X 1×IC50 1×IC50 1×IC50 1×IC50 X 1×IC50 1×IC50 1×IC50 1×IC50 X 
X 5×IC50 5×IC50 5×IC50 5×IC50 X 5×IC50 5×IC50 5×IC50 5×IC50 X 
X 10×IC50 10×IC50 10×IC50 10×IC50 X 10×IC50 10×IC50 10×IC50 10×IC50 X 
X X X X X X X X X X X 
 
After drug incubation, cells were washed twice with 2 volumes of culture medium by 
repeated centrifugation of the culture plates. The cells were resuspended in their respective 
culture medium and the plates returned into the candle jar. Parasites were allowed to 
complete their development until reinvasion.  
The experiment was stopped at approximately 62h post invasion (p.i.) to assure that re-
invasion was fully completed. Smears were made from all samples at time zero and time 
62h p.i. Parasitemia was determined by optical counting of 2000 RBCs (red blood cells) 
per smear. Reinvasion rate in percent was established for each culture and incubation 
period, taken that the 100% value was the parasitemia from the corresponding untreated 
control culture.    
Drug effect on early (ring) and late development stages (trophozoites and schizonts) was 
assessed similarly. Therefore, Rings (aged 0-4h) or trophozoites (aged 24-28h) were 
incubated for 22- 24 h in normal medium (control) or in medium with benzylMD 1c or 
chloroquine at 1×IC50, 5×IC50, 10×IC50 or 50×IC50 final concentrations.  
Inhibition of parasite egress and / or invasion: 
Drug effect on parasite egress and / or invasion was assessed similarly to the stage specific 
drug activity described before. The experiment started when the culture showed 
appreciable enrichment in mature schizonts (segmenters). Parasitemia and hematocrit were 
adjusted to 1% and 1.5%, respectively. The initial number and proportion (in percentage) 
of schizonts and rings was established by optical counting on a Diff-Quick-stained thin 
smear. The culture was then splitted into five sub-cultures, transferred on 96-well plates 
and incubated with either 10 µM E64, 100 nM Cytochalasin D or with 5×IC50 or 10×IC50 
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concentrations of benzylMD 1c (final concentrations) or normal culture medium for 
control. Treated parasites were incubated for 8 h in a candle jar of 37°C to allow egress and 
reinvasion to proceed. At the end of the incubation period, parasitemia and number and 
proportion (in percentage) of schizonts and rings in each culture were determined by 
optical examination of Diff-Quick-stained smears. At least 2,000 RBC were counted per 
smear.  
 
2.2.4 In vitro speed of action or killing speed experiment 
The in vitro speed of action (or killing speed) of benzylMD 1c, artemisinin and atovaquone 
were assessed according to the original protocol established by Sanz and colleagues 
(2012). Treatment was performed with concentrations representing 5×IC50 value of each 
drug, which were established prior to the experiment under the respective conditions  
(0.5% parasitemia, 2% final hematocrit, 48 h incubation time). In principle, the experiment 
is based on determination of parasite viability in response to drug treatment by assessing 
re-growth of treated parasites over time. 
Briefly, a culture of P. falciparum 3D7 blood-stage parasites (asynchronous culture with a 
predominant ring-stage population) was treated with 5×IC50 concentrations for a total 
duration of 6 days (144 h). Every 24 h, a defined sample of parasites was taken from the 
treated culture, washed with drug-free medium and transferred to a 96-well plate. On the 
96-well plate, parasites were diluted in a 12-step, 1:3 series in order to obtain a limiting 
dilution (i.e. one single parasite per well). Parasites were cultured for a total duration of 
28 days to allow viable parasites to grow to higher parasitemia, which can be detected by 
SYBR
®
 green (alternatively by 
3
H-hypoxanthine). On days 21 and 28, a part of the culture 
was analyzed for the detection of viable, growing parasites using SYBR
®
 green. The 
number of the last dilution step containing growing parasites was used to recalculate the 
number of viable parasites present in the initial aliquot. Results are presented in graphical 
form as numbers of viable parasites over time of drug treatment. These results furthermore 
allow to determine a drug’s lag phase (i.e. time needed to reach the maximal killing rate) 
and to calculate the parasite reduction ratio over one parasitic life cycle of 48 h (short 
PRR) and the parasite clearance time (i.e. time needed to kill 99.9% parasites, short PCT).  
MATERIALS AND METHODS 
54 
On the day of the assay, one asynchronous culture was established at 0.5% parasitemia and 
2% hematocrit, which corresponds to 10
6
 iRBC / ml, and distributed in small culture flasks 
(10 ml per flask per drug treatment). An aliquot of 1 ml of the initial culture was kept 
separately in order to establish the first serial dilution of untreated parasite (0 h). Drug 
solutions for the complete experiment were prepared as 100× working solutions in culture 
medium by diluting a freshly thawed stock solution, aliquoted for each day and stored at  
-20 °C. Culture medium and drug were renewed daily over the entire treatment period.  
Drug treatment was started on day 0 by adding 100× working solution (10 µl / 1 ml) into 
prepared culture flasks that were subsequently maintained under usual conditions in the 
incubator. At different time points (8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h), 3 aliquots of 
treated parasites à 150 µl (i.e. 1.5×10
5
 iRBC) were taken from the treated culture. Before 
preparing the serial dilutions, treated parasites were thoroughly washed 3 times with fresh 
culture medium (> 1 ml) to wash out the drug. After the last washing step it was important 
to restore the original volumes and thereby the original hematocrit (i.e. number of cells 
/ µl).  
Serial dilutions (12 steps, 1:3 dilutions) of untreated or treated parasites were prepared in 
triplicates on 96-well plates (V-bottom). Therefore, a solution of non-infected red blood 
cells (niRBC) at 2% hematocrit was prepared (ca 4 ml per drug, per day). The plates were 
prepared as follows. The outer rows were omitted from use due to extensive evaporation 
and were filled with 150 µl culture medium. Wells 2-12 of the serial dilution (in triplicates) 
were filled with 100 µl of the prepared niRBC solution, leaving the first well empty for the 
treated parasite culture. These ones were then filled with the washed parasites (150 µl). A 
1:3 serial dilution was obtained by transferring 50 µl each from one row to the next row 
containing 100 µl niRBC solution. One additional column of wells was filled with 100 µl 
niRBC solution as negative control for SYBR
®
 green detection. At the end, another 50 µl 
of prewarmed culture medium was added to each well (final conditions: 150 µl volume, 
1.33% hematocrit).  
Plates were maintained under usual conditions in the incubator for a total duration of  
28 days. Medium was replaced twice a week (100 µl), once a week with addition of fresh 
erythrocytes (100 µl niRBC solution of 0.66% hematocrit). For detection of viable 
parasites, the cultures were divided in halves on day 21. Therefore, a solution of non-
infected erythrocytes (niRBC) at 2% hematocrit (ca 4 ml per dilution series in triplicates) 
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and black 96-well plates were prepared. A maximal volume of supernatant was removed 
from the cell pellet, the wells refilled with 100 µl niRBC solution and the cell solution 
thoroughly mixed. Then, 100 µl of the resuspended solution were transferred to the black 
96-well plate, which was maintained in the incubator for another 3 days before analysis. 
The original wells were filled again with 100 µl niRBC solution and maintained in the 
incubator for another 7 days until day 28.  
Detection of viable parasites was performed using SYBR
®
 green according to the protocol 
described before, without measuring background fluorescence (section 2.2.2). Giemsa-
stained blood smears of all wells were prepared to confirm results from SYBR
®
 green 
detection.  
Calculation of viable parasites, parasite reduction ratio and parasite clearance time 
All parameters were calculated as described in the original protocol established by Sanz 
and colleagues (2012). The number of viable parasites was back-calculated by using the 
formula X
(n-1)
. X stands for the dilution factor (i.e. 3) and n is the number of wells detected 
positive for viable parasites (in other words, the number of the last dilution step containing 
growing parasites). In the case that no parasites recovered in all wells (n=0), the number of 
viable parasites was estimated as zero. The numbers of viable parasites after drug treatment 
are presented in graphical form as “viable parasites +1” in logarithmic scale (log10). This 
presentation was adopted from the original protocol (Sanz et al, 2012) since only values 
greater than zero can be plotted on a logarithmic scale. A possible stagnation of parasite 
numbers during the first days (hours) of drug treatment is generally considered as lag phase 
(i.e. time needed to reach the maximal killing rate) and is characterized by a plateau of the 
curve. The parasite reduction ratio (PRR) was calculated as the decrease of viable parasite 
numbers over 48 h in the phase of maximal killing, meaning by excluding the period of lag 
phase. As an example, if a drug has a lag phase of 72 h, the PRR is calculated by dividing 
the number of viable parasites at 72 h by the number of viable parasites at 120 h. The 
parasite clearance time (i.e. time needed to kill 99.9% parasites, PCT) was determined 
using a linear regression of the time-response curve. The linear regression was calculated 
from time-point 0 h until the first time point at which parasites were cleared (parasite 
number =0) and included a possible lag phase.  
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2.2.5 In vitro parasite resistance development 
Experiments on parasite resistance were performed with the P. falciparum Dd2 strain, 
owing to its ability to easily acquire resistance to drugs under in vitro conditions, 
commonly designated as accelerated resistance to multiple drugs (ARMD) phenotype 
(Rathod et al, 1997; Trotta et al, 2004; Castellini et al, 2011). The ARMD phenotype was 
linked to a defective DNA repair machinery, which could explain the acquisition of 
beneficial point mutations under drug pressure (Castellini et al, 2011).  
2.2.5.1  Risk of de novo resistance development  
The intrinsic potential of benzylMD 1c to induce parasite resistance was assessed by 
continual exposure of blood-stage parasites to lethal drug concentrations, based on the 
method established by Rathod and colleagues (Rathod et al, 1997). By using different 
parasite inocula, this experiment allows to determine the minimum number of parasites 
necessary for the development of resistant mutants (so-called frequency of resistance 
selection). Therefore, a series of P. falciparum Dd2 blood-stage cultures with high parasite 
inocula (10
8
, 10
7
, 10
6
, 10
5
 iRBC) were maintained in the presence of 5×IC50 or 10×IC50 
concentrations of benzylMD 1c (corresponds to approx. 2×IC90 and 4×IC90 
concentrations). According to the original protocol, control cultures were maintained in the 
presence of 100nM 5-fluoroorotate. The cultures were regularly checked for the emergence 
of resistant parasites on blood smears.  
Two lethal benzylMD 1c concentrations were chosen for drug treatment: 250 nM and 
500 nM. Those concentrations were chosen according to the IC50 value that was 
determined directly before the experiment: IC50 value of 51 nM (Appendix, Table A5). 
Working solutions (1 000×) of benzylMD 1c and 5-fluoroorotate were prepared in pure 
DMSO in the following concentrations: 0.5 mM and 0.25 mM for benzylMD 1c, as well as 
0.1 mM for 5-fluoroorotate. Small aliquots were stored at -20°C and thawed freshly before 
use.  
Parasites were prepared as follows. Drug-pressure experiments were started with 
P. falciparum Dd2 ring-stages parasites. Several big parasite cultures (i.e. 40 ml volume, 
1.5 ml erythrocytes) were allowed to grow to high parasite density (ca 5-8% parasitemia). 
Parasites were synchronised with the sorbitol method and washed once with culture 
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medium. Cells were resuspended in one big culture flask at 2% hematocrit. The parasites 
were allowed to rest for at least two hours in the incubator at 37°C. In the meantime, the 
total number of erythrocytes in the culture was determined using a cell counter. 
Parasitemia was counted on a freshly prepared blood smear and used to calculate the 
number of infected erythrocytes per 1 ml of culture.  
A series of 10 ml cultures were inoculated with decreasing numbers of parasites: 10
8
, 10
7
, 
10
6
 and 10
5
 infected erythrocytes (in total). Therefore a serial dilution of infected 
erythrocytes was prepared in a non-infected erythrocyte suspension of 2% hematocrit. For 
each condition, two independent cultures of synchronous ring-stage parasites were 
established from two individual stock cultures and maintained in parallel. Treatment was 
initiated by adding 1 l drug working solution (1 000×) per 1 ml culture. Three control 
flasks with untreated parasite cultures were maintained to survey the quality of 
erythrocytes and culture medium.  
Cultures were maintained as follows. Parasites were initially cultured in a volume of 10 ml 
and at 2% hematocrit. Culture medium was changed regularly: daily during the first week 
of the experiment, four times in the second week, twice a week from week 3-12 and also 
twice a week for the last 4 weeks. Parasites were challenged with drug with every medium 
change, besides after drug removal for the last 4 weeks of culturing. Therefore 1 l drug 
working solution (1 000×) per 1 ml culture was added to the medium. A blood smear was 
prepared with every medium change to check for the emergence of resistant parasites and 
for the state of erythrocytes. Fresh erythrocytes were added regularly to the cultures 
regarding their appearance on the blood smear. To maintain a hematocrit between 2-4%, 
the culture volume was increased over the time to a final volume of 25 ml by the end of the 
experiment.   
The original time scale of the experiment (8 weeks) was prolonged to an overall duration 
of 16 weeks. Over week 1-12, cultures were exposed continuously to the drug to allow the 
emergence of resistant mutants. By the end of week 12, treatment with benzylMD 1c was 
stopped. The drug was removed by washing the cultures twice in fresh culture medium and 
cells were resuspended in fresh culture medium (2% hematocrit). The cultures were 
maintained for another 4 weeks to allow the proliferation of possibly retained tolerant 
parasites.   
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2.2.5.2 Selection of drug-adapted parasites 
Drug-adapted or resistant parasites were selected under drug pressure with stepwise 
increasing concentrations of benzylMD 1c according to the protocol established by Beez et 
al. (2011). Therefore, a culture of P. falciparum strain Dd2 with high parasite inoculum 
was maintained in the presence of sublethal concentrations of benzylMD 1c until the 
reappearance of normally growing parasites. Subsequently, concentrations for drug 
pressure were increased according to the altered susceptibility of drug-selected parasites. 
BenzylMD 1c concentrations for selection were chosen in the order of the 
IC90 concentration of the respective parasite population.  
The sublethal benzylMD 1c concentration of 125 nM, representing the IC90 value was 
chosen for drug treatment. This concentration was chosen according to the IC90 value that 
was determined directly before the experiment. For the second selection cycle, culture F3 
was treated with 800 nM. Culture F2 was initially challenged with 500 nM benzylMD 1c 
but the concentration was raised to 550 nM at the end of the first week. Working solutions 
(1 000×) of benzylMD 1c were prepared in pure DMSO at concentrations of 0.125 mM 
(first selection cycle) and 0.5 mM or 0.8 mM (second selection cycle). Small aliquots were 
stored at -20°C and thawed freshly before use.  
Parasites for each selection step were prepared as follows. Drug-pressure experiments were 
started with P. falciparum Dd2 ring-stages parasites (see below for detailed conditions of 
each selection step). To obtain a maximal parasite inoculum, several big parasite cultures 
(i.e. 40 ml volume, 1.5 ml erythrocytes) were allowed to grow to high parasite density (ca 
10-14% parasitemia). These cultures were pooled and adjusted to the starting conditions: 
200 ml total volume at 2% hematocrit. The parasites were allowed to rest for at least one 
hour until further use in the incubator at 37°C. In the meantime, the total number of 
erythrocytes in the culture was determined using a cell counter. Parasitemia was counted 
on a freshly prepared blood smear and used to calculate the total parasite inoculum. Drug 
pressure was started by adding 1 l drug working solution (1 000×) per 1 ml culture. 
Subsequently, the initial culture was distributed in four culture flasks à 50 ml each. 
Conditions of the first selection cycle: Initial culture was established with an inoculum of 
3.6 × 10
9
 iRBC. The parasitemia increased to high levels over the first three days. To avoid 
crashing of parasites, pooled iRBC were diluted with non-infected RBC (1:0.625). The 
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resulting culture was assessed to 250 ml volume, 2,6% hematocrit and distributed into 5 
culture flasks. The 1
st
 selection cycle was independently repeated with the same parasite 
inoculum (3.6 × 10
9
 iRBC). The initial culture was challenged with 125 nM benzylMD 1c. 
During the first week of drug treatment, parasites continued to multiply to high 
parasitemia. Therefore, drug concentration was increased to 150 nM and the cultures were 
divided into 6 culture flasks in total that were subsequently treated identically. 
Conditions of the second selection cycle: Initial cultures were established with an inoculum 
of 1.1 × 10
9
 iRBC for culture F2 and 1.0 × 10
9
 iRBC for culture F3. This culture was 
subsequently divided into 4 culture flasks that were treated identically. 
Cultures were maintained as follows. Parasites were initially cultured in a volume of 50 ml 
and at 2-2,6% hematocrit. Culture medium was changed regularly: 3-4 times during the 
first 3 weeks of the experiment and twice a week until appearance of growing parasites. 
Parasites were challenged with benzylMD 1c with every medium change. Therefore 1 l 
drug working solution (1 000×) per 1 ml culture was added to the medium. A blood smear 
was prepared with every medium change to check for the emergence of resistant parasites 
and for the state of erythrocytes. Fresh erythrocytes were added regularly to the cultures 
regarding their appearance on the blood smear.  
Cultures with growing parasites were checked daily. Parasites were allowed to recover 
from drug pressure until they presented a normal multiplication rate and a regular life 
cycle. As soon as they grew nicely, the cultures were splitted into two parts: one part was 
kept further with treatment and the other one without treatment. The cells of the latter ones 
were washed twice with fresh medium. After two life cycles, these parasites were used for 
growth-inhibition assays to determine their susceptibility to benzylMD 1c (i.e. IC50 and 
IC90 values). Additionally, parasites were prepared for cryopreservation.  
Growth inhibition assays were conducted according to the standard protocol (refer to 
section 2.2.2). A culture of progenitor P. falciparum Dd2 parasites was used as control. 
BenzylMD 1c was tested in 3 different starting concentrations: 10 M, 5 M and 3 M for 
the cultures of the first selection cycle and the Dd2 control culture, as well as 20 M, 
10 M and 5 M for the cultures of the second selection cycle. Chloroquine was used as a 
control drug (5 µM starting concentration).   
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2.2.6 In vitro drug combination assays 
In vitro drug-drug interactions between two agents of choice were investigated using the 
fixed-ratio isobologram method established by Fivelman and colleagues (2004). This 
approach is based on determining the IC50 values of each individual drug alone and the 
IC50 values of a mixture of both drugs at fixed concentration ratios. In principle, the shift of 
a drug’s IC50 value determined in combination with a second agent compared to the 
IC50 value determined for this drug alone is indicative for the nature of drug-drug 
interaction. Arithmetical analysis requires several calculation steps to reveal the unit of 
measurement, the so-called mean sum of fractional 50% inhibitory concentration 
(mean ∑ FIC50). Arithmetical analysis was furthermore supported by graphical analysis of 
results in form of isobolograms.  
The principle experimental set-up is similar to the growth-inhibition assay for 
determination of IC50 values, please refer to section 2.2.2. Briefly, an asynchronous culture 
of P. falciparum blood-stage parasites was incubated for 48 h in the presence of decreasing 
drug concentrations in a 96-well microtiter plate. The final conditions of the test were 
100 µl volume per well, 1% parasitemia and 1.5% final hematocrit (2% final hematocrit at 
the MNHN, Paris) and 48 h incubation time at 37 °C.  
On the day of the assay, an asynchronous parasite culture was established at 
1% parasitemia and 3% final hematocrit (4% final hematocrit at the MNHN, Paris). Drugs 
were applied alone (A or B) and in combination at fixed concentration ratios (A:B) and 
analyzed in threefold serial dilutions. Drug mixtures were prepared from 2× working 
solutions of each drug in the following fixed concentration ratios (v/v): ratio A : B = 1:4, 
2:3, 2.5:2.5, 3:2, 4:1 (ratios 1:4, 2:3, 3:2, 4:1 at the MNHN, Paris). Drug mixtures were 
prepared directly on the 96-well plates in a total volume of 100 µl (see below). IC50 values 
of drugs A and B alone were determined on the same plate to ensure accurate calculation 
of drug interactions.  
Drug combination assays were performed on black 96-well plates according to the plate 
scheme depicted below. The outer rows were omitted from use due to extensive 
evaporation and were filled with 100 µl culture medium. Firstly, 50 µl of culture medium 
was filled in wells 2-12 of the serial dilution, leaving the first well empty for the drug 
solutions. For preparation of serial drug dilutions, a total of 100 µl of 2× drug working 
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solution (individual or as mix of drug A and B) was added in the first wells and thoroughly 
mixed. 25 µl of drug solution was discarded. An 8-point 1:3 serial dilution was obtained by 
transferring 25 µl each from one row to the next row containing 50 µl of culture medium. 
The 25 µl drug solution from the final row was discarded. One column of wells was 
reserved for non-infected erythrocytes (negative control) and another one for infected 
erythrocytes (positive control). Subsequently, 50 µl of prepared parasite culture was added 
to each well, 50 µl niRBC solution were added to respective wells. Plates were covered 
with clear lids and incubated for 72 h in the usual incubator. At the MNHN Paris, drug 
incubation on 96-well plates was performed in a candle jar. After the incubation period, 
plates were wrapped in aluminum foil and frozen at -80 °C until use in order to obtain 
complete lysis of erythrocytes (for 2 h at least).  
Plate scheme of drug combination assay 
1 RBC iRBC 
Drug A 
5:0 
Drug mix 
4:1 
Drug mix 
3:2 
Drug mix 
2.5:2.5 
Drug mix 
2:3 
Drug mix 
1:4 
Drug B 
0:5 
X 
2 RBC iRBC Highest concentrations     X 
3 RBC iRBC        X 
4 RBC iRBC        X 
5 RBC iRBC  1:3 dilution     X 
6 RBC iRBC        X 
7 RBC iRBC        X 
8 RBC iRBC X X X X X X X X 
Abbreviations: RBC= non-infected red blood cells, iRBC = infected red blood cells. 
 
Parasite growth was assessed using the SYBR
®
 green method or the 
3
H-hypoxanthine 
incorporation assay at the MNHN Paris as described in section 2.2.2. At the MNHN Paris, 
drug incubation on 96-well plates was performed in a candle jar. Calculation of IC50 values 
was performed as described before, please refer to section 2.2.2. 
For arithmetical analysis, the FIC50 of each drug in a given combination was calculated 
according to the following definitions:  
FIC50 (A) = IC50 of A in combination / IC50 of A alone  
FIC50 (B) = IC50 of B in combination / IC50 of B alone.  
The sum of FIC50 (A) and FIC50 (B) (∑ FIC50) was established for each combination and 
then the mean value of the four ∑ FIC50s was calculated. A mean ∑ FIC50 ≤ 0.7 was 
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assumed to reflect a synergistic interaction and a mean ∑ FIC50 ≥ 1.3 an antagonistic 
interaction between the tested drugs. Any value in between (0.7 - 1.3) was considered as 
indifferent interaction. The inherent variability of the experimental set-up was estimated by 
combining two individual working solutions of lead compound 1c. 
Graphical analysis was performed on isobolograms, which were established by plotting 
pairs of FIC50 values of drug A and drug B for each combination. Figure 20 illustrates the 
characteristic isoboles for different drug-drug interactions, as they have been assessed 
during this project. A straight line  indicated an indifferent interaction (in other words no 
interaction, formerly described as additive), a concave curve towards the origin of the axes 
represented synergy and a convex curve towards the opposite indicated antagonism.  
An essential prerequisite of the fixed-ratio isobologram method is a precise calculation of 
the IC50 values of both drugs. For some experimental compounds (e.g. ascorbic acid, 
nicotinamide, 6-aminonicotinamide) it was not possible to determine their IC50 values due 
to poor growth inhibition activities and poor solubility of the compounds. Thus, the fixed-
ratio isobologram method was not applicable for such agents. Though, to explore the in 
vitro interactions with these agents, the IC50 values of lead compound 1c were determined 
in the presence of a fixed dose of the agent of choice that showed no inhibition of parasitic 
multiplication when applied alone. Therefore, the compound was added directly in the 
required concentration (i.e. 2× final concentration) to the parasite culture before this was 
distributed on the 96-well plate. The IC50 values of lead compound 1c in the absence of the 
second agent were determined on the same plate to ensure accurate interpretation of drug 
interactions. The IC50 values were determined as described before (section 2.2.2). For 
interpretation of results, the shift of the IC50 value of lead compound 1c in the presence or 
absence of a second agent was calculated and expressed in percentage.   
 
2.2.7 Morphological analysis of drug-treated parasites 
Morphological analysis of drug-treated parasites was performed as previously described 
(Ehrhardt et al, 2013). Briefly, Pictures of Giemsa-stained blood smears of treated and 
untreated parasite cultures of strain 3D7attB-yDHODH were taken at different time points 
with an AxioCam ICc 3 at an Axioplan microscope using the software ZEN 2011 blue 
edition (Zeiss). Individual images were imported into Fiji/Image J, cropped, and stored as a 
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TIF file. The TIF file was imported into CorelDraw, labels were added, and the figure was 
saved without any gamma, contrast or color adjustments. 
2.2.8 In vitro cytotoxicity against hepatic HepG2 cells determined using the 
Trypan Blue Exclusion Assay, Laboratoire SRSMC, Université de Lorraine, France 
Ms. T. Tzanova 
5
 assessed the cytotoxicity of benzylMD 1c and chloroquine against 
hepatic HepG2 cells using the Trypan Blue Exclusion Assay according to a standard 
protocol (Freshney, 1987). Briefly, a cell suspension containing the floating and adherent 
cells detached by trypsin is mixed with Trypan Blue Stain (0,04% final concentration). The 
dye is excluded from the live cells displaying intact membranes whereas the dead cells will 
have a blue cytoplasm. Viable and dead cell number were determined with a Malassez cell. 
 
                                                          
5
 Ms. T. Tzanova (Laboratory Dr. D. Bragel) Laboratoire SRSMC, Université de Lorraine, France. 
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3 RESULTS 
3.1 In vitro antimalarial activity of benzylMD derivatives 
The first evaluation of new antimalarial compounds is generally assessed by measuring the 
inhibition of multiplication or survival of cultured P. falciparum blood-stage parasites 
under drug treatment, designated as antimalarial activity. The unit of measurement used to 
express the effectiveness of a compound is the so-called half maximal inhibitory 
concentration (in short IC50 value), that indicates the concentration needed to inhibit the 
parasite’s development by 50% over a chosen time period. Standard techniques all have in 
common to determine IC50 values and differ mostly in the method applied to measure 
parasite multiplication, amongst others by microscopy (“WHO micro-test”, Rieckmann et 
al, 1978), or by incorporation of radio-labeled 
3
H-hypoxanthine or fluorescent dyes, such 
as SYBR
®
 green, into parasitic DNA (Desjardins et al, 1979; Smilkstein et al, 2004). The 
IC50 values presented in this work were determined using the protocol based on the 
detection of parasitic DNA with SYBR
®
 green, unless stated otherwise.  
3.1.1 In vitro antimalarial activity and cytotoxicity of lead benzylMD 1c  
To determine its in vitro antimalarial activity, lead benzylMD 1c was tested against two 
common P. falciparum laboratory strains, the chloroquine-sensitive (CQs) 3D7 strain and 
the chloroquine-resistant (CQr) Dd2 strain. Their chemosusceptibility to common 
antimalarials is given in the Appendix (Table A3). The following antimalarial agents were 
used as reference drugs: chloroquine, the most common 4-aminoquinoline; atovaquone, a 
1,4-naphthoquinone structurally related to benzylMD 1c and methylene blue, another 
antimalarial redox-cycler. Lead compound 1c displayed a potent antimalarial activity 
against both strains in the low nanomolar concentration range with IC50 values of 
46 nM to 60 nM (Table 1). A comparable low IC50 value for benzylMD 1c was formerly 
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determined against the P. falciparum Dd2 strain by using the 
3
H-hypoxanthine 
incorporation assay (Müller et al, 2011). Similar to benzylMD 1c, chloroquine resistance 
of P. falciparum Dd2 strain had no influence on the activities of atovaquone and methylene 
blue, as reflected in their IC50 values (Table 1). The IC50 values for control antimalarials 
chloroquine, atovaquone and methylene blue corresponded well with values reported 
elsewhere (Vennerstrom et al, 1995; Baniecki et al, 2007; Wein et al, 2010).  
Table 1  In vitro activity against P. falciparum blood-stage parasites and cytotoxicity against 
mammalian cell lines of lead benzylMD 1c and control antimalarial agents 
 
P. falciparum strain 
a
 Human cell line 
c
 
Selectivity index 
 
IC50  ± SD (nM) IC50  ± SD (µM) 
Agent 3D7 (CQs) 
b
 Dd2 (CQr) HepG2 
IC50 HepG2 /  
IC50 P. falciparum 
1c 46 ± 3.5 60 ± 11 10 ± 0.6 166 - 217 
CQ 10 ± 0.6 116 ± 3.4 24 ± 2.2 207 - 2400 
Ato 0.2 ± 0.05 0.2 ± 0.06 ND ND 
MB 3.1 ± 0.4  3.6 ± 0.9 ND ND 
a Activity against cultured P. falciparum parasites is presented as mean IC50 values ± standard deviation (SD) determined 
from 3 independent experiments using the SYBR® green technique. b IC50 values of all agents determined on P. falciparum 
3D7 strain were previously published (Ehrhardt et al, 2013) and are presented in identical form in section 3.3.1.  
c Cytotoxicity of benzylMD 1c and CQ against human HepG2 cells, a hepatocellular carcinoma cell line, is presented as 
mean IC50 values ± standard deviation (SD) determined from 4 independent experiments using the Trypan blue exclusion 
method. Cytotoxicity results were kindly provided by Ms. T. Tzanova and Dr. D. Bragel, Université de Lorraine, Laboratoire 
SRSMC, France. 1c, lead benzylMD 1c; Ato, atovaquone; CQ, chloroquine; CQs, chloroquine sensitive; CQr, chloroquine 
resistant; MB, methylene blue; ND, not determined. 
The cytotoxicity of benzylMD 1c against human cell lines was recently assessed on the 
human buccal carcinoma cell line cell (KB) and the human lung MRC-5 fibroblasts using 
the Alamar blue assay (Müller et al, 2011). In these tests, benzylMD 1c displayed low 
cytotoxicity against both cell lines, with an IC50 value of 80 µM for KB cells and  an IC50 
value > 32 µM (i.e. the highest tested concentration) for MRC-5 cells. To further explore 
the cytotoxicity profile of benzylMD 1c towards a human cell line of different origin, 
Ms. T. Tzanova and Dr. D. Bragel 
6
 tested benzylMD 1c for cytotoxicity on a liver 
carcinoma cell line (HepG2) using the trypan blue exclusion method. The dye trypan blue 
penetrates the cell membranes of death cells, staining their cytoplasm blue, but is not 
                                                          
6
 Ms. T. Tzanova and Dr. D. Bragel, Laboratoire SRSMC, Université de Lorraine, France 
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absorbed by intact living cells (Freshney, 1987). After incubation of HepG2 for 48 hours, 
the IC50 values measured for benzylMD 1c and the control agent chloroquine were 10 µM 
and 24 µM, respectively (Table 1). Given that benzylMD 1c had an IC50 of ~50 nM against 
P. falciparum, the cytotoxicity data on HepG2 cells established an in vitro selectivity index 
(i.e. IC50 HepG2 / IC50 P. falciparum) of 166 -217 (Table 1).   
The presented results on in vitro antimalarial activity and cytotoxicity of lead 
benzylMD 1c are currently prepared for publication (Ehrhardt et al, in preparation).  
3.1.2 In vitro antimalarial activity of lead benzylMD 1c against multiple drug-
resistant P. falciparum strains originating from different countries 
The emergence and spread of drug resistance is not only a drawback for most currently 
applied antimalarials, but also represents an important challenge for the development of 
new antimalarial compounds. It is therefore important to identify possible cross-resistance 
patterns with structurally related as well as unrelated antimalarial compounds (Ding et al, 
2012). For this purpose, Dr. Bruno Pradines 
7
 investigated the activity of lead 
compound 1c against drug resistant parasites. Therefore, he selected a panel of twelve 
P. falciparum strains of different geographical origins: 3D7 (Africa), D6 (Sierra Leone), 
8425 (Senegal), Vol (Djibouti), L1 (Niger), PA (Uganda), Bres (Brazil), FCR3 (the 
Gambia), W2 (Indochina), FCM29 (Cameroon), K2 and K14 (Cambodia). Those strains 
can be regarded as representatives of common resistance mechanisms to clinically used 
antimalarial compounds, namely the resistances to quinolines, mefloquine, 
monodesethylamodiaquine and / or pyrimethamine. The chemosusceptibility profiles of 
these P. falciparum strains to common antimalarials in use and the multidrug resistance 
(MDR) phenotypes of these strains are given in the Appendix (Table A3). More 
information about these strains, such as genetic mutations of known resistance markers, 
can be obtained from a recent publication (Briolant et al, 2010). Important to note is that 
nine strains are resistant to chloroquine (IC50 > 100 nM) and seven strains have an 
intermediate susceptibility to quinine (500 nM < IC50 > 800 nM). The respective resistance 
cut-off values are presented in the Appendix (Table A3). In parallel to benzylMD 1c, Dr. 
Bruno Pradines determined the IC50 values of chloroquine, quinine, 
monodesethylamodiaquine and mefloquine, as reference drugs.  
                                                          
7
 Dr. Bruno Pradines, Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Recherche 
Biomédicale des Armées, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France 
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Figure 14 illustrates the in vitro activities (presented as IC50 values) of benzylMD 1c, the 
4-methanolquinoline quinine and 4-aminoquinoline chloroquine against the twelve 
P. falciparum strains. Remarkably, benzylMD 1c exhibited a potent activity against all the 
strains, irrespective of their resistance to chloroquine or quinine or to any other 
antimalarial drug (e.g. mefloquine, monodesethylamodiaquine or pyrimethamine, see 
Appendix, Table A3). The IC50 values ranged from 41 nM (FCM29) to 215 nM (W2) for 
benzylMD 1c, from 21 nM (3D7) to 829 nM (FCM29) for chloroquine and from 62 nM 
(D6) to 684 nM (Bres) for quinine (Figure 1). Interesting to note is that benzylMD 1c 
showed the highest activity against FCM29, the most resistant strain to chloroquine.  
A table listing all IC50 and IC90 values of benzylMD 1c, chloroquine and quinine is given 
in the Appendix (Table A4).  
 
 
Figure 14  In vitro antimalarial activity of benzylMD 1c, chloroquine and quinine against twelve drug-sensitive or 
drug-resistant P. falciparum strains originating from Asia, Africa or South America 
Antimalarial activity (presented as IC50 values) was determined on P. falciparum blood-stage parasites using the  
3
H-hypoxanthine incorporation assay. The chemosusceptibility profiles and multi-drug resistance phenotypes of the 
strains are given in the Appendix (Table A3). Strains are ordered according to increasing degree of chloroquine 
resistance. Results are presented as mean IC50 values ± 95% confidence interval from 3 - 5 independent growth-
inhibition assays. Collective IC50 and IC90 values of all agents are given in the Appendix (Table A4). Results were kindly 
provided by Dr. Bruno Pradines, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France. 1c, 
benzylMD 1c; CQ, chloroquine; I, intermediate; R, resistant; RS, reduced susceptibility; QN, quinine.  
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To reveal a possible in vitro cross-resistance between benzylMD 1c and clinical 
antimalarials, a correlation analysis of the in vitro drug responses of the twelve 
P. falciparum strains was performed. Four clinical antimalarial compounds were selected, 
namely chloroquine, quinine, monodesethylamodiaquine and mefloquine. A table listing 
all IC50 values of these antimalarial agents is given in the Appendix (Table A4). In vitro 
cross-resistance is indicated by a positive correlation between the IC50 values of two 
antimalarial agents and is estimated with the coefficient of correlation (rs, Spearman 
nonparametric correlation coefficient). The correlation coefficient quantifies the direction 
and strength of correlation and ranges from -1 (i.e. strong negative correlation) over 0  
(i.e. no correlation) to +1 (i.e. strong positive correlation). The correlation analysis was 
conducted in GraphPad Prism by pairwise correlation of the IC50 values of benzylMD 1c 
and four antimalarials as previously described (Briolant et al, 2010; Pradines et al, 2010).  
Strikingly, no significant correlation could be determined between the in vitro responses of 
all P. falciparum strains to benzylMD 1c and to antimalarials chloroquine, quinine, 
monodesethylamodiaquine or mefloquine (Table 2).   
Table 2  Correlation of in vitro responses of twelve P. falciparum strains to lead benzylMD 1c and 
clinically used antimalarials 
Correlation of in vitro response to drug pairs rs  P value Significance 
BenzylMD 1c Chloroquine -0,08392 0,8004 NS 
BenzylMD 1c Quinine 0,3217 0,3085 NS 
BenzylMD 1c MDAQ -0,01399 0,9739 NS 
BenzylMD 1c Mefloquine 0,08392 0,8004 NS 
Chloroquine Quinine 0,6503 0,0257 S 
Chloroquine MDAQ  0,9161 < 0,0001 S 
Quinine MDAQ 0,5455 0,0708 NS 
Correlation of in vitro responses of P. falciparum strains to lead benzylMD 1c and clinical antimalarials was determined by 
pairwise correlation of mean IC50 values using the nonparametric Spearman correlation. Results are presented as 
coefficient of correlation (rs) and statistical p value. IC50 values for benzylMD 1c and antimalarial agents are given in the 
Appendix (Table A4). The IC50 values were kindly provided by Dr. Bruno Pradines, Institut de Médecine Tropicale du Service 
de Santé des Armées, Marseille, France. MDAQ, monodesethylamodiaquine; rs,  Spearman nonparametric correlation 
coefficient; S, significant; NS, not significant.   
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In accordance with previous studies, a significant positive correlation was found for 
chloroquine and quinine (rs = 0.6503, p < 0.05), as well as chloroquine and 
monodesethylamodiaquine (rs = 0.9161, p < 0.0001) (Briolant et al, 2010; Pradines et al, 
2010). In contrast, the reported positive correlation of in vitro responses to quinine and 
monodesethylamodiaquine was not confirmed in the current analysis. This might be 
explained by a higher number of P. falciparum strains analyzed in the previous studies. 
In conclusion, benzylMD 1c presented a high activity against multiple drug-sensitive and 
drug-resistant strains. The statistical correlation analysis revealed the lack of in vitro cross-
resistance to a set of clinical antimalarials. Based on this analysis, the observed variation of 
benzylMD 1c’s IC50 values (41 nM to 215 nM) might be attributable to natural phenotypic 
variations of the tested P. falciparum strains.  
The presented results on in vitro activity of lead benzylMD 1c against multiple drug-
resistant P. falciparum strains and cross-resistance with four clinical antimalarials are 
currently prepared for publication (Ehrhardt et al, in preparation).   
 
3.1.3 Structure-activity relationships of benzylMD derivatives 
The first series of antimalarial benzylMD derivatives, represented by benzylMD 1a and 1c, 
were synthesized in only one step starting from menadione and phenylacetic acid 
derivatives, in a silver-catalyzed radical decarboxylation reaction (Müller et al, 2011). 
While numerous phenylacetic acid derivatives are commercially available, this is only the 
case for two menadione derivates, which highly limits the spectrum of functional groups 
on the menadione core at varying R1 groups (see Figure 15). To overcome this limitation, 
a versatile, regioselective and high yielding synthetic methodology was established that 
allows building of polysubstituted menadione cores for a fast synthesis of benzylMD 
derivatives. This new synthesis methodology is currently prepared for publication and will 
not be described in this work (Cesar-Rodo et al, in preparation; Urgin et al, in preparation). 
It is worth mentioning that the medicinal chemistry team in Strasbourg first aimed at 
establishing the synthetic methodologies, to prepare polysubstituted benzylMD derivatives 
and predicted benzylMD metabolites, before screening benzylMD derivatives for detailed 
structure-activity relationships.  
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The derivatization of the benzylMD core was performed based on the structures of the first 
hit (benzylMD 1a) that harbours a bromide group and the lead compound benzylMD 1c 
that contains a triﬂuoromethyl group. Figure 15 illustrates the structure of a non-substituted 
benzylMD core with numeration of positions for derivatization as well as the structures of 
benzylMD 1a and 1c. 
 
 
Figure 15  Structures of a non-substituted benzylMD, first hit benzylMD 1a and lead compound benzylMD 1c 
 
A series of recently synthesized compounds was tested during this doctoral thesis on their 
in vitro antimalarial activity against cultured parasites of the P. falciparum Dd2 strain 
(expressed as IC50 values).  
As a first attempt, a methyl group was introduced on positions 5, 6, 7 or 8 to identify 
tolerant positions for derivatization (see Figure 15). The IC50 values are presented in the 
Appendix (Table A8). To conclude, positions 6 and 7 are the most tolerant towards 
substitutions. Those derivatives (EC019, EC020, EC146, EC145) showed acceptable 
antimalarial activities with IC50 values below 1 µM. Introduction of a methyl group on 
other positions (5 or 8 or 6 and 7) rendered the compounds inactive, reflected in IC50 
values in the micromolar range (2 µM to 4 µM).  
The next set of derivatives was synthesized containing a fluorine atom or a diethyl-
phosphate at positions 6 or 7. Substitution with a fluorine atom increases the lipophilicity 
of the compound and furthermore renders it more resistant to oxidation by cytochrome 
P450 (CYP450) enzymes in the human liver. The latter group increases compound 
solubility in aqueous mediums. The IC50 values of those compounds are presented in the 
Appendix (Table A9). Substitution with a fluorine atom at C6 or C7 showed no effect on 
the IC50 values, while 6- and 7-diethyl-phosphate-benzylMD 1c analogues were slightly 
less active than the parent compound benzylMD 1c.  
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The intention for the third set of compounds was to synthesize benzylMD 1a and 1c 
derivatives with increased metabolic stability in the human liver. This is attempted by 
derivatization of the phenyl ring of the benzyl chain, which hinders the attack of CYP450 
enzymes. These modifications caused only little alterations of the in vitro antimalarial 
activities, the IC50 values are presented in the Appendix (Table A10). Drug metabolism 
studies with human liver microsomes are currently ongoing.  
Group 4 of the benzylMD derivatives comprises structures substituted with methoxy 
groups at different positions. Precursor material containing methoxy groups are very 
cheap. Again, position 6 was found to be very tolerant for modification, while 
methoxylation of position 7 appeared to disturb the antimalarial activity of the final 
compounds. The IC50 values are presented in the Appendix (Table A11). 
The objective for the next set of compounds was the introduction of a protonable  
N-dimethyl or N-diethyl group as found in the antimalarials chloroquine and methylene 
blue. According to their example, the compounds should be trapped inside the digestive 
vacuole and thereby hinder the shuttling and possibly redox cycling of benzylMD 
derivatives. To conclude, most of these compounds presented a moderate in vitro activity 
with IC50 values in the range of 300 nM to 500 nM. One might speculate that the 
antimalarial activity stems from inhibition of hematin formation in the digestive vacuole. 
The IC50 values are presented in the Appendix (Table A12).  
The last group of compounds contains putative metabolites of benzylMD 1c (EC195, 
EC199, EC277), their synthetic intermediates (EC172, EC197) and “blocked” metabolites 
(EC276, EC279, EC285). These compounds were primarily synthesized for an extensive 
study of intracellular drug metabolisms (in terms of metabolite formation by redox-
cycling) by a mass spectrometry approach.  
In conclusion, the presented data (IC50 values) on in vitro antimalarial activity of 
benzylMD derivatives will be used together with their chemical and electro-
physicochemical properties to generate a virtual library and database for 
chemoinformatics. In addition, benzylMD derivatives with promising in vitro activities 
will be selected for further in vivo activity and pharmacokinetic studies. The results 
presented in this section are currently prepared for publication (Cesar-Rodo et al, in 
preparation; Urgin et al, in preparation).   
RESULTS 
73 
3.2 Detailed characterization of benzylMD 1c’s in vitro activity profile  
Drug development for malaria treatment is a rather complex process that is not only 
challenged by the changing parasite landscape (i.e. emergence of drug resistance) but also 
has to adapt to strategies of malaria control and elimination, developed by the WHO and 
leading experts of the scientific community (e.g. represented by malEra or MMV) (for 
instance mal, 2011; Burrows et al, 2013). In the recent years, the scientific community has 
provided several robust in vitro methodologies and frameworks in order to standardize 
drug development in academic research (Ding et al, 2012; Sanz et al, 2012; Burrows et al, 
2013). Worth mentioning is the research and development portfolio, published by MMV, 
that informs about essential experiments and data required at different stages of the drug-
development process (MMV).  
There are several features of a drug’s activity profile that are important to be characterized 
during the early phase of drug development (i.e. lead evaluation stage). Speed of action 
and stage specificity will help to estimate clinical efficiency in patients (Sanz et al, 2012). 
Furthermore, together with pharmacokinetic properties, the speed of action will determine 
whether a drug will be used for acute treatment or chemoprotection. Assessing the risk of 
in vitro resistance selection will help to estimate whether the effectiveness of a drug will be 
compromised easily by resistance development in the field. The risk of resistance 
development is further minimized by using drug combinations, which again renders the 
drug development more complex and time consuming.  
3.2.1 Stage specificity of benzylMD 1c action 
Depending on their mode of action, most antimalarials express a particular stage specificity 
by acting at different time points during the intraerythrocytic development of the parasite. 
Most of the antimalarials currently in use act against the trophozoite or schizont stages 
with the rare exception of artemisinin that effectively kills ring-stage parasites. In the last 
years, ring stages have obtained increasing attention as promising drug target to 
circumvent the adhesion of trophozoite-infected erythrocytes and related symptoms but 
also to decrease the formation of gametocytes, which differentiate from this stage. Two 
other events of the asexual development, namely schizont rupture and merozoite invasion, 
are suitable drug targets but technically challenging and therefore not yet fully exploited 
(Wilson et al, 2013). Knowing a drug’s preferential target stage(s) contributes to 
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understand its mode of action and will help to estimate clinical efficiency in patients (Sanz 
et al, 2012). The experiments on stage specificity of benzylMD 1c were conducted at the 
Museum National d’Histoire Naturelle in Paris. The culture conditions are described in the 
Materials and Methods chapter (see section 2.2.1.1). In these conditions, 3D7 parasites 
fulfill their development in 48 hours, although faster development was reported in other 
studies. Dr. Christiane Deregnaucourt 
8
 kindly contributed to the preparation, execution 
and analysis of the experiments presented in this section.  
3.2.1.1 BenzylMD 1c’s activity throughout the course of the intraerythrocytic 
parasite development 
In order to reveal the preferential target stage(s) of benzylMD 1c, its activity profile was 
explored throughout the course of the intraerythrocytic parasite development. Therefore, 
highly synchronous P. falciparum 3D7 parasites were transiently incubated with 
benzylMD 1c concentrations representing 1×IC50, 5×IC50 and 10×IC50 values for 
consecutive 8-hour periods (with the exception of a first, 4-hour period). Subsequently, 
cells were washed, resuspended in drug-free medium and maintained until reinvasion was 
completed. The parasite development under drug treatment was assessed by counting 
parasitemia after reinvasion on Giemsa-stained blood smears. The cultures were treated in 
the same way with chloroquine as a control agent.  
The stage-specific activity of benzylMD 1c was clearly different from that of chloroquine, 
with young ring stages being the most sensitive to the drug. The strongest inhibition of 
parasite development was observed after incubation of young ring stages for 8 hours (aged 
8 h-16 h p.i.) with 5×IC50 and 10×IC50 concentrations of benzylMD 1c (~60% and ~80% 
inhibition, respectively, Figure 16B, plot b). Remarkably, inhibition by benzylMD 1c was 
detected also after short (4-hour) incubation of even younger parasites (aged 4 h-8 h p.i.) 
(~40% and ~55% inhibition, respectively, Figure 16B, plot a), whereas a 4-hour 
application of chloroquine had no effect on the development of such young ring-stage 
parasites. In these experimental conditions, parasites older than 12 h-16 h p.i. were not 
sensitive to benzylMD 1c when incubated for 8 hours with the same concentrations of the 
drug: inhibition of reinvasion did not exceed 20%; only reinvasion of the 10×IC50-treated 
schizonts was inhibited by approximately 35% (Figure 16B, plot f).  
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Figure 16  Stage-specific activity of benzylMD 1c and CQ over the course of P. falciparum’s intraerythrocytic life cycle 
Stage-specific activity was explored on highly synchronous P. falciparum 3D7 parasites by transient incubations with 
drug concentrations representing multiples of the IC50 concentrations (×IC50, x-axes). Drugs were applied on individual 
parasite stages starting 0-4 hours p.i. as illustrated in the pictures. Parasite development was assessed by counting 
parasitemia after reinvasion on Giemsa-stained blood smears. Parasite growth in percent (%, y-axes) was calculated 
based on a corresponding untreated control culture (dark blue) and is presented as mean and standard deviation from 
4 independent experiments (i.e. 4 independent cultures assessed in parallel). (A) Parasite growth after treatment with 
benzylMD 1c (purple) or CQ (blue) for full duration of parasite development (48 hours). (B a-f) Parasite growth after 
treatment with benzylMD 1c (purple) or CQ (blue) for short time periods of 4 hours (a) or 8 hours (b-f). In all plots, the 
x-axes represent drug concentrations (×IC50) and the y-axis represents parasite development (%), as exemplified by 
plot A. 1c, benzylMD 1c (purple); Cont, control culture (dark blue); CQ, chloroquine (blue); h; hours. Scale bar: 1 µm 
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Results obtained from chloroquine treated parasites were in good accordance with the well 
known specificity of chloroquine against the trophozoite stage. As expected, transient 
application of chloroquine (5×IC50 and 10×IC50) on trophozoites fully prevented parasite 
development (Figure 16B, plot d and e), whereas application on rings (Figure 16B, plot b 
and c) and schizonts (Figure 16B, plot f) inhibited parasite development only slightly.  
The selected IC50 values for benzylMD 1c and chloroquine, were experimentally validated 
a posteriori by measurement of the re-invasion rate after a full cycle (48 h) application of 
the drugs: 48 hours application of the 1×IC50 concentration of benzylMD 1c inhibited 
reinvasion by around 50%, whereas the 1×IC50 concentration of chloroquine induced 
almost 60% inhibition (Figure 16A). Given that chloroquine concentrations were slightly 
too high, the effect of the drug on the different parasite stages might be overestimated and 
the difference between trophozoites and the other stages artificially reduced. Though, it 
may be important to note that short time incubations with chloroquine showed generally 
higher effects on parasite development than with benzylMD 1c.  
Overall, these results demonstrated that chloroquine and benzylMD 1c act on different 
blood stages, early ring-stage parasites being the preferential target of benzylMD 1c.  
 
3.2.1.2 BenzylMD 1c’s activity against early or late developmental stages 
In order to assess whether benzylMD 1c targets young ring stages either preferentially or 
exclusively, its ability to inhibit the development of the mature parasite stages 
(i.e. trophozoites and schizonts) was tested by incubating rings or trophozoites with high 
drug concentrations for an extended period of time. Therefore, highly synchronous 
P. falciparum 3D7 parasites were transiently incubated with benzylMD 1c concentrations 
representing 1×IC50, 5×IC50, 10×IC50 and 50×IC50 values for 22-24 hours starting at the 
ring stage (aged 0 h - 4 h p.i.) or at the trophozoite stage (aged 20 h – 24 h).  
Using longer incubation times, it became clear that benzylMD 1c activity was not 
restricted to early stages but occurred during the entire intraerythrocytic life cycle. A major 
inhibition (approx. 60%) of ring stage development was achieved using 1×IC50 
concentrations; whereas 5×IC50 concentrations were necessary to observe the same effect 
on trophozoite and schizont stages (Figure 17). Similarly, a two-fold higher drug 
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concentration was required to fully inhibit development of mature parasites (10×IC50) 
compared to ring stages (5×IC50) (approx. 96% each). Interestingly, while a 24-hour 
application of 10×IC50 benzylMD 1c leaded to almost full inhibition of trophozoite and 
schizont development, the same concentration applied for 8 hours had failed to inhibit 
parasites at the same stages (see Figure 16B, plots d-f). Compared to the former 
experiment, prolonged incubation times induced much higher inhibition of parasite 
development, independent of the affected stage. These results thus pointed towards dose 
and time dependent differences in drug susceptibility of individual intraerythrocytic stages.  
 
 
Figure 17  Activity of benzylMD 1c against early or late developmental stages 
Activity of benzylMD 1c on different developmental stages was assessed on highly synchronous P. falciparum 3D7 
parasites by successive incubations with drug concentrations representing multiples of the IC50 concentrations (×IC50). 
BenzylMD 1c was applied either on ring stages (aged 0-4 h p.i.) or on trophozoites (aged 20-24 h p.i.) for a duration of 
22-24 hours. Parasite development was assessed by counting parasitemia after reinvasion on Giemsa-stained blood 
smears. Parasite growth in percent (%) was calculated based on a corresponding untreated control culture (cont) and is 
presented as mean and standard deviation from 3 independent experiments.   
 
3.2.1.3 BenzylMD 1c’s activity on parasite egress or invasion 
Although benzylMD 1c targets primarily young rings (as demonstrated before), a low 
inhibition of schizont development could be observed with high benzylMD 1c 
concentrations (approx. 35% inhibition, 10×IC50 concentration, see Figure 16B, plot f). 
This observation suggests that the drug might also interfere with parasite egress from its 
host cell and / or invasion into new erythrocytes. To test this possibility, a culture highly 
enriched in mature schizonts (i.e. segmenters) was incubated for 8 hours with 5×IC50 and 
10×IC50 concentrations of benzylMD 1c and parasite reinvasion was analyzed by the 
number and proportion of remaining schizonts and newly invaded ring stages at the end of 
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the incubation period. The cysteine protease inhibitor E64 and mycotoxin cytochalasin D, 
an inhibitor of actin polymerization, were used as controls for inhibition of parasite egress 
and invasion, respectively (Bouillon et al, 2013).    
As expected, treatment of mature schizonts with E64 and cytochalasin D resulted in a 
higher number of unruptered schizonts (E64) or a lower number of newly invaded ring 
stages (cytochalasin D), respectively, compared to untreated control cultures. In contrast, 
the number and proportion of schizont and ring stages in benzylMD 1c-treated cultures 
were similar to the controls, indicating that benzylMD 1c had no effect on parasite egress 
or reinvasion. The differences in total parasitemia between the two benzylMD 1c-treated 
cultures (2.7% and 3.6%) and control culture (2.9%) were regarded to be in the range of 
experimental variation (e.g. disposition of culture on 96-well plate, preparation and 
coloration of blood smear).   
 
 
 
Figure 18  BenzylMD 1c activity against parasite egress or invasion 
Activity of benzylMD 1c on parasite egress or invasion was assessed on highly synchronous P. falciparum 3D7 parasites 
by short-time incubation with drug concentrations representing multiples of the IC50 concentrations (×IC50). E64 and 
cytochalasin D (cyt D) were used as controls for inhibition of parasite egress and invasion, respectively. Drugs were 
applied on mature schizonts (segmenters) for a duration of 8 hours to cover the majority of the parasite’s egress and 
invasion process. Subsequently, parasite development was assessed by counting numbers of ring and schizont stages on 
Giemsa-stained blood smears. Results from 3 independent experiments are presented as mean of parasitemia of the 
individual stages in percent (%) plus standard deviation (error bar). Graph demonstrates numbers of ring or schizonts 
stages present in a control culture at the beginning of drug treatment (cont t0) and after drug treatment (cont t8h) for 
comparison of parasite development.  
  
RESULTS 
79 
All together, the results on stage specificity demonstrated a very strong activity of 
benzylMD 1c against ring-stage parasites, especially young ring stages (aged 0-4 h p.i). 
This result is in agreement with the morphology of drug-treated parasite cultures. Indeed, 
several times it was observed that ring-stage parasites developed into residual pyknotic 
bodies (Müller et al, 2011; Ehrhardt et al, 2013) (see also section 3.3.2). Though, it is 
important to note that benzylMD 1c activity was not restricted to these early stages. The 
full arrest of trophozoite and schizont development was observed using longer incubation 
times and higher drug concentrations. As the parasite develops, digestion of host’s 
hemoglobin takes place, generating pulses of reactive oxygen species and redox-active 
heme (see Introduction, section 1.2.2.1). The concomitant destruction of drug molecules 
(e.g. by Fenton reactions) is an important process that has to be considered to explain the 
apparent lower activity of benzylMD 1c in trophozoite and schizont stages (see also 
section 3.3.3.4).  
The results on stage-specific activity of lead benzylMD 1c presented in this section are 
currently prepared for publication (Ehrhardt et al, in preparation).  
 
3.2.2 Speed of action 
The efficiency of antimalarials to decrease blood parasitemia and cure patients is mediated 
in part by their speed of action. Recently, Sanz and colleagues (2012) developed an in vitro 
protocol to examine the speed of action of antimalarials in culture and to calculate the 
parasite reduction ratio as a predictive therapeutic index for clinical efficiency. The 
principle is based on determination of parasite viability in response to incubation with drug 
at a several-fold IC50 concentration for increasing periods of time. Parasite viability is 
assessed by examining re-growth of treated parasites over time. Accordingly, artemisinin 
and related endoperoxides were characterized as very fast acting drugs able to clear 
parasites within 48 hours, whereas atovaquone killed parasites very slowly after an 
extended cytostatic lag phase. Following this protocol, the speed of action (also called 
killing speed) profile of benzylMD 1c was investigated on an asynchronous culture of 
P. falciparum 3D7 parasites. Atovaquone and artemisinin were used as a reference for 
slow- and fast-acting drugs, respectively. Different to the original protocol, a 5×IC50 
concentration of each drug, instead of a 10×IC50 concentration, was used for treatment.  
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A 10×IC50 concentration of benzylMD 1c was shown to fully inhibit parasite development 
within incubation times of only 20-24 hours (please refer to section 3.2.1.2) and was 
therefore considered too high for a treatment period of several days. Please note that the 
results (i.e. number of viable parasites after drug treatment) are presented in logarithmic 
form (log10) as “viable parasites +1” (Figure 19). This presentation was adopted from the 
original protocol (Sanz et al, 2012) since only values greater than zero can be plotted on a 
logarithmic scale. 
BenzylMD 1c showed a very fast speed of action with an almost immediate onset of action 
and a rapid parasite clearance within 72 hours (Figure 19), similar to artemisinin and in 
contrast to the slow acting atovaquone. In contrast to artemisinin, a very short lag phase of 
8 hours was observed for benzylMD 1c, indicating an initial cytostatic drug effect. The lag 
phase describes the time period necessary to reach the maximal killing rate. However, this 
delay was rapidly compensated by the high killing rate observed in the following 40 hours.  
 
 
 
Figure 19  In vitro speed of action profile of benzylMD 1c in comparison to antimalarial agents 
Graph displays numbers of viable parasites in response to drug treatment at 5×IC50 concentrations of lead 
benzylMD 1c (1c), artemisinin (ART) and atovaquone (ATO). Values are presented as mean of two independent 
experiments performed in triplicates and twofold detection of parasite growth on days 21 and 28, each. Error 
bars represent the standard deviation. According to the original protocol, results are presented in logarithmic 
form (log10) as “viable parasites +1” (Sanz et al, 2012).   
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In our experimental set-up using 5×IC50 concentrations of the drug, atovaquone had a very 
pronounced lag phase of 72 hours and could not clear parasitemia within 144 hours. It is 
important to note that the killing speed profiles of atovaquone revealed from 2 independent 
experiments differed importantly from each other. A pronounced lag phase (> 48 hours) 
was observed in both experiments, but complete clearance of drug-treated parasites was 
only achieved in one experiment.  
The parasite reduction ratio (PRR) accounts for the decrease of viable parasite numbers 
over 48 hours (i.e. one parasite’s life cycle) in the phase of maximal killing speed. The 
PRR was 10
4.8
 parasites for benzylMD 1c, 10
5
 parasites for artemisinin and 10
1.6
 parasites 
for atovaquone (presented as log10 in Table 3). The parasite clearance time (PCT) describes 
the time needed to kill 99.9% of the initial parasite load. The PCT was determined by a 
linear regression of the time-response curve. Clearance of 99.9% parasites by 
benzylMD 1c was achieved after 36 hours and thereby close to artemisinin, which was 
slightly faster (30 hours). In contrast, atovaquone exhibited substantially delayed clearance 
with a PCT of 115 hours (Table 3). In conclusion, benzylMD 1c showed a very fast speed 
of action close to that of the endoperoxide artemisinin and can therefore be counted among 
the fastest compounds described so far in vitro (Sanz et al, 2012). 
Table 3  Parameters of in vitro speed of action: lag phase, parasite 
reduction ratio (PRR) and parasite clearance time (PCT) 
Agent Lag phase (h) Log(PRR) 99.9% PCT (h) 
Artemisinin 0 5.0 30 
BenzylMD 1c 8 4.8 36 
Atovaquone 72 1.6 115 
 
 
The results on benzylMD 1c’s in vitro speed of action presented in this section are 
currently prepared for publication (Ehrhardt et al, in preparation).  
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3.2.3 Parasite resistance development 
The rapid development of parasite resistance to new drugs is a major challenge in 
antimalarial drug design. Several in vitro protocols have been successfully used to 
reproduce resistance development observed in patients and to investigate the genetic basis 
and the molecular mechanisms underlying resistance (reviewed in Nzila & Mwai, 2010; 
Witkowski et al, 2010). It is considered as highly important to assess the risk of de novo 
resistance development as early as possible during drug development (Nzila & Mwai, 
2010; Sanz et al, 2011; Ding et al, 2012). In the frame of this thesis, two different 
experimental settings were selected in order to (I) estimate the risk of resistance 
development under benzylMD 1c treatment and (II) select for drug-adapted parasites as a 
tool to investigate the underlying mechanism.  
Experiments on resistance development were performed with the P. falciparum Dd2 strain, 
owing to its ability to easily acquire resistance to drugs under in vitro conditions, 
commonly designated as accelerated resistance to multiple drugs (ARMD) phenotype 
(Rathod et al, 1997; Trotta et al, 2004; Castellini et al, 2011). The ARMD phenotype was 
linked to a defective DNA repair machinery, which could explain the acquisition of 
beneficial point mutations under drug pressure (Castellini et al, 2011). The results on in 
vitro parasite-resistance development under benzylMD 1c-treatment presented in this 
section are currently prepared in modified form for publication (Ehrhardt et al, in 
preparation).   
3.2.3.1 Risk of de novo resistance development 
The intrinsic potential of benzylMD 1c to induce parasite resistance was assessed by 
continual exposure of blood-stage parasites to lethal drug concentrations, based on the 
method established by Rathod and colleagues (1997). By using different parasite inocula, 
this experiment allows to determine the minimum number of parasites necessary for the 
development of resistant mutants (so-called frequency of resistance selection).  
Therefore, a series of P. falciparum Dd2 blood-stage cultures with high parasite inocula 
(10
8
, 10
7
, 10
6
, 10
5
 infected erythrocytes) were maintained in the presence of 5×IC50 or 
10×IC50 concentrations of benzylMD 1c (i.e. approx. 2×IC90 and 4×IC90 concentrations). 
Similar to the original protocol (Rathod et al, 1997), 5-fluoroorotate treatment (100 nM) 
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was used as a positive control. For each condition, two independent cultures of 
synchronous ring-stage parasites were established from individual stock cultures.  
During the first 2 days of benzylMD 1c treatment, some parasites were able to continue 
their development, as observed by the formation of schizonts. The major developmental 
arrest occurred at the ring stage, which is in agreement with benzylMD 1c’s stage 
specificity profile (section 3.2.1). After 5 days of continuous drug pressure, no living 
parasites were observed in any treated culture. Dead parasites presented a distinct 
condensed (i.e pyknotic) morphology that was first described by Dr. C. Deregnaucourt (in 
Müller et al, 2011) (see also section 3.3.2). It is interesting to note that erythrocytes 
harbouring such pyknotic parasites were present for several days and did not undergo lysis, 
as observed during a morphological study on benzylMD 1c treated parasites (see also 
section 3.3.2). 
Over 12 weeks of continuous drug pressure, no living parasites reappeared in any of the 
benzylMD 1c-treated cultures (Table 4). In contrast, upon 5 weeks of 5-fluoroorotate 
treatment, parasites were able to grow under drug pressure in all cultures, indicating that 
drug treatment had raised resistant parasites (Table 4). Control cultures treated with  
5-fluoroorotate were subsequently discarded without further investigation. By the end of 
week 12, cultures treated with benzylMD 1c were washed and maintained drug free for 
another 4 weeks to allow the proliferation of possibly retained tolerant parasites (see 
following section).  
Table 4  Frequency of resistance to benzylMD 1c or 5-fluoroorotate 
Initial parasite population 
(iRBC per flask) 
100 nM 
5-fluoroorotate 
250 nM (5×IC50) 
benzylMD 1c 
500 nM (10×IC50) 
benzylMD 1c 
10
8
 2 / 2 0 / 2 0 / 2 
10
7
 2 / 2 0 / 2 0 / 2 
10
6
 2 / 2 0 / 2 0 / 2 
10
5
 2 / 2 0 / 2 0 / 2 
Ratios represent the number of flasks yielding growing parasites after 12 weeks of drug treatment, divided by the 
number of initial cultures. iRBC, infected red blood cells. 
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Other studies using the same experimental setup reported a high frequency of spontaneous 
resistance for the antimalarial atovaquone (Rathod et al, 1997) and a lead cyclopropyl 
carboxamide (GSK2645947, Sanz et al, 2011). 
 
Induction of parasite dormancy 
At that time, recent studies with the first line antimalarial artemisinin reported the ability of 
parasites to tolerate drug pressure by arresting their cell cycle (Witkowski et al, 2010). 
Upon drug removal, some parasites succeeded in reactivating their cell cycle and continue 
development. Interestingly, these parasites did not present a decreased susceptibility to 
artemisinin, as reflected in their IC50 values. This phenomenon was originally described as 
“quiescence” (Witkowski et al, 2010) but is today generally designated as “dormancy” 
(Teuscher et al, 2012; Witkowski et al, 2013b). Only recently, novel phenotypic assays for 
the evidence of drug-induced cell cycle arrest were developed (Witkowski et al, 2013b) 
(see also Discussion, section 4.1.4).  
Based on the observations of Witkowski et al. (2010), the question arose whether parasites 
could similarly tolerate benzylMD 1c drug pressure and continue their development upon 
drug release. To address this possibility, cultures of the P. falciparum Dd2 strain that had 
been treated continuously for 12 weeks with high benzylMD 1c concentrations were 
further maintained without drug treatment for another 4 weeks. Therefore, cells were 
washed twice and resuspended in drug-free medium.  
Three weeks after benzylMD 1c removal, growing parasites were observed in 2 of 
16 flasks (Table 5). These cultures initially contained high parasite inocula (10
8
 and 10
7
 
infected erythrocytes, respectively) and were, surprisingly, both treated with the highest 
(10×IC50) benzylMD 1c concentration. No more growing parasites were observed in any 
other culture over the last week of the experiment. Those cultures with no re-emerging 
parasites were discarded at the end of the 4-weeks period.  
RESULTS 
85 
Table 5  Frequency of reappearing parasites after removal of benzylMD 1c drug pressure 
Initial parasite population 
(iRBC per flask) 
250 nM (5×IC50) 
benzylMD 1c 
500 nM (10×IC50) 
benzylMD 1c 
10
8
 0 / 2 1 / 2 
10
7
 0 / 2 1 / 2 
10
6
 0 / 2 0 / 2 
10
5
 0 / 2 0 / 2 
Ratios represent the number of flasks yielding growing parasites within 4 weeks after drug removal, 
divided by the number of initial cultures. Initially, cultures were treated continuously with specified 
benzylMD 1c concentrations for a total period of 12 weeks. No living parasites were observed during 
this time.  
Parasites from the 2 positive flasks were allowed to grow to a higher density in order to 
assess their susceptibilities to benzylMD 1c. They showed no altered susceptibilities to 
benzylMD 1c or to the control drug chloroquine. The IC50 values were comparable to the 
ones determined before drug selection and to that of a culture of Dd2 parasites assessed in 
parallel (Table 6).  
Table 6  Susceptibility of reappearing parasites to benzylMD 1c  
 
Antimalarial agent IC50  ± SD (nM) 
Culture benzylMD 1c chloroquine  
Flask 1 (10
8
) 71 ± 22  93 ± 15  
Flask 2 (10
7
) 69 ± 25  92 ± 7  
Control Dd2 67 ± 9  111 ± 22  
IC50 values are presented as mean ± standard deviation (SD) determined from 3 independent 
experiments using the SYBR® green technique.  
In conclusion, this experiment clearly showed that benzylMD 1c has a very low potential 
to induce drug resistance of cultured blood-stage parasites. This was proven with two 
different lethal concentrations, representing 5×IC50 and 10×IC50 concentrations. A 
reappearance of growing parasites was observed in 2 of 16 cultures (2 of 20 flasks in total) 
upon drug release. However, these parasites showed no altered susceptibility to 
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benzylMD 1c as reflected in their IC50 values. Whether these parasites acquired a tolerance 
mechanism, as it was shown for artemisinin, would need further investigation.   
A second observation on parasite dormancy was attained during the experiment on 
generation of drug-adapted parasites (see section 3.2.3.2). In this experiment, a culture of 
parasites (drug-adapted Dd2
MD1
 F3) was maintained in the presence of sublethal 
benzylMD 1c concentrations (800 nM corresponds to approx. 1×IC90 concentration). 
Similar to the cultures challenged with 5×IC50 or 10×IC50 concentrations (described 
above), no living parasites were observed over 12 weeks culturing with constant drug 
pressure. In order to test for the reappearance of dormant parasites, cells were washed and 
cultures were maintained without drug treatment for further 4 weeks. In contrast to the 
cultures challenged with 5×IC50 or 10×IC50 concentrations (described above), these 
4 cultures revealed no growing parasites upon drug removal (section 3.2.3.2). 
 
3.2.3.2 Selection of drug-adapted parasites 
In vitro selection of drug-resistant parasites provides a powerful tool for the investigation 
of genetic or molecular determinants accounting for resistance development. In patients, 
parasites are often exposed to inappropriately low (i.e. sublethal) drug concentrations, 
which are regarded to favor the selection of resistant parasites (White & Pongtavornpinyo, 
2003). Consequently, the second experiment on resistance development intended to induce 
adaptation or resistance to benzylMD 1c by exposing a high parasite inoculum to sublethal 
drug concentrations (modified after Beez et al, 2011).  
For selection of drug-adapted parasites, a culture of P. falciparum strain Dd2 with high 
parasite inoculum was maintained in the presence of sublethal concentrations of 
benzylMD 1c until the reappearance of normally growing parasites under drug pressure. 
Subsequently, concentrations for drug pressure were increased according to the altered 
susceptibility of drug selected parasites. BenzylMD 1c concentrations for selection were 
chosen in the order of the IC90 concentration of the respective parasite population.  
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First selection cycle: 
The selection of drug-adapted parasites was initiated from a culture of synchronous ring 
stage P. falciparum strain Dd2 with high parasite inoculum (3.6 × 10
9
 iRBC). The initial 
culture was challenged with 125 nM of benzylMD 1c. The mean IC50 and IC90 values of 
benzylMD 1c on original Dd2 parasites, as assessed prior to drug selection, were 51 nM 
and 138 nM, respectively (see Appendix, Table A5). During the first week of drug 
treatment, parasites continued to multiply and therefore the initial culture was divided 
stepwise into 5 culture flasks that were subsequently treated identically.  
Parasites were slowly killed over the first 10-14 days of drug treatment, as monitored on 
Giemsa-stained blood smears. After 5 weeks of continuous drug pressure, living parasites 
reappeared in 2 of 3 flasks, indicating successful adaptation of parasites to drug pressure. 
Drug-adapted parasites (hereafter designated Dd2
MD1
 F2 and F3 
9
) were allowed to grow to 
a higher density before dividing the cultures in halves. One part of the culture was 
maintained in the presence of benzylMD 1c in order to initiate a second selection cycle. 
The other half was further cultured without drug pressure in order to assess the 
susceptibility of drug-selected parasites to benzylMD 1c. At the same moment, several 
samples of parasites were prepared for cryopreservation. The 3 remaining cultures were 
discarded; two because of bacterial contamination, while the last one did not reveal living 
parasites.  
The susceptibility of drug-selected parasites (Dd2
MD1
 F2 and F3) was regularly assessed 
over a period of 6 weeks after treatment stop. Over the first 3 weeks after drug removal, 
both parasite cultures Dd2
MD1
 F2 and F3 showed a 3-4 fold decreased susceptibility to 
benzylMD 1c compared to progenitor Dd2 parasites, indicating successful adaptation of 
parasites to drug pressure. The measured IC50 values were 162 nM (Dd2
MD1
 F2) or 208 nM 
(Dd2
MD1
 F3) and the IC90 values 703 nM (Dd2
MD1
 F2) and 983 nM (Dd2
MD1
 F3) (Table 7). 
It is important to note that the IC50 values determined post-selection were only slightly 
higher than the benzylMD 1c concentration used for selection. The susceptibility to 
chloroquine was unaffected compared to original Dd2 parasites (see Appendix, Table A5). 
Cultures Dd2
MD1
 F2 and F3 were used to initiate a 2
nd
 selection cycle using higher drug 
concentrations (see below).   
                                                          
9
 Drug adapted parasites, raised after the 1
st
 selection cycle with 125 nM benzylMD 1c, were designated as 
follows: Dd2
MD1
 F2 or F3. This denotation stands for: Dd2, progenitor parasite strain; MD, selected with 
benzylMD 1c; 1, 1
st
 selection cycle; F2, F3, growing parasites were recovered from flasks number 2 and 3.  
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However, the described phenotype was not stable over time. Around 4 weeks after 
treatment stop, parasites no longer presented altered susceptibilities to benzylMD 1c. The 
IC50 values measured 4-6 weeks after drug removal were comparable to the ones 
determined before drug selection and to a culture of Dd2 parasites that was assessed in 
parallel (Table 7 and Table A5, Appendix).  
Table 7  Susceptibility of drug-adapted parasites to benzylMD 1c after 1
st
 selection cycle 
 
Weeks 1-3 after drug removal Weeks 4-6 after drug removal 
Culture IC50 (nM) ± SD IC90 (nM) ± SD IC50 (nM) ± SD IC90 (nM) ± SD 
Dd2
MD1
 F2 162 ± 15 (3) 703 ± 250 (3) 52 ± 9 (2) 105 ± 21 (2) 
Dd2
MD1
 F3 208 ± 17 (3) 983 ± 125 (3) 57 ± 0,4 (2) 110 ± 14 (2) 
Dd2 55 ± 20 (3) 180 ± 52 (3) 
  
Susceptibility to benzylMD 1c was assessed on Dd2MD1 parasites after removal of drug pressure and over a total period 
of 6 weeks. Susceptibility of progenitor Dd2 parasites was assessed in parallel. IC50 and IC90 values are presented as 
mean ± standard deviation (SD) determined from (n) independent experiments using the SYBR® green technique.  
Culturing of drug-adapted parasites Dd2
MD1
 F2 and F3 under continuous drug pressure was 
attended by difficulties. At first, parasites showed a normal multiplication rate under drug 
treatment (no quantification of multiplication rate performed). However, after several 
cycles, parasites started to suffer visibly and died. Parasites died particularly fast in 
cultures with low parasite inoculum concentrations (e.g. culture dilution before weekends). 
This observation might indicate a selective uptake of the drug by infected erythrocytes, a 
so-called inoculum effect, that was previously reported for other antimalarial drugs  
(e.g. chloroquine and artemisinin derivatives) (Gluzman et al, 1987; Duraisingh et al, 
1999).  
The 1
st
 selection cycle was independently repeated with a culture of synchronous ring 
stages of progenitor Dd2 parasites with high parasite inoculum (3.6 × 10
9
 iRBC). The 
initial culture was challenged with 125 nM of benzylMD 1c. During the first week of drug 
treatment, parasites continued to multiply to high parasitemia. Consequently, drug 
concentration was increased to 150 nM and the cultures were divided into 6 culture flasks 
in total that were subsequently treated identically. This selection cycle revealed growing 
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parasites in all 6 culture flasks. Similar to the first experiment, parasite susceptibility to 
benzylMD 1c was 3-4 fold decreased (IC50 values ranging from 104 nM to 223 nM, IC90 
values ranging from 227 nM to 947 nM, Table A6 in the Appendix). The IC50 values 
measured on different days varied importantly and most cultures were difficult to maintain. 
For the latter reason, it was not possible to use drug-adapted parasites for further 
experiments or another selection cycle. In conclusion, the independent repetition of the 
1
st
 selection cycle confirmed the selection of drug-adapted parasites with 3-4 fold decrease 
in susceptibility to benzylMD 1c.    
 
Second selection cycle:  
A 2
nd
 selection cycle with increased benzylMD 1c concentrations was initiated from 
cultures Dd2
MD1
 F2 and F3. Therefore, parasites were allowed to grow to a high density in 
the presence of benzylMD 1c. For Dd2
MD1
 F2 and F3 each, one initial culture of ring-stage 
parasites at high inoculum (1.1 × 10
9
 and 1.1 × 10
9
 infected erythrocytes, respectively) was 
set up and challenged with 550 nM (Dd2
MD1
 F2) or 800 nM (Dd2
MD1
 F3) benzylMD 1c, 
respectively. This culture was subsequently divided into 4 culture flasks that were treated 
identically.  
Parasites were slowly killed over the first 10-14 days of drug treatment, as monitored on 
Giemsa-stained blood smears. The first reappearing parasites were observed after 5 weeks 
in all 4 flasks challenged with 550 nM benzylMD 1c (Dd2
MD1
 F2). However, parasites 
developed very slowly, thus insufficient to perform growth-inhibition assays. After another 
3 - 4 weeks culturing with constant benzylMD 1c concentration, parasites multiplied 
normally in all 4 cultures. Drug adapted parasites are hereafter designated as Dd2
MD2
 F1, 
F2, F3 and F4 
10
. Subsequently, the experiment was proceeded as described before for 
cultures of the 1
st
 selection cycle.  
The susceptibility of the selected parasites (Dd2
MD2
 F1 - F4) was regularly assessed over a 
period of 10 weeks. After the 2
nd
 selection cycle, all selected parasites presented a 4-5 fold 
decreased susceptibility to benzylMD 1c compared to the original Dd2 strain (Table 8). 
                                                          
10
 Drug adapted parasites, raised after the 2
nd
 selection cycle with 550 nM benzylMD 1c, were designated as 
follows: Dd2
MD2
 F1 to F4. This denotation stands for: Dd2, progenitor parasite strain; MD, selected with 
benzylMD 1c; 2, 2
nd
 selection cycle; F1 – F4, growing parasites were recovered from flasks number 1 to 4. 
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Remarkably, parasite adaptation to increased benzylMD 1c concentrations (550 nM) was 
less pronounced than adaptation observed after the 1
st
 selection cycle (125 nM). The IC50 
and IC90 values ranged from 178 nM to 259 nM or from 495 nM to 917 nM, respectively 
(Table 8). Thus, IC50 values were only slightly higher than before selection (Dd2
MD1
 F2, 
Table 7) and moreover, below the benzylMD 1c concentration applied during drug 
pressure (550 nM). This observation could partially explain the slow parasite development 
under drug pressure.  
Similarly to their progenitors (Dd2
MD1
 F2), drug adaptation was not stable over time. This 
time, the reverse of phenotype occurred after 5-6 weeks following drug removal (compared 
to 3 weeks after the 1
st
 selection cycle). Dd2
MD2
 F1 - F4 parasites presented then the same 
susceptibility to benzylMD 1c as before drug selection and compared to a culture of Dd2 
parasites that was assessed in parallel (Table 8 and Table A5 in the Appendix). The 
susceptibility of Dd2
MD2
 F1 - F4 parasites to chloroquine was slightly lower compared to 
Dd2 parasites, though this might be no real effect (Table A5 in the Appendix). The IC50 
values of chloroquine were consistent during the complete duration of the experiment and 
not affected by the reverse of adaptation observed with benzylMD 1c. In addition, 
culturing of parasites under continuous drug pressure was attended by the same difficulties 
as observed for parasites raised after the 1
st
 selection cycle (Dd2
MD1
 F2 and F3).  
Table 8  Susceptibility of drug-adapted parasites to benzylMD 1c after 2
nd
 selection cycle  
 
Weeks 1-6 after drug removal Weeks 7-10 after drug removal 
Culture IC50 (nM) ± SD IC90 (nM) ± SD IC50 (nM) ± SD IC90 (nM) ± SD 
Dd2
MD2
 F1 178 ± 68 (4) 495 ± 306 (4) 74 (1) 170 (1) 
Dd2
MD2
 F2 250 ± 30 (3) 917 ± 76 (3) 90 ± 22 (3) 213 ± 40 (3) 
Dd2
MD2
 F3 197 ± 58 (5) 586 ± 176 (5) 67 ± 18 (3) 145 ± 40  (3) 
Dd2
MD2
 F4 259 ± 63 (5) 812 ± 250 (5) 86 ± 9 (3) 183 ± 42 (3) 
Dd2 63 ± 17 (8) 176 ± 45 (8) 
 
Susceptibility to benzylMD 1c was assessed on Dd2MD2 parasites after removal of drug pressure and over a total period 
of 10 weeks. Susceptibility of progenitor Dd2 parasites was assessed in parallel. IC50 and IC90 values are presented as 
mean ± standard deviation (SD) determined from (n) independent experiments using the SYBR® green technique.   
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In contrast to cultures Dd2
MD1
 F2, Dd2
MD1
 F3 parasites were not able to acquire adaptation 
to high drug concentrations of 800 nM benzylMD 1c. No living parasites could be 
recovered from any of the 4 cultures after 12 weeks of constant drug pressure. 
Subsequently, the drug treatment was stopped; cells were washed and resuspended in drug-
free medium. The cultures were maintained for another 4 weeks without drug pressure to 
allow the reappearance of possibly retained tolerant parasites. However, no living parasites 
appeared in any of the 4 cultures. As described before (section 3.2.3.1), reappearance of 
living parasites upon drug removal was observed after drug pressure with 500 nM 
benzylMD 1c for 12 weeks.  
The protocol used for growth-inhibition assays includes one step to measure the 
background fluorescence of the assay contents (e.g. autofluorescence of compounds) (see 
Materials and Methods, section 2.2.2).  Interestingly, the background fluorescence of drug-
adapted parasites was notably increased compared to progenitor Dd2 parasites. This 
observation was done repeatedly on several days and did not stem from different 
benzylMD 1c concentrations. An increase of autofluorescence yielded from drug-adapted 
parasites might point towards differences in the formation of drug metabolites or heme 
catabolites that are both known to be fluorescent. Alternatively, the signal might stem from 
intrinsic intracellular fluorophores, for instance NAD(P)H and flavoproteins, as reported 
before in a study with Leishmania parasites (Eckers & Deponte, 2012).  
Cloning of drug-adapted parasites: 
It should be assumed that drug selected parasite cultures comprise a mixture of parasites 
with different phenotypes. Accordingly, clonal parasite lines are required to explore the 
basis of altered drug susceptibility. Two cultures, Dd2
MD2
 F2 and F4, were selected for 
further analysis, as they presented the lowest susceptibility to benzylMD 1c, as reflected in 
their IC50 values (Table 8).  
Cloning of drug-adapted parasites was performed by limiting dilution on 96-well plates, 
either in the absence or presence of 550 nM benzylMD 1c. Unfortunately, no parasite clone 
with decreased susceptibility to benzylMD 1c was retained. After 4 weeks of culturing, ten 
clonal parasite lines were obtained in the absence of benzylMD 1c treatment, whereas none 
were obtained in the presence of the drug. These parasites were isolated and frozen for 
further analysis. The drug susceptibility of 3 clonal lines was assessed directly after 
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isolation. The IC50 values of all cultures were comparable to a culture of original Dd2 
parasites that was assessed in parallel (data not shown). This outcome confirmed that drug-
adapted Dd2
MD2 
parasites easily reverted to their original phenotype (as Dd2) upon 
removal of drug pressure as observed before. Cloning of parasites under drug treatment 
was unsuccessful: even after 6 weeks of culturing, no parasitic DNA was detected by 
SYBR
®
 green in any well of the two 96-well plates. Possibly, drug concentration of 
550 nM was too high regarding the very low starting parasitemia of the cloning procedure. 
Once again, this observation would suggest an inoculum effect of benzylMD 1c.  
 
In conclusion, the selection of drug-adapted parasites under continuous exposure to 
sublethal benzylMD 1c concentrations revealed that parasites succeeded at counteracting 
drug pressure, although to a very limited extent. Parasites were able to multiply in the 
presence of up to 550 nM benzylMD 1c but failed to recover from higher drug 
concentrations (800 nM). However, this adaptation was lost after short time upon drug 
release. This observation is similarly reflected in the failure to obtain clonal parasites with 
decreased susceptibility to benzylMD 1c or to recover them after freezing. Several 
attempts to thaw parasites in the presence of different drug concentrations or to apply drug 
pressure only 24 to 48 hours after freezing were unsuccessful, parasites were killed rapidly 
by benzylMD 1c (data not shown). Moreover, no prolonged survival of drug selected 
parasites was achieved under continuous benzylMD 1c treatment, which also prevented to 
recover clonal parasites under drug pressure. Together, these observations suggested a 
selective uptake of benzylMD 1c by infected erythrocytes (inoculum effect). Altogether, 
these results suggest that the decreased susceptibility to benzylMD 1c might be caused by a 
metabolic adaptation rather than a stable genetic mutation.  
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3.2.4 In vitro drug interactions with clinical antimalarial agents 
For treatment of malaria, drug-combination therapies are preferred to monotherapies in 
order to prevent the emergence and spread of drug resistance (White & Olliaro, 1996; 
WHO, 2010). In the search for a possible future co-formulation partner, we investigated 
the in vitro interactions of benzylMD 1c with clinically used antimalarials from different 
subclasses and with different modes of action.  
The interaction profiles were assessed on the P. falciparum 3D7 or K14 strain using the 
fixed-ratio isobologram method (Fivelman et al, 2004). This approach is based on 
determining the IC50 values of two individual drugs alone and the IC50 values of these two 
drugs in combination at different concentration ratios. In principle, the shift of a drug’s 
IC50 value assessed in combination compared to the one determined for this drug alone is 
indicative for the nature of drug-drug interaction. The in vitro interactions were evaluated 
based on arithmetical and graphical analyses.  
For arithmetical analysis, the mean sum of fractional 50% inhibitory concentrations 
(mean ∑ FIC50 value) was calculated based on the shift of a drug’s IC50 value observed  in 
several combinations with a second agent (for more details please refer to Materials and 
Methods, section 2.2.6). The inherent variability of the experimental set-up was estimated 
by combining two separate (or: individual) working solutions of lead compound 1c. Those 
tests revealed a clear indifferent interaction (mean ∑ FIC50: 1.0) with very low variation 
(SD: 0.02, n=3) (Figure 21 A-C). Based on the observed inherent variability, we defined 
the cut-off values for synergistic and antagonistic interactions as follows: Synergy was 
classified as a mean ∑ FIC50 ≤ 0.7, antagonism as a mean ∑ FIC50 ≥ 1.3 and any value in 
between as indifferent interaction (in other words no interaction, formerly described as 
additive interaction). These definitions are in agreement with the ones applied in other 
studies (for instance Bell, 2005; Schleiferbock et al, 2013). Arithmetical results of the 
complete set of combinations are reported in Table 9. Graphical analysis was performed on 
isobolograms, which were established by plotting pairs of FIC50 values of drug A and drug 
B for each combination. Figure 20 illustrates the characteristic isoboles for different drug-
drug interactions, as they have been assessed during this project. A straight line indicated 
an indifferent interaction, a concave curve towards the origin of the axes represented 
synergy and a convex curve towards the opposite indicated antagonism. To provide an 
example for in vitro synergy, the partners of the antimalarial co-formulation Malarone
®
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(atovaquone and proguanil, GlaxoSmithKline) were tested in combination. Indeed, the 
interaction between atovaquone and proguanil was found to exhibit the strongest synergy 
amongst all the tested combinations, with a mean ∑ FIC50 of 0.2 (Table 9) and a 
characteristic concave shaped isobole (Figure 21A).   
 
 
Figure 20  Isobologram illustrating characteristic curves (“isoboles”) for different in vitro drug-drug interactions  
Interaction profiles were assessed on P. falciparum 3D7 strain according to the fixed-ratio isobologram method.  
Indifferent interaction is indicated by a straight line, synergy by a concave curve and antagonism by a convex curve. 
Graph displays pairs of FIC50 values of compound A (x axis) and compound B (y axis) tested at different combinations. 
Depicted isoboles are representative plots for indifferent, synergistic or antagonistic interactions, as they have been 
assessed in this study. The dotted lines represent theoretical isoboles. 
Combinations of benzylMD 1c with the 4-methanolquinoline quinine and the current first 
line drug artemisinin were found synergistic (mean ∑ FIC50: 0.7 and 0.8, respectively), 
although for the latter one, it appeared like a tendency to synergism rather than true 
synergism (Table 9). A pronounced synergistic effect was however observed using the 
active metabolite of artemisinin, dihydroartemisinin (mean ∑ FIC50: 0.6). Synergistic 
effects of benzylMD 1c in combination with dihydroartemisinin was also observed with 
the CQ-resistant strain K14 (mean ∑ FIC50: 0.7), whereas the combination of benzylMD 1c 
and quinine behaved indifferently on strain K14 (mean ∑ FIC50: 1.1, Table 9). The 
isobolograms of quinine and dihydroartemisinin combinations determined on 
P. falciparum strain 3D7 show the concave shape characteristic for synergistic interactions 
(Figure 21A). 
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In contrast to quinine, 4-aminoquinolines chloroquine and amodiaquine showed no 
interaction when combined to benzylMD 1c (Table 9, no graphical representation). The  
4-aminoquinoline amodiaquine and ferroquine, an organometallic analogue of chloroquine, 
both showed a slight trend towards antagonism when combined with benzylMD 1c 
(mean ∑ FIC50: 1.2), as further indicated by weakly convex shaped isoboles (Figure 21B). 
Though based on the mean ∑ FIC50 values, we have to consider it to be an indifferent 
interaction.   
Antagonistic interactions with benzylMD 1c were found for the antibiotic fosmidomycin 
(mean ∑ FIC50: 1.4), the purine analogue allopurinol (mean ∑ FIC50: 1.5) and for the 
antifolate proguanil (mean ∑ FIC50: 1.4). The respective isobolograms showed 
characteristic convex shaped curves (Figure 21C). Other antimetabolite compounds 
(pyrimethamine, cycloguanil) showed a trend towards antagonism (mean ∑ FIC50: 1.2- 1.3) 
with weakly convex isoboles (Table 9, Figure 21).  
Recently, we demonstrated that benzylMD 1c and the structurally related antimalarial 
atovaquone do not share the same mode of action (see section 3.3.1) (Ehrhardt et al, 2013). 
In line with these results, atovaquone and benzylMD 1c revealed a clear indifferent 
interaction when tested in combination (mean ∑ FIC50: 1.0, Table 9, Figure 21D). Based 
on the same study (Ehrhardt et al, 2013), we expected to obtain a similar result for the 
combination of atovaquone with the redox-cycler methylene blue. While a slight trend 
towards an antagonistic interaction was observed, the result was classified as indifferent 
interaction (mean ∑ FIC50: 1.2; no graphical representation). Interestingly, the combination 
of benzylMD 1c with methylene blue, that is supposed to follow a similar mode of action 
as redox-cycler, was also found indifferent (mean ∑ FIC50: 1.1, Table 9, Figure 21D). Both 
compounds are supposed to be reduced by the GR, which represents an essential step in 
their activation as redox-cyclers.  
The experiments on in vitro drug interactions with amodiaquine, chloroquine, quinine, 
ferroquine, dihydroartemisinin, atovaquone and methylene blue were kindly provided by 
Dr. Christiane Deregnaucourt (MNHN, Paris). The experiments were performed under the 
routine culture conditions described in Materials and Methods, section 2.2.1.1. The 
synergistic interactions between benzylMD 1c and quinine or artemisinin were 
experimentally confirmed at the Department of Parasitology, Heidelberg (data not shown).  
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Figure 21  Isobolograms illustrating in vitro interactions of benzylMD 1c with clinically used antimalarials 
Interaction profiles were assessed on P. falciparum 3D7 strain according to the fixed-ratio isobologram method.  
(A) Synergistic interactions of benzylMD 1c with 4-methanolquinoline quinine and endoperoxide dihydroartemisinin 
(DHA) and synergistic interactions of atovaquone with proguanil for comparison (B) Interactions with quinoline 
antimalarials: amodiaquine and ferroquine (trend to antagonism) and quinine (synergistic) (C) Interactions with 
antimetabolite compounds: allopurinol and proguanil (antagonistic), pyrimethamine and cycloguanil (trend to 
antagonism) (D) Interactions with further antimalarial agents: antibiotic fosmidomycin (antagonistic), naphthoquinone 
atovaquone (indifferent), redox-cycler methylene blue (indifferent) and endoperoxide artemisinin (trend to synergy). 
Graphs display pairs of FIC50 values of benzylMD 1c (x axis) and the antimalarial agent (y axis) tested at different 
combinations. Plots are from one representative experiment, arithmetical values from 3-4 independent experiments 
are reported in Table 9. The dotted line indicates theoretical indifferent interaction; indifferent interaction of 
benzylMD 1c with itself (control of variability, grey) is shown for comparison. FIC50, fractional 50% inhibitory 
concentration; DHA, dihydroartemisinin. Experiments with amodiaquine, chloroquine, quinine, ferroquine, 
dihydroartemisinin, atovaquone and methylene blue were performed by Dr. C. Deregnaucourt, Muséum National 
d’Histoire Naturelle, Paris. A selection of the presented isobolograms is currently prepared for publication (Ehrhardt et 
al, in preparation). 
Results on in vitro interactions of lead benzylMD 1c and clinical antimalarials are 
currently prepared for publication (Ehrhardt et al, in preparation).   
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Table 9  In vitro interactions between benzylMD 1c and clinical antimalarial agents 
Antimalarial agent tested in 
combination with benzylMD 1c 
Mean ∑ FIC50 ± SD (n)   
P. falciparum 3D7 (K14) strain 
In vitro interaction 
Quinolines 
a
 
  
Amodiaquine 1.2 ± 0.1 (3) indifferent 
Chloroquine 1.0 ± 0.2 (4) indifferent 
Quinine 
0.7 ± 0.1 (4) 
1.1 ± 0.3 (4) (K14) 
synergistic 
indifferent (K14) 
Ferroquine 1.2 ± 0.1 (3) indifferent 
Mefloquine 1.0 (1) indifferent 
   
Divers modes of action 
 
Artemisinin 0.8 ± 0.1 (4) indifferent 
Dihydroartemisinin 
a
 
0.6 ± 0.1 (3); 
0.7 ± 0.1 (4) (K14) 
synergistic 
Atovaquone 
a
 1.1 ± 0.1 (3) indifferent 
Methylene blue 
a
 1.1 ± 0.1 (3) indifferent 
Fosmidomycin 1.4 ± 0.1 (3) antagonistic 
   
Antimetabolites 
  
Allopurinol 1.5 ± 0.3 (3) antagonistic 
Pyrimethamine 1.3 ± 0.2 (3) antagonistic 
Proguanil 1.4 ± 0.1 (3) antagonistic 
Cycloguanil 1.2 ± 0.1 (3) indifferent 
   
Control combinations 
 
Control of variability 
b
 1.0 ± 0.02 (3) indifferent 
Atovaquone  + Proguanil 0.2 ± 0.1 (2) synergistic 
Atovaquone  + Methylene Blue 1.2 ± 0.1 (3) indifferent 
In vitro drug-drug interactions were assessed on P. falciparum 3D7 strain according to the fixed-ratio isobologram method. 
Results are presented as mean sum of fractional 50% inhibitory concentration (mean ∑ FIC50) ± standard deviation (SD) 
determined from (n) independent experiments. Calculation of mean ∑ FIC50 values is detailed in the Materials and Methods 
chapter, section 2.2.6. a Results were kindly provided by Dr. C. Deregnaucourt, Muséum National d’Histoire Naturelle, Paris; 
b Control of variability: benzylMD 1c tested in combination to itself. Graphical visualization of individual in vitro interactions 
is presented in Figure 21. The results presented in this table are currently prepared for publication (Ehrhardt et al, in 
preparation).    
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3.3 Studies on the mode of action of lead compound benzylMD 1c 
3.3.1 BenzylMD 1c activity against transgenic atovaquone resistant parasites 
The presented work on lead benzylMD 1c’s activity against transgenic atovaquone 
resistant P. falciparum strain 3D7attB-yDHODH and control strains 3D7attB and 3D7 was 
recently published (Ehrhardt et al, 2013). The following section is a full citation from this 
article. Tables are presented in modified form. Dr. Marcel Deponte 
11
 proposed the use of 
this transgenic parasite strains and contributed to this study.  
“The commercial drug atovaquone (a 3-hydroxy-1,4-naphthoquinone) as well as other 
non-approved agents and compounds under development block complex III of the 
mitochondrial electron transport chain (mETC) (Fry & Pudney, 1992; Srivastava et al, 
1997; Srivastava et al, 1999; Vaidya & Mather, 2009; Biagini et al, 2012) […]. The major 
function of the mETC in asexual blood-stage cultures of P. falciparum is to regenerate 
ubiquinone as the electron acceptor of the mitochondrial dihydroorotate dehydrogenase 
(DHODH), which catalyzes a key step in pyrimidine biosynthesis (Painter et al, 2007). […] 
Since pyrimidine biosynthesis is essential, a functional DHODH and mETC are necessary 
for parasite survival (Painter et al, 2007; Vaidya & Mather, 2009; Booker et al, 2010). 
Accordingly, atovaquone was demonstrated to loose its antimalarial activity in the 
presence of an episomal (Painter et al, 2007; Biagini et al, 2012) or chromosomal copy 
(Ke et al, 2011) of a yeast gene encoding an alternative cytosolic DHODH (yDHODH) 
that does not require the mETC as an electron acceptor. Transgenic P. falciparum strains 
with or without yDHODH therefore provide an excellent tool for the study of potential 
inhibitors of the mETC. […] 
Methylene blue and benzylMD were proposed to act as redox-cyclers. […] However, 
owing to their redox properties and structural similarities with mETC inhibitors, both 
agents might also alter or inhibit the mETC. […] Consequently, the importance of the 
P. falciparum mETC to the antimalarial activities of methylene blue and lead benzylMD 1c 
was investigated using the transgenic atovaquone resistant P. falciparum strain 3D7attB-
yDHODH, such as control strains 3D7attB and 3D7. The first two strains contain a 
chromosomal attB site for the site-specific integration of a segment of DNA, which disrupts 
the gene encoding glutaredoxin-like protein 3 (PfGlp3) (Deponte et al, 2005; Nkrumah et 
                                                          
11
 Apl. Prof. Dr. Marcel Deponte, Department of Parasitology, University Hospital Heidelberg, Germany 
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al, 2006). The first strain, 3D7attB-yDHODH, contains the gene encoding yDHODH (Ke 
et al, 2011), which confers resistance to atovaquone as well as other mETC inhibitors, 
whereas the second strain, 3D7attB, has no insert at the attB site. The wild type strain 3D7 
was included as a control to assess the possibility that the agents affect a PfGlp3-
dependent redox pathway. The IC50 values of chloroquine and atovaquone were 
determined in parallel as a negative and positive control, respectively.  
The IC50 values for the negative control chloroquine were very similar for all three strains 
(Table 10). In contrast, the antimalarial activity of the positive control atovaquone was 
significantly reduced against the strain 3D7attB-yDHODH, and the IC50 value increased 
by almost four orders of magnitude. Methylene blue and benzylMD 1c displayed potent 
antiplasmodial activities against all of the strains. The IC50 values for atovaquone, 
methylene blue, and chloroquine presented in Table 10 correspond well with values 
reported elsewhere (Vennerstrom et al, 1995; Baniecki et al, 2007; Ke et al, 2011; Biagini 
et al, 2012). […] It is worth noting that the presence or absence of PfGlp3 did not affect 
the IC50 values of the redox-active agents (strains 3D7 and 3D7attB, respectively). Of 
particular importance, the presence of cytosolic yDHODH altered the activity of the mETC 
inhibitor atovaquone, but had no effect on the antimalarial activities of chloroquine, 
methylene blue, or benzylMD 1c. Hence, the latter three agents do not exert their activity 
as inhibitors of the mETC in asexual blood-stage parasites.” (Ehrhardt et al, 2013).  
Table 10  In vitro activities of redox-cyclers benzylMD 1c and methylene blue and control agents 
against transgenic atovaquone resistant P. falciparum 3D7attB-yDHODH and control strains 
 Antimalarial activity (IC50 (nM) ± SD) 
Agent 3D7 
a
 3D7attB 3D7attB-yDHODH 
Atovaquone 0.2 ± 0.05 0.5 ± 0.06 2230 ± 726 
Methylene blue 3.1 ± 0.4 4.7 ± 0.5 3.3 ± 0.2 
BenzylMD 1c 46 ± 3.5 48 ± 8.3 55 ± 5.6 
Chloroquine 10 ± 0.6 11 ± 1.9 8.6 ± 2.1 
Activity against cultured P. falciparum blood-stage parasites is presented as mean IC50 values ± standard deviation 
determined from 3 independent experiments using the SYBR® green technique. a IC50 values of all agents determined on P. 
falciparum 3D7 strain are presented in identical form in section 3.1.1. Results were previously published in (Ehrhardt et al, 
2013).   
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3.3.2 Morphological investigation of benzylMD 1c treated parasites in 
comparison to atovaquone and methylene blue 
The morphological investigation of benzylMD 1c, atovaquone or methylene blue-treated 
parasites was recently published (Ehrhardt et al, 2013). The following section is a full 
citation from this article. Figures are presented in modified form. Dr. Marcel Deponte 
kindly contributed to the performance of this study.  
“Certain antimalarial agents and oxidants such as hydrogen peroxide can alter the 
morphology of P. falciparum (Deponte & Becker, 2004), which can sometimes provide 
clues to the mode of action of the drug. [The morphology of drug-treated parasites was 
analyzed for lead compound 1c in comparison to antimalarials methylene blue and 
atovaquone. Therefore, a synchronous P. falciparum 3D7attB-yDHODH culture was 
incubated over 46 hours with IC50 and IC90 concentrations of each drug and morphology of 
treated and untreated parasites was assessed at different time points on Giemsa-stained 
blood smears. Figure 22 illustrates the morphologies of blood-stage parasites after 
treatment with atovaquone, methylene blue or benzylMD 1c.] The morphologies of 
atovaquone-treated parasites were very similar to the untreated controls, which is in 
agreement with previous reports (Painter et al, 2010). In contrast, the growth of parasites 
that were treated with benzylMD 1c was retarded, and an important increase of abnormal 
parasite morphologies was observed (Figure 22A). After 14 hours of drug treatment, fewer 
trophozoite-stage parasites and more ring-stage parasites were detected than in the 
control culture. Some of the abnormal ring-stage parasites had a distorted mesh-like 
morphology, which has been previously observed in stressed cultures and usually indicates 
that the parasite is incapable of further development (Deponte & Becker, 2004). Others 
ring-stage parasites developed into residual pyknotic bodies as previously described 
(Müller et al, 2011) (Figure 22A). After 24 hours of drug treatment, trophozoites and 
schizonts appeared to be younger than in the control, which contained predominantly 
older mid- to late-stage schizonts (Figure 22B). After 46 hours, the benzylMD-treated 
culture contained remaining schizonts from the first infection cycle and numerous very 
small ring-stage parasites from the second infection cycle, whereas the controls did not 
contain schizonts and instead consisted of late ring-stage parasites from the second 
infection cycle (Figure 22C). The effect was more pronounced at higher drug 
concentrations, resulting in a significant increase of residual pyknotic bodies and 
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disordered schizont stage-parasites (Figure 22D). Thus, parasites treated with 
benzylMD 1c presented a distinct morphology and became predominantly pyknotic at the 
ring stage. [A detailed investigation of the stage-specific activity of benzylMD 1c during 
the intraerythrocytic development was conducted separately and is presented in section 
3.2.1 of this thesis. The observations on parasite morphology after drug treatment are in 
agreement to the benzylMD 1c’s pronounced activity against ring-stage parasites compared 
to later stages (see section 3.2.1).]  
An even more pronounced effect on ring-stage parasites was observed for methylene blue 
as indicated by the clearance of these parasite stages after 24 hours of drug treatment 
(Figure 22B). In addition, for methylene blue, the ratio between mesh-like and pyknotic 
ring-stage parasites seemed to be shifted towards the mesh-like morphology. Another 
difference between the methylene blue parasites and the other cultures was that numerous 
trophozoite- and schizont-stage parasites were surrounded by faintly stained erythrocytes 
after methylene blue treatment at IC90 concentrations (Figure 22D). Since the surrounding 
uninfected erythrocytes in the blood smears remained intact, the results suggest a selective 
lysis of infected red blood cells after prolonged treatment with methylene blue. 
In summary, [the morphological differences observed for parasites treated with either 
atovaquone, methylene blue or benzylMD 1c] might be indicative of differences in drug 
action […]. [Together with the results on transgenic atovaquone resistant P. falciparum 
strains (section 3.3.1),] these observations support the conclusion that atovaquone, 
methylene blue, and benzylMD 1c do not share a common mechanism of action.” 
(Ehrhardt et al, 2013).  
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Figure 22  Parasite morphology after treatment with atovaquone, methylene blue or benzylMD 1c 
Synchronous P. falciparum 3D7attB-yDHODH parasites were treated with one of the drugs starting at the ring stage 
(approx. 16 h post infection). An untreated control culture was analyzed in parallel.  (A)-(C) Treatment with the IC50 
concentrations for 14, 24, and 46 h. (D) Treatment with the IC90 concentration for 46 h. Color differences between the 
microscopic images are due to white balance settings and were not adjusted in order to avoid image manipulation. This 
figure was recently published in modified form (Ehrhardt et al, 2013).   
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3.3.3 Identifying key factors behind benzylMD 1c’s redox-cycling using in vitro 
drug interaction studies with experimental molecules 
The postulated mechanism of action of the benzylMD series involves a continuous cascade 
of redox reactions leading to the formation of several redox-active drug metabolites, which 
interact with different intracellular components and altogether contribute to the global 
antimalarial activity (see Introduction, section 1.4.1 for more details).   
Direct proof that this redox cycling occurs in situ in the parasite, as well as evidence of the 
proposed metabolites, is difficult to find and technically complicated to measure, because 
(i) conventional approaches disrupt the cellular integrity thereby leading to oxidation of 
drug species and (ii) redox-cyclers are supposed to act as catalysts, existing only in trace 
amounts. To overcome these limitations, in vitro drug interaction studies were chosen as a 
tool to explore key features of benzylMD 1c’s mode of action in a whole cell assay. Drug-
drug interactions are commonly explored in the frame of mechanistic studies on 
antimicrobial drugs and provide information about molecular drug targets, the relationships 
between different drug targets and / or the cellular consequences of drug action (Bell, 
2005; Jia et al, 2009).  
Several experimental molecules were carefully selected in order to explore the role of  
(i) GR activity, (ii) NADPH flux, (iii) interaction with iron and (iv) Fenton reactions for 
benzylMD 1c’s antimalarial activity. Another set of compounds was selected to shed light 
on the influence of (v) intracellular GSH balance on drug activity.  
In vitro interaction profiles were assessed on P. falciparum 3D7 strain using the fixed-ratio 
isobologram method (Fivelman et al, 2004) and based on arithmetical and graphical 
analyses of results as described in detail in section 3.2.4 of this chapter. The cut-off values 
for synergistic and antagonistic interactions were defined as follows: Synergy was 
classified as a mean ∑ FIC50 ≤ 0.7, antagonism as a mean ∑ FIC50 ≥ 1.3 and any value in 
between as indifferent interaction. The IC50 values determined for the experimental 
molecules, together with their chemical structures, are given in the Appendix (Table A7). 
The following results on in vitro interactions of benzylMD 1c with the agents 
benzylMD 7a, nicotinamide, 6-aminonicotinamide, CB83, ML276 and desferrioxamine B 
are presented in the article of Bielitza et al. that was recently submitted (Bielitza et al, 
submitted, 2014.).   
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3.3.3.1 Redox-cycling: the role of the glutathione reductase 
The oxidoreductase GR is proposed to play a crucial role in the benzylMD’s mechanism of 
action by reducing benzoylMD species and thereby activating them for further redox-
cycling. To test this hypothesis, the prodrug of a GR suicide inhibitor was selected for in 
vitro interaction studies, namely the diﬂuoromethyl analogue of a bromo benzylMD, the 
benzylMD 7a (structure see Table A7, Appendix). BenzylMD 7a is the postulated prodrug 
form of an effective suicide substrate of both GRs of the infected erythrocyte (hGR and 
PfGR) (so-called benzoylMD 8a), both described in Müller et al., 2011. In contrast to other 
benzylMD derivatives, benzylMD 7a has lost its antimalarial activity, as evidenced by 
IC50 values in the high micromolar range.  
The in vitro interaction of lead benzylMD 1c and benzylMD 7a was found antagonistic 
(mean ∑ FIC50: 1.3, Table 12), though this effect was rather weak compared to the 
antagonistic interactions with other compounds, such as desferrioxamine B or ascorbic acid 
(see below). Figure 23A illustrates the resulting isobologram. This result would rather 
indicate towards an alternative or supplementary drug activation pathway upon inactivation 
of the GR by suicide inhibitors.  
3.3.3.2  Redox-cycling: the role of NADPH 
NADPH is an important reducing agent of the intracellular antioxidant defense and is the 
essential electron donor for GR and other oxidoreductases. BenzylMD-derived metabolites 
are proposed to be continuously recycled (or: regenerated) in a NADPH-dependent 
reaction. To test this hypothesis, different precursors of the NAD
+ 
/ NADP
+
 biosynthesis 
and inhibitors of the NADPH regeneration pathways were selected for in vitro interaction 
studies.  
In higher eukaryotes, two major biochemical pathways, the salvage and the de novo 
pathway, are involved in the biosynthesis of NAD
+
, which is consequently phosphorylated 
to generate NADP
+
. Recent studies revealed important differences in the NAD
+
 / NADP
+
 
metabolisms of non-infected and P. falciparum-infected erythrocytes. While nicotinamide 
is apparently not utilized in the normal erythrocyte for NAD
+ 
/ NADP
+
 synthesis, it is 
consumed by P. falciparum-infected erythrocytes, accounting for a substantial increase in 
NAD
+
 levels and slight increases in NADP
+
 levels compared to non-infected cells (Zerez et 
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al, 1990; Olszewski et al, 2009; O'Hara et al, 2014). Likewise, the antimetabolite of 
nicotinamide, 6-aminonicotinamide, was shown to decrease NAD
+
 levels of parasitized 
erythrocytes (Zerez et al, 1990). 
Nicotinic acid, nicotinamide and 6-aminonicotinamide showed no effect on in vitro 
P. falciparum proliferation even in high concentrations, consistent with observations by 
Zerez et al. (1990). Hence, it was not possible to establish the IC50 values of these 
compounds, which is essential to perform the fixed-ratio isobologram method. Therefore, 
in vitro interactions between these compounds and benzylMD 1c were established 
differently: the IC50 value of benzylMD 1c was determined in the presence of a fixed 
concentration of nicotinic acid, nicotinamide or 6-aminonicotinamide, which had no effect 
on parasite multiplication by themselves (Table 11). In the presence of of nicotinamide 
(3 mM), a ca. 50%-decreased IC50 value was measured for benzylMD 1c, suggesting a 
synergistic interaction of nicotinamide and the lead compound. This observed effect was 
counteracted by the according antimetabolite 6-aminonicotinamide (ca. 40% increased 
IC50 value). Addition of up to 2 mM nicotinic acid had no affect on benzylMD 1c’s 
IC50 value (data not shown).   
Table 11  In vitro interaction of benzylMD 1c with NAD
+
/NADP
+
 precursor or respective 
antimetabolite 
Compounds tested in 
combination 
IC50 (nM) ± SD (n) Mean IC50 shift (%) 
In vitro  
interaction 
BenzylMD 1c  68.2 ± 17.5 (6) 
  
+ nicotinamide 35.3 ± 13.9 (3) - 48.2 synergistic 
+ 6-aminonicotinamide 95.4 ± 19.2 (3) + 39.9 antagonistic 
IC50 values of benzylMD 1c were determined in the absence or presence of 3 mM nicotinamide or 0.5 mM 6-
aminonicotinamide on P. falciparum 3D7 parasites using the SYBR® green technique. Results are presented as mean 
IC50 values ± standard deviation (SD) determined from (n) independent experiments. Results are presented in modified 
form in Bielitza et al. (Bielitza et al, submitted, 2014.).  
Taken together, only NAD
+ 
/ NADP
+
 precursor nicotinamide, which is preferentially used 
by infected erythrocytes, showed an effect on benzylMD 1c’s activity that is furthermore 
confirmed by the use of nicotinamide’s antimetabolite 6-aminonicotinamide.  
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In P. falciparum and its hosting erythrocyte, NADPH is mainly generated in the PPP with 
the key enzymes PfGluPho and hG6PD, respectively (see also Introduction, section 1.2.3). 
The small molecule CB83 was recently identified as a selective irreversible inhibitor of the 
human G6PD, which was shown to inhibit parasite development in vitro (Preuss et al, 
2012a). High-throughput screening of a NIH compound library identified a series of 
benzothiazinones as highly selective inhibitors of PfGluPho and a lead compound 
(ML276) with antiparasitic in vitro activity (Preuss et al, 2012a; Preuss et al, 2012c). The 
in vitro interactions were assessed using the fixed-ratio isobologram method. 
Tested in combination with benzylMD 1c, the hG6PD inhibitor CB83 showed a strong 
antagonistic interaction (mean ∑ FIC50: 2.3, Table 12), possibly explained by the decreased 
rate of NADPH-dependent bioactivation of benzylMD 1c in the host cell. The combination 
of PfGluPho inhibitor ML276 with benzylMD 1c showed a clearly indifferent interaction 
(mean ∑ FIC50: 1.0, Table 12). The isobolograms of in vitro interactions of benzylMD 1c 
with CB83 or ML276 are illustrated in Figure 23.  
  
RESULTS 
107 
 
Figure 23  Isobolograms illustrating in vitro interactions of benzylMD 1c with experimental molecules 
Interaction profiles were assessed on P. falciparum 3D7 strain according to the fixed-ratio isobologram method.  
(A) Interaction of benzylMD 1c with GR suicide inhibitor benzoylMD 8a (indifferent) or respective prodrug benzylMD 7a 
(antagonistic); interaction with iron chelator desferrioxamine B (DFO, antagonistic) (B) Interactions of benzylMD 1c with 
hG6PD inhibitor CB83 (antagonistic) or PfGluPho inhibitor ML276 (indifferent) (C) Interactions with GSH depletor 
acetaminophen (antagonistic), precursor of GSH synthesis acetylcysteine (antagonistic) or inhibitor of γ-GCS BSO 
(indifferent) (D) Interactions with inducers of Fenton reactions ferroquine (slightly antagonistic) or ascorbic acid 
(antagonistic). Indifferent interaction of benzylMD 1c with itself (control of variability, grey) is shown for comparison. 
Graphs display pairs of FIC50 values of benzylMD 1c (x axes) and the experimental molecule (y axes) tested at different 
combinations. Plots are from one representative experiment, arithmetical values from 3-4 independent experiments 
are reported in Table 12. The dotted line indicates theoretical indifferent interaction. BSO, Buthionine sulfoximine; DFO, 
desferrioxamine B; FIC50, fractional 50% inhibitory concentration; γ-GCS, γ-glutamyl-cysteine synthetase. 
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3.3.3.3 Iron complexation as a key factor of benzylMD 1c global activity 
Numerous sources of iron (ferrous iron Fe
2+
, ferric iron Fe
3+
) are present within the 
parasitized erythrocyte (methemoglobin, hemoglobin, heme, hemozoin, hemichrome, labile 
iron pool) and play an important role in metabolic reactions (reviewed in Scholl et al, 
2005). Iron is a transition metal that exists in different oxidation states and can transfer 
electrons between molecules, thereby participating in redox reactions. It was considered 
that benzylMD 1c-derived metabolites act as metal chelators, which could play a critical 
role for the global drug activity (Müller et al, 2011). Chelation of ferric iron (Fe
3+
) might 
catalyse key bioactivation steps or assist in drug transport within the pathogen’s main 
compartments (siderophore-like transport).  
In order to explore the importance of iron complexation for global benzylMD 1c 
antiparasitic activity, benzylMD 1c was tested in combination with the iron chelator 
desferrioxamine B (DFO). DFO is a bacterial siderophore from actinobacteria 
Streptomyces that strongly binds ferric iron (Fe
3+
) species (structures see Table A7, 
Appendix). Along with other iron chelators, DFO was characterized as antimalarial 
compound with modest antiparasitic activity (reviewed in Mabeza et al, 1999). The in vitro 
interaction of DFO and benzylMD 1c revealed a very strong antagonistic effect 
(mean ∑ FIC50: 2.4), thus indicating that chelation of iron species by benzylMD 1c-derived 
metabolites is crucial for benzylMD 1c’s antimalarial activity. The resulting isobole had a 
pronounced convex shape (Figure 23A). A modest antimalarial activity of DFO was 
confirmed in this test (IC50: 12.3 µM, Table A7, Appendix). Interestingly, the observed 
antagonism between benzylMD 1c and DFO was, together with ascorbic acid, the strongest 
interaction among all tested drug combinations.  
3.3.3.4  Fenton reactions as a cause of intracellular drug degradation 
Pro-oxidative Fenton reactions are generally occurring under oxidative conditions in the 
presence of transition metals like copper or iron. Thereby, hydrogen peroxide reacts with 
ferrous iron (Fe
2+
) leading to reduction to ferric iron (Fe
3+
) under generation of reactive 
hydroxyl radicals (H2O2 + Fe
2+
 → Fe3+ + OH• + OH-). In the presence of reductants, ferric 
iron (Fe
3+
) can be easily reduced to ferrous iron (Fe
2+
), providing additional electron 
acceptors for Fenton reactions. Several endogenous reductants are known to accelerate 
these reactions, such as ascorbic acid, GSH, or reduced redox-drugs (e.g. benzoylMD). 
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Fenton reactions are prone to occur in the digestive vacuole of the parasite, where they 
could contribute to the formation of harmful reactive oxygen species and the degradation 
of macromolecules like hemoglobin or heme. These reactions could also cause a 
degradation of drug molecules in the digestive vacuole, as it has been reported for 
ferrocenic dual molecules (Chavain et al, 2009). The observation that benzylMD 1c 
exerted a lower activity against trophozoites raises the question whether Fenton reactions 
might cause degradation of drug molecules.  
In order to test this hypothesis, lead compound 1c was tested in combination with 
ferroquine or ascorbic acid, two compounds reported to trigger Fenton reactions in the 
parasite’s digestive vacuole. The increase of hydroxyl radical formation by a Fenton-like 
mechanism was proposed to be a considerable part of the mode of action of ferroquine 
(Chavain et al, 2008). Ascorbic acid (also called vitamin C) is broadly known as 
antioxidant. Though, in the presence of iron and oxygen in the parasite’s digestive vacuole, 
ascorbic acid turns into a pro-oxidant agent by acting as reductant of ferric iron (Fe
3+
), 
thereby accelerating Fenton reactions (Marva et al, 1989; Winter et al, 1997). Similarly, 
the sterilizing effect of ascorbic acid on Mycobacterium tuberculosis could be explained by 
its pro-oxidant activity and induction of Fenton reactions (Vilcheze et al, 2013).  
As described in section 3.2.4, ferroquine showed an indifferent interaction in combination 
with benzylMD 1c, with a slight tendency towards antagonism (mean ∑ FIC50: 1.2, Table 
12, Figure 23D). In contrast, the combination of benzylMD 1c with ascorbic acid revealed 
a strong antagonistic interaction (mean ∑ FIC50: 2.4) with a convex shaped isobole (Table 
12, Figure 23D). Ascorbic acid itself showed no effect on parasite survival or 
multiplication with IC50 values in the millimolar concentration range (IC50: 7 mM, Table 
A7, Appendix). The latter result indicates that Fenton reactions occurring in the digestive 
vacuole of the parasite could contribute to degradation of benzylMD 1c-derived drug 
species, thereby explaining the reduced activity of benzylMD 1c against mature parasite 
stages (i.e. trophozoite and schizont stages). 
3.3.3.5 Influence of intracellular GSH levels on benzylMD 1c’s activity 
BenzylMD redox-cyclers are proposed to disturb the redox equilibrium of the host-parasite 
unit and would therefore be expected to affect the level of the major antioxidant thiol GSH. 
The cytosolic GSH:GSSG ratio of the parasite is maintained by GSSG efflux to the host 
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cell or by regulating expression levels of GR and enzymes of GSH de novo biosynthesis 
(Patzewitz et al, 2012). Increase or depletion of intracellular GSH levels was shown to 
affect drug activity or parasites resistance of others antimalarials, such as ellagic acid and 
chloroquine (Ginsburg & Golenser, 2003; Soh et al, 2009). One could speculate that 
modulations of the intracellular GSH levels might similarly affect the activity of the pro-
oxidant benzylMD 1c.  
To address this hypothesis, different compounds known to either deplete or increase 
intracellular GSH levels were selected for in vitro drug combination assays. The  
4-aminoquinoline amodiaquine and acetaminophen (more precisely its metabolite  
N-acetyl-p-benzoquinone) were shown to deplete GSH stocks in cells (Moore et al, 1985; 
Tingle et al, 1995). Buthionine sulfoximine (BSO) is an inhibitor of the parasite’s γGCS, 
the first enzyme of the GSH de novo synthesis pathway. BSO was shown to reduce GSH 
levels in iRBC and parasite compartments upon application to culture medium (Luersen et 
al, 2000; Meierjohann et al, 2002). N-acetyl-cysteine is intracellular converted to cysteine, 
which is used for GSH synthesis. Based on its capacity to increase intracellular GSH 
levels, N-acetyl-cysteine is, amongst others, clinically applied as an antidote of 
acetaminophen intoxications (reviewed in Rushworth & Megson, 2014) and was used for 
former in vitro studies of cultured P. falciparum parasites (Soh et al, 2009; Njomnang Soh 
et al, 2012; Patzewitz et al, 2013).  
The in vitro interaction of benzylMD 1c and amodiaquine was found to be indifferent 
(mean ∑ FIC50: 1.2, Table 12, Figure 21B). The antioxidant N-acetyl-cysteine behaved 
antagonistic in combination with benzylMD 1c (mean ∑ FIC50: 1.8, Table 12), suggesting 
that increased GSH levels might neutralize the pro-oxidative effects of benzylMD 1c. 
Alternatively, one might speculate that increased GSH levels induce Fenton reactions in 
the digestive vacuole and consequently lead to drug degradation, as discussed in the 
section before. The according isobole, which is characteristic for an antagonistic 
interaction, is illustrated in Figure 23C. Conversely, an antagonistic interaction was also 
observed for the GSH-depleting agent acetaminophen (mean ∑ FIC50: 1.8, Table 12, 
Figure 23C), which were expected to act in an opposite way than N-acetyl-cysteine. In 
contrast to the latter result, in vitro interaction of benzylMD 1c with BSO, which was 
similarly shown to reduce GSH levels in iRBC, was found clearly indifferent 
(mean ∑ FIC50: 1.1, Table 12, Figure 23C).  
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Table 12  In vitro interactions between lead benzylMD 1c and experimental molecules 
Compounds tested in combination with benzylMD 1c  Mean ∑ FIC50 ± SD (n) 
In vitro  
interaction 
Glutathione reductase activity  
 
benzylMD 7a 
a
 
Prodrug of a GR suicide substrate 
(hGR and PfGR) 
1.3 ± 0.1 (4) 
slightly 
antagonistic 
    
Iron complexation  
  
DFO 
a
 Iron chelator 2.4 ± 0.6 (3) antagonistic 
    
Fenton reactions  
 
Ferroquine Inducer of Fenton reactions  1.2 ± 0.1 (3) indifferent 
Ascorbic acid Inducer of Fenton reactions 2.4 ± 0.3 (3) antagonistic 
    
NADPH balance of the infected erythrocyte   
ML276 
a
 PfGluPho inhibitor 1.0 ± 0.1 (3) indifferent 
CB83 
a
 hG6PDH inhibitor 2.3 ± 0.6 (4) antagonistic 
    
GSH balance of the infected erythrocyte  
 
Amodiaquine GSH depletor 1.2 ± 0.1 (3) indifferent 
Acetaminophen GSH depletor 1.8 ± 0.2 (3) antagonistic 
BSO γ-GCS inhibitor 1.1 ± 0.1 (3) indifferent 
N-acetyl-cysteine Precursor of GSH synthesis 1.8 ± 0.3 (3) antagonistic 
    
Control combination 
 
Control of variability 
b
 1.0 ± 0.02 (3) indifferent 
In vitro drug-drug interactions were assessed on P. falciparum 3D7 strain according to the fixed-ratio isobologram method. 
Results are presented as mean sum of fractional 50% inhibitory concentration (mean ∑ FIC50) ± standard deviation (SD) 
determined from (n) independent experiments. Calculation of mean ∑ FIC50 values is detailed in Materials and Methods, 
section 2.2.6. Structures of compounds and individual IC50 values are presented in the Appendix (Table A7).a 
 Results are 
presented in modified form in Bielitza et al. (submitted, 2014.); b Control of variability: benzylMD 1c tested in combination to 
itself. Graphical visualization of individual in vitro interactions is presented in Figure 23. BSO, Buthionine sulfoximine; DFO, 
desferrioxamine B; γ-GCS, γ-glutamyl-cysteine synthetase; GSH, glutathione; hGR, human glutathione reductase; PfGR, 
P. falciparum GR. 
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4 DISCUSSION 
4.1 Lead benzylMD 1c possesses a very attractive in vitro activity profile  
The presented doctoral project represents an essential part of the lead evaluation stage of 
the benzylMD drug-development process. One major focus of this was dedicated to 
exploring in detail the in vitro potency of lead benzylMD 1c on cultured P. falciparum 
blood-stage parasites. Next to antiparasitic activity and cytotoxicity on human cells, this 
comprises further safety aspects such as the risk of resistance development. Not less 
important are the properties of drug action, which help to predict the clinical efficacy of a 
drug (i.e. the speed of action and stage specificity). Particular attention was directed to 
identifying potential combination partners for lead benzylMD 1c in the portfolio of 
existing antimalarial drugs.  
Based on the characterization of its in vitro activity profile, benzylMD 1c fulfills the 
requirements of a first-line treatment and is best described as target candidate profile 1 
(TCP1), as classified by MMV (Burrows et al, 2013). Most importantly, benzylMD 1c 
showed an excellent in vitro speed of action with an immediate and rapid clearance of 
parasites. Therefore it could be expected to significantly decrease the initial parasite 
burden, as well as reduce related symptoms. The drug’s pronounced activity against ring-
stage parasites might be an important factor for good clinical efficacy (further discussed in 
the following sections). In addition, benzylMD 1c has been shown to effectively inhibit the 
development of drug-sensitive and multiple drug-resistant P. falciparum isolates, which 
represent common resistance-mechanisms to clinical antimalarials. The outcomes of in 
vitro drug-pressure experiments suggest a low probability of parasite-resistance 
development.   
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As a fast-killing compound (TCP 1), benzylMD 1c should be combined with a long-acting 
companion with a prolonged plasma half-life that would kill residual parasites in the 
patient (TCP 2) (Burrows et al, 2013). Several clinical antimalarials showed synergistic or 
indifferent in vitro interactions with benzylMD 1c, including long-acting compounds 
currently used as artemisinin partner-drugs, such as mefloquine, atovaquone and 
cycloguanil. The lack of pre-existing cross-resistance to those antimalarials increases the 
chance of finding a suitable drug partner in the portfolio of existing antimalarials.  
Further pharmacological and pharmacokinetic studies are essential to determining the oral 
bioavailability and plasma half-life of lead compound 1c and additional benzylMD 
derivatives of the second generation. Additionally, it is of obvious importance to test the 
activity of lead 1c in mouse models, for instance the humanized P. falciparum model.  
In conclusion, this work elucidated the attractive in vitro activity profile of lead 
benzylMD 1c and supports further development of the benzylMD series as antimalarial 
drug candidates. The individual aspects of benzylMD 1c’s in vitro activity profile are 
discussed in more detail in the following sections of the discussion.   
 
4.1.1 BenzylMD 1c is selectively active against P. falciparum parasites and    
strongly inhibits the development of drug-sensitive and drug-resistant strains 
Consistent with former studies (Müller et al, 2011), lead benzylMD 1c was demonstrated 
to be a potent inhibitor of P. falciparum blood-stage development, with IC50 values in the 
low nanomolar range (section 3.1.1). Moreover, Dr. B. Pradines has shown that 
benzylMD 1c is also active in the low nanomolar range against a panel of drug-sensitive 
and drug-resistant P. falciparum strains of different geographical origins (section 3.1.2). A 
statistical correlation analysis revealed the lack of cross-resistance with a set of clinically 
used antimalarials, namely chloroquine, quinine, monodesethylamodiaquine and 
mefloquine. These data suggests that the observed variation of benzylMD 1c’s antimalarial 
activity might be attributable to natural phenotypic variations of the different P. falciparum 
strains. Furthermore, the lack of pre-existing resistance to benzylMD 1c supports its 
specific mechanism of action, which is unaffected by the resistance mechanisms to 
common clinical antimalarials.  
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Lead benzylMD 1c presented a low cytotoxicity against several human cell lines, as 
reflected in the micromolar IC50 values. The cytotoxicity against buccal carcinoma cells 
(KB) and lung fibroblasts (MRC-5) have been published previously (Müller et al, 2011). 
Ms. T. Tzanova and Dr. D. Bragel further tested the cytotoxicity of benzylMD 1c against a 
liver carcinoma cell line (HepG2) (see Results, section 3.1.1).  It is of interest to note, that 
further toxicity studies revealed no risk of geno- or cardiotoxicity and a lack of intrinsic 
mutagenic potential of lead benzylMD 1c. These results will be presented and further 
discussed in a future publication (Ehrhardt et al, in preparation). Despite its elusive pro-
oxidative activity in infected erythrocytes, benzylMD 1c exerts no risk of hemolysis or 
intrinsic toxicity on uninfected G6PD-deficient or G6PD-sufficient cells. The latter 
observation could be further confirmed in a humanized G6PD-deficient mouse model 
(Rochford et al, 2013).    
 
4.1.2 Lead benzylMD 1c inhibited the development of all intra-erythrocytic 
stages but was most effective against ring-stage parasites 
The stage-specific activity of benzylMD 1c was found to be clearly different from most 
others antimalarials, with young ring stages being the most sensitive to the drug (Results, 
section 3.2.1). This observation is supported by a morphological investigation of drug-
treated parasites, which revealed that mainly drug-affected ring stages presented a 
characteristic pyknotic morphology under benzylMD 1c treatment (Results, section 3.3.2), 
as it was first described by Dr. Christiane Deregnaucourt (Müller et al, 2011; Ehrhardt et 
al, 2013). Still, it is indispensable to highlight that benzylMD 1c activity was not restricted 
to early stages, as the development of mature-parasite stages (trophozoites and schizonts) 
was completely inhibited by prolonged drug treatment, as shown in further experiments. 
The drug’s potency against all stages is similarly reflected in the high parasite reduction 
ratio that was assessed over 48 hours using a mixed-stage culture (Results, section 3.2.2).  
Together, these results thus point towards dose- and time-dependent differences in drug 
susceptibility among individual intraerythrocytic stages. The observation that 
benzylMD 1c was less active against trophozoites could be partially explained as a result 
of drug degradation by Fenton reactions. This hypothesis was addressed by assessing the 
in vitro interactions of benzylMD 1c in combination with ferroquine and ascorbic acid, 
both of which were shown to induce Fenton reactions in the digestive vacuole of the 
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parasite (section 3.3.3.4) (Marva et al, 1989; Winter et al, 1997; Chavain et al, 2008). 
Indeed, the latter combination revealed a strong antagonistic interaction, indicating that 
Fenton reactions can contribute to drug destruction in the digestive vacuole and thereby 
explaining the reduced activity of benzylMD 1c against mature parasite stages.  
The majority of antimalarial compounds, with the rare exceptions of artemisinin and 
methylene blue, act on the trophozoite or schizont stages. Several authors have stressed the 
importance of developing new drugs with novel modes of action that affect parasite stages 
other than the trophozoite (Burrows et al, 2013; Wilson et al, 2013). The redox-cycler 
methylene blue has a stage-specificity profile very similar to that of benzylMD 1c, with a 
pronounced activity against ring-stage parasites (section 3.3.2) (Akoachere et al, 2005; 
Ehrhardt et al, 2013). Interestingly, the third group of antimalarial redox-cyclers, namely 
INODs, has also been shown to preferentially inhibit the development of ring-stage 
parasites. Therefore one might speculate that ring stages are particularly vulnerable to an 
overload of oxidative stress. Only recently, very young ring stages (< 4 hours p.i.) were 
shown to be hypersensitive to artemisinin (Klonis et al, 2013) and an altered ex vivo 
response of those stages to artemisinin pulses was correlated with prolonged in vivo 
parasite clearance times (Witkowski et al, 2013a) (please also refer to the discussion on 
parasite dormancy in the following section).  
Compounds killing ring stages can be expected to be beneficial for patients. Several 
arguments support this hypothesis. First, in the course of infection, a subpopulation of ring-
stage parasites differentiates to sexual gametocytes, which are responsible for the 
transmission of the parasite to the mosquito vector (Baker, 2010). In the idea that a given 
compound will kill the sexually committed ring-stage parasites before differentiation to 
gametocytes, this drug would decrease the gametocyte load in patients and parasite 
transmission. Secondly, erythrocytes infected with trophozoite or schizont stages adhere to 
endothelia of small blood vessels in important organs and consequently cause severe forms 
of the disease, including cerebral and placental malaria or respiratory distress (White et al, 
2014). Any drug treatment leading to increased killing or phagocytosis of ring-stage 
infected erythrocytes can be expected to prevent the attachment of infected erythrocytes to 
the endothelium and would consequently lower related symptoms and prevent progression 
of the disease to severe forms (previously discussed in more detail in Ayi et al, 2004). In 
support of this hypothesis is the observation that several genetic disorders of the 
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erythrocyte, such as G6PD-deficiency, confer resistance against severe forms of malaria. 
The resistance of G6PD-deficient patients was shown to be related to a rapid removal of 
ring-stage infected erythrocytes by phagocytosis. Parasite development in G6PD-deficient 
cells encounters an enormous oxidative stress on the host cell, which results in the 
increased denaturation of hemoglobin species and membrane binding of hemichromes, a 
key determinant for phagocytosis (Cappadoro et al, 1998) (see also Introduction, section 
1.2.2.3). Recent spectrophotometric studies with benzylMD 1c-derived metabolites 
(benzoylMD 2c and dihydrobenzoylMD 3c) and hemoglobin species in solution approved 
the degradation of different hemoglobin species accompanied by the formation of reactive 
oxygen species and ferrylhemoglobin upon extended redox-cycling (Bielitza et al, 
submitted, 2014.) (described in detail in the Introduction, section 1.4.1). Of particular 
importance for drug activity was the evidence of ferrylhemoglobin formation and the 
precipitation of irreversible hemichromes. In support of this finding, treating ring-stage 
infected erythrocytes with benzylMD 1c induced a significantly increased binding of 
hemichromes to the host cell membrane, as it was shown before for ring-stage infected 
G6PD-deficient cells (in collaboration with Dr. P. Arese, Bielitza et al, submitted, 2014.). 
Early hemichrome deposition and subsequent opsonisation in ring-stage infected 
erythrocytes is considered to be advantageous for the phagocytic removal of infected cells 
(Turrini et al, 2003). First of all, circulating ring-stage infected erythrocytes can be 
recognized by residual macrophages in the liver or spleen and secondly, those cells contain 
only few hemozoin, which was shown to inhibit macrophage functions in higher amounts 
as present in trophozoites (previously discussed in more detail in Turrini et al, 2003; Ayi et 
al, 2004).   
Thus, it can be expected that benzylMD 1c-induced hemichrome formation will be a key 
factor in triggering phagocytosis of drug-treated cells in vivo. As stated before, the 
phagocytosis of drug-treated infected erythrocytes can be expected to contribute 
significantly to parasite clearance in vivo and can be expected to protect from severe 
malaria. Therefore it would be of particular interest to further explore this topic in adequate 
in vitro and in vivo experiments (e.g. Chan et al, 2012).   
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4.1.3  Lead 1c can be counted among the fastest compounds described so far 
The efficiency of antimalarials in decreasing blood parasitemia and curing patients is 
mediated in part by their speed of action. Lead compound 1c showed a very fast speed of 
action comparable to artemisinin, one of the fastest compounds described so far (section 
3.2.2). A quick onset of action is considered to be necessary for first-line treatment because 
the drug will rapidly decrease blood parasitemia and consequently related symptoms (Sanz 
et al, 2012; Burrows et al, 2013). Still, a slightly delayed onset of benzylMD 1c action 
(< 24 h, 8 h lag phase) was observed and may indicate an initial cytostatic drug effect. On 
the basis of our proposed mechanism of action, this observation might point towards an 
exponential formation of drug metabolites, reactive oxygen species and / or degradation of 
hemoglobin species. Regardless, this short delay was rapidly compensated by the high 
parasite killing rate observed in the following 40 hours. In conclusion, the fast speed of 
action of benzylMD 1c promises a high therapeutic efficacy and furthermore minimizes the 
time window for parasites to develop drug resistance (White & Pongtavornpinyo, 2003; 
Sanz et al, 2012; Burrows et al, 2013).  
4.1.4 Lead benzylMD 1c showed a low potential to induce drug resistance 
The rapid development of parasite resistance to new drugs is a major challenge for 
antimalarial drug design. Whether the emergence of drug resistance will be slow or fast is 
depending on several factors and in vitro protocols may only give limited predictions of 
resistance development in the field (White & Pongtavornpinyo, 2003; Nzila & Mwai, 
2010). However, it has been clearly shown that some compounds induce resistance more 
easily than others. In the case of atovaquone, treatment failure related to resistant parasites 
was already observed with its first clinical use (Looareesuwan et al, 1996). The genetic 
basis of the parasite’s resistance to spiroindolone NITD609 (2012 in clinical Phase IIa, 
Anthony et al, 2012) was already resolved during preclinical studies (Rottmann et al, 2010) 
and the extremely fast selection of resistant parasites by cyclopropyl carboxamides stopped 
their further development as antimalarial drug candidates (Sanz et al, 2011; Ding et al, 
2012). All these examples highlight the importance of assessing the risk of de novo 
resistance development as early as possible during drug development (Sanz et al, 2011; 
Ding et al, 2012). 
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Recently, MMV proposed a framework to evaluate the risk of resistance development of 
new antimalarial compounds (Ding et al, 2012). This strategy covers several aspects of 
drug resistance, such as potential cross-resistance with clinical antimalarials, the risk of 
de novo resistance development or the elucidation of molecular mechanisms underlying 
resistance. As discussed before, benzylMD 1c’s activity was not impaired by one of the 
pre-existing resistances to single or multiple antimalarials in the tested parasite strains, for 
instance resistance to chloroquine, quinine, mefloquine or monodesethylamodiaquine  
(see also section 4.1.1).  
Drug-pressure experiments conducted with lethal benzylMD 1c concentrations failed to 
select for resistant parasites, indicating a very low intrinsic potential of the drug to induce 
de novo resistance (Results, section 3.2.3.1). The lack of intrinsic mutagenic potential 
observed in genotoxicity studies supports this conclusion (Müller et al, 2011). Other 
studies using the same experimental setup, reported a high frequency of spontaneous 
resistance to 5-fluoroorotate, atovaquone and a lead cyclopropyl carboxamide 
(GSK2645947) (Rathod et al, 1997; Sanz et al, 2011). Moreover, this protocol was 
successfully used to select for chloroquine resistant parasites and to reveal the responsible 
mutation in the pfcrt gene (Cooper et al, 2002). 
Molecules with multiple drug targets or a pleiotropic mode of action are considered to be 
less prone to select for resistance (Ding et al, 2012 and others). This is expected to account 
for redox-active drugs, such as benzylMD 1c, that interfere with a highly complex and 
tightly regulated redox network in the host-parasite unit (Nepveu & Turrini, 2013). So far, 
there are almost no reports about resistance to methylene blue, the only redox-active 
antimalarial currently in clinical use (Schirmer et al, 2003).   
Within this work, the selection of drug-adapted or resistant parasites was further 
encountered by exposing a high parasite inoculum to sublethal benzylMD 1c 
concentrations (in the range of IC90 values), as this is regarded to favor the selection of 
resistant parasites (White & Pongtavornpinyo, 2003; Walliker et al, 2005). Indeed, the 
ARMD strain Dd2 was able to adapt to constant drug exposure but only to a very limited 
extent (section 3.2.3.2). Using a selection strategy with stepwise increasing drug 
concentrations, parasites succeeded to multiply in the presence of 550 nM benzylMD 1c 
but failed to recover from higher drug concentrations (800 nM). Drug-adapted parasites 
presented a 4-5 fold decrease in susceptibility to benzylMD 1c compared to progenitor 
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Dd2 parasites, as reflected in their IC50 values. However, this phenotype was not stable 
over time and parasite susceptibility reversed to original levels 4-6 weeks after drug 
removal. In addition, a prolonged culturing of drug-adapted parasites under continuous 
drug pressure was not possible, parasites suffered visibly and died rapidly. These 
observations are similarly reflected in the loss of drug adaptation during cloning or 
cryopreservation. Unstable drug-resistant phenotypes arising from in vitro drug selections 
were observed frequently (discussed in Nzila & Mwai, 2010), even in cases of prolonged 
drug pressure for as long as 16 months, as reported in a study on lumefantrine (Mwai et al, 
2012). The transient nature of drug resistance might be explained by reduced parasite 
fitness, such that upon drug removal, resistant mutants are outnumbered by sensitive ones 
(Walliker et al, 2005; Nzila & Mwai, 2010). Alternatively, one might assume that 
adaptation to benzylMD 1c pressure may not originate from a stable genetic mutation but 
from metabolic adaptations, such as changes in enzymatic activities (i.e. NADPH-
dependent flavoenzymes), protein expression levels (Prieto et al, 2008), protein  
S-glutathionylation (Kehr et al, 2011) or epigenetic regulation (Merrick & Duraisingh, 
2010). Very recently, epigenetic histone modifications were reported for the first time as 
being responsible for the development of drug resistance (Sharma et al, 2013).  
In line with Ding et al. (2012), it can be concluded that the lack of pre-existing resistance 
and the inability to select for stable de novo resistance indicates that benzylMD 1c’s 
effectiveness may not be easily compromised by resistance development in the field. 
Nevertheless, from a basic research perspective, it would be interesting to further explore 
the mechanisms underlying the observed parasite adaptation to benzylMD 1c drug 
pressure. Regarding the increasing frequency of reports about treatment failures with 
artemisinin, it would be of particular interest to explore a possible cross-resistance with 
artemisinin-resistant field isolates. Artemisinin tolerance is partly related to the transient 
dormancy of drug-treated ring stages, which is discussed in more detail in the next section.   
Parasite dormancy as a mode of drug resistance 
Previous in vitro studies reported about a mechanism of artemisinin tolerance, by which 
parasites resisted drug pressure and continued their development after drug removal 
(Witkowski et al, 2010; Teuscher et al, 2012). This phenomenon, which is referred to as 
dormancy, was attributed to temporary cell cycle arrest within ring-stage parasites under 
drug pressure (Witkowski et al, 2010). Novel phenotypic assays characterizing 
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P. falciparum field isolates and mathematical simulations provided further understanding 
of this resistance mechanism (Klonis et al, 2013; Witkowski et al, 2013a; Witkowski et al, 
2013b). Culture-adapted P. falciparum field isolates from regions of artemisinin resistance 
were characterized by an altered drug susceptibility of young ring-stage parasites, as 
assessed with a recently established ring-stage survival assay (RSA) (Witkowski et al, 
2013b). In addition, artemisinin resistance was correlated with a high proportion of 
dormant ring stages that successfully resumed growth after drug removal (Witkowski et al, 
2013b). The RSA assay was successfully implemented to identify artemisinin-resistant 
clinical parasite isolates (i.e. slow clearing parasites) in ex vivo conditions (Witkowski et 
al, 2013a).  
It might be speculated that other antimalarials, for instance lead compound 1c, might also 
induce dormant parasites. Accordingly, the possible reappearance of benzylMD 1c-treated 
parasites was monitored in cultures from drug pressure experiments after drug removal 
(sections 3.2.3.1 and 3.2.3.2). Occurrence of growing parasites was observed 3 weeks after 
stopping treatment in only 2 out of 20 flasks in total. Similar to artemisinin-tolerant 
parasites, these parasites showed no altered susceptibility to benzylMD 1c compared to 
progenitor parasites. However, this observation does not provide sufficient evidence to 
conclude whether the parasites tolerated benzylMD 1c by entering a dormancy state, as 
described for artemisinin. This assumption should be further pursued using adequate in 
vitro protocols, which have been developed in the meantime. Witkowski and colleagues 
established a panel of in vitro assays for the identification of artemisinin-tolerant parasite 
strains (Witkowski et al, 2013b). In contrast to classical in vitro drug susceptibility assays, 
which are performed over 48 to 72 hours of drug incubation, novel in vitro assays are 
based on a short-time exposure of ring or mature parasite stages to pulses of high 
artemisinin concentrations. Culture-adapted artemisinin-resistant P. falciparum field 
isolates and the simple RSA assay provide an excellent tool for the identification of 
possible cross-resistance between artemisinin and novel drug candidates. It would be of 
particular importance to test compounds that share the same stage specificity with 
artemisinin (i.e. the ring stage), such as benzylMD 1c and methylene blue. In addition to 
the RSA assay, the authors proposed a standardized setup for detecting drug-induced cell 
cycle arrest, which relies on morphological identification of persistent ring stages and their 
unresponsiveness to sorbitol-induced lysis (so-called ring stage growth arrest assay, RGA, 
Witkowski et al, 2013b). Alternatively, the presence of dormant ring-stage parasites in 
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drug-treated cultures can be shown by flow cytometry analysis using DAPI (staining of 
DNA) and rhodamine 123 (mitochondria) staining (Witkowski et al, 2010). The RGA 
assay would be particularly suitable to screen other drugs, such as benzylMD 1c, for their 
potential to induce dormancy and could be easily adapted for large panels of drugs 
(medium throughput) by the use of flow cytometry analysis, thus eliminating the need of 
time consuming microscopical read-out.   
 
4.1.5 Antimalarial combination partners for lead benzylMD 1c 
Our investigations on the in vitro drug interactions between benzylMD 1c and clinical 
antimalarials revealed synergistic interactions with quinine and artemisinin and a 
pronounced synergy with dihydroartemisinin, the active metabolite of artemisinin 
(section 3.2.4). The nature of drug interactions between benzylMD 1c and 
dihydroartemisinin was independent of the drug-resistance pattern of the tested 
P. falciparum strain. Companions for drug combinations should preferably interact 
synergistically to allow for smaller doses and prevent potentially toxic side effects, but also 
a combination based on indifferently interacting partners could be favored (Bell, 2005; 
Burrows et al, 2013). BenzylMD 1c interacted indifferently with amodiaquine, 
chloroquine, atovaquone, cycloguanil and methylene blue. Owing to its fast speed of 
action, lead 1c could most likely be combined to a compound with long serum half-life, 
such as combination partners of artemisinin (e.g. amodiaquine, mefloquine, atovaquone or 
cycloguanil).  
A potential partner drug cannot be chosen without complete knowledge of the in vivo 
pharmacokinetic and pharmacodynamic behavior of all candidates (White & Olliaro, 1996; 
Bell, 2005; Jia et al, 2009). Thus, potential drug combinations should be further tested 
using in vivo models to confirm the nature of their interaction and to explore possible 
pharmacological interactions, as well as additional toxicity (White & Olliaro, 1996; Bell, 
2005). Until now, the pharmacokinetic and pharmacological properties of benzylMD 1c 
have been little explored, but the synergistic interactions with existing antimalarials and 
the lack of cross-resistance to clinically used antimalarials increase the chance of finding a 
suitable drug partner in the portfolio of existing drugs.   
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4.3 Unraveling benzylMD 1c’s mechanism of action  
Compounds of the benzylMD series are postulated to act as pro-oxidative redox-cyclers 
that degrade hemoglobin species, consume intracellular NADPH and ultimately perturb the 
sensitive redox homeostasis of the parasite-host unit (Müller et al, 2011; Bielitza et al, 
submitted, 2014.). Results of previous electrochemical, biochemical and physicochemical 
studies have provided important insights into the functions of predicted benzylMD 1c-
derived metabolites (Müller et al, 2011; Johann et al, 2012; Bielitza et al, submitted, 
2014.). Moreover, recent studies in P. falciparum-infected erythrocytes have evidenced the 
denaturation of hemoglobin species and the perturbation of the GSH-redox equilibrium and 
therefore provided further support for the postulated mechanism of action (see 
Introduction, section 1.4.1) (Bielitza et al, submitted, 2014.).    
 
4.3.1  Identifying key factors behind benzylMD 1c’s redox-cycling  
As described in detail in the introduction, antimalarial benzylMDs are proposed to act as 
redox-cyclers. However, direct proof that this redox cycling occurs in situ in a parasite, as 
well as evidence of the proposed metabolites, is technically highly complicated and 
remained so far without success. To overcome this limitation, in vitro drug interaction 
studies were chosen as a tool to explore key features of benzylMD 1c’s mode of action in a 
whole cell assay. Drug-drug interactions are commonly explored in the framework of 
mechanistic studies on antimicrobial drugs (Bell, 2005; Jia et al, 2009). Synergistic or 
antagonistic interactions provide information about molecular drug targets, the 
relationships between different drug targets and / or the cellular consequences of drug 
action. Thus, they might also, but rarely, originate from actual physical or chemical contact 
between combined molecules. In agreement with Bell (2005), it is important to emphasize 
that a mechanistic interpretation of drug interaction data might provide only limited proof 
of any given hypothesis. 
At this point, it is important to mention that the identification of benzylMD 1c-derived 
metabolites in treated infected erythrocytes was attempted during this doctoral thesis by 
using a high resolution mass spectrometry approach. Even after cells were treated with 
high concentrations of benzylMD 1c, only considerably low drug signals (from either 
benzylMD 1c or derived metabolites) were detected. This result might indicate that 
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benzylMD 1c or its metabolites are only present in very low amounts (in unbound forms) 
but could also be explained by technical reasons. Preliminary studies indicated a high 
affinity of benzylMD 1c and metabolites to human serum proteins. In the near future, the 
search for benzylMD 1c-derived metabolites will be further realized with a fully  
C
13
-enriched 1c molecule and the use of optimized extraction procedures.  
Is glutathione reductase the only electron donor for benzylMD bioactivation? 
A continuous GR-catalyzed reduction of benzylMD-derived metabolites was proposed to 
be an essential pre-requisite for further redox-cycling and thus for the antimalarial activity 
of benzylMDs. This hypothesis was initially supported by the loss of the antimalarial 
activity of benzylMD analogues that act as suicide substrates of both GRs of the infected 
erythrocyte (hGR and PfGR), namely benzylMD 7a and benzoylMD 8a (Müller et al, 
2011). Moreover, benzylMD 1c and its predicted metabolites were characterized as 
substrates of hGR and PfGR. While benzylMD 1c itself has been shown to be a poor GR 
substrate (Müller et al, 2011), metabolite benzoylMD 2c possesses a markedly altered 
redox property and therefore significantly enhanced efficiency to act as a substrate of both 
GRs (i.e. hGR and PfGR). The redox-cycler could therefore act synergistically in different 
compartments of the parasite-host unit (Müller et al, 2011; Blank et al, 2012; Bielitza et al, 
submitted, 2014.). As emphasized before, in all biochemical studies carried out with 
benzylMD 1c and predicted metabolites, the metabolite benzoylMD 2c was shown to be 
the key player in NADPH-dependent GR-mediated redox-cycling and drug-induced 
hemoglobin catabolism. Similar to benzylMDs, the redox-cycler methylene blue has been 
described as an inhibitor and / or subversive substrate of human and parasitic GR (Färber 
et al, 1998; Buchholz et al, 2008b). 
The question whether the GR is the crucial electron donor for methylene blue and 
benzylMD 1c in vivo was discussed in our recent publication (Ehrhardt et al, 2013).  
“Is GR the electron donor for methylene blue and benzylMD 1c in vivo? A key study by 
Pastrana-Mena et al. revealed that the absence of P. berghei GR has no significant effect 
on the sensitivity of the rodent malaria parasite to methylene blue (2010). Even though 
these findings point to an alternative electron donor for this drug, it is important to note 
that there seems to be substantial differences between the glutathione metabolisms of 
human and rodent malaria parasites. For example, a recent study by Patzewitz et al. 
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suggests that glutathione biosynthesis is essential for the asexual blood stages of 
P. falciparum in contrast to P. berghei (2012). To date, there is no P. falciparum GR 
knock-out strain. Thus, we could not analyze the IC50 values for methylene blue and 
benzylMD 1c in such a genetic background. […]” (Ehrhardt et al, 2013) 
In the absence of a P. falciparum GR knock-out strain, in vitro drug interaction studies 
with GR suicide substrates were regarded as a valuable tool for providing further evidence 
of the aforementioned hypothesis (section 3.3.3.1). The rather weak antagonistic 
interaction observed between benzylMD 1c and benzylMD 7a suggests that another 
NADPH-dependent oxidoreductase could partially bioactivate benzylMD 1c upon 
irreversible GR inactivation. However, it might also be possible that the intracellular GR 
activity (hGR and / or PfGR) is not fully inhibited upon treatment with benzylMD 7a and 
the remaining enzyme activity would still contribute to drug bioactivation. Such a scenario 
could explain the observation of only a weak antagonistic interaction. Therefore, this result 
does not fully exclude the possibility that GR acts as an electron donor in situ, but raises 
doubts about its being the sole electron donor responsible for accomplishing continuous 
redox-cycling of benzylMD-derived metabolites. As already mentioned, a Plasmodium GR 
knock-out strain would be the ideal tool to address this question. Therefore, Alice-Anne 
Goetz, a PhD student under Dr. Stephanie Blandin’s 12 supervision, is currently assessing 
the activity of benzylMD 1c against the P. berghei GR knock-out strain under ex vivo 
conditions. 
In the case of methylene blue, alternative disulfide reductases were identified as putative 
drug targets, such as P. falciparum thioredoxin reductase (TrxR) or parasitic and human 
mitochondrial dihydrolipoamide dehydrogenase (LipDH) (Buchholz et al, 2008b). 
Furthermore, methylene blue’s trypanocidal activity might be explained by a similar 
mechanism, meaning by acting as subversive substrate of disulfide reductase orthologues 
from Trypanosoma cruzi (trypanothione reductase, TR and LipDH) (Buchholz et al, 
2008a). P. falciparum thioredoxin reductase and T. cruzi trypanothione reductase are 
important components of the parasitic antioxidant systems (Müller et al, 2003; Jortzik & 
Becker, 2012).  
                                                          
12
 Dr. Stephanie Blandin and Ms. Alice-Anne Goetz, Institut de Biologie Moléculaire et Cellulaire,  
Université de Strasbourg, France 
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Furthermore, based on their redox state, benzylMD 1c and methylene blue could also act as 
electron donors (after being reduced) and acceptors at various sites in the mETC, as we 
previously discussed (Ehrhardt et al, 2013).  
“If methylene blue or benzylMD 1c target the mETC as a subversive substrate, the mETC 
could act as their electron donor/acceptor regardless of the presence or absence of 
cytosolic yDHODH. For instance, both inhibitors might be suited to accept electrons from 
the endogenous type 2 DHODH or from complex III. The reduced redox-cycler could 
subsequently catalyze the formation of reactive oxygen species - and / or of Fe
2+
 species as 
suggested earlier (Müller et al, 2011) - without depletion of the pyrimidine pool. Reduced 
menadione species with antitrypanosomal activities were, for example, shown to generate 
superoxide anions and to reduce cytochrome c (Fe
3+
) in vitro (Blumenstiel et al, 1999; 
Salmon-Chemin et al, 2001). Future work is needed to address whether methylene blue or 
benzylMD 1c are subversive substrates of the mETC of malaria parasites.” (Ehrhardt et al, 
2013) 
In conclusion, although this study did not exclude the possibility of GR acting as an 
electron donor, it provided a basis to speculate about alternative drug activation pathways. 
Several oxidoreductases would be valuable candidates, for instance P. falciparum 
thioredoxin reductase or other flavorenzymes like DOX reductase or lipoamide 
dehydrogenase. Future work is needed to elucidate the activation of benzylMD-metabolites 
for intracellular redox cycling.  
The role of NADPH in benzylMD 1c’s activity 
NADPH is an important reducing agent of intracellular antioxidant defense and is the 
essential electron donor for GR and other oxidoreductases. BenzylMD-derived metabolites 
have been proposed to be continuously regenerated in a NADPH-dependent reaction. 
Consequently, one might speculate that benzylMD 1c activity is depending on available 
NADPH, which would be consumed by prolonged drug action. This would substantially 
contribute to the perturbation of the redox homeostasis upon drug treatment. In vitro 
interaction studies with compounds that presumably affect intracellular NADPH flux have 
not revealed a clear perspective (Results, section 3.3.3.2). Interestingly, the antiparasitic 
activity of benzylMD 1c increased in the presence of nicotinamide, an effect that was 
counteracted by the antimetabolite 6-aminonicotinamide.  
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Augmentation of NAD
+
 levels by nicotinamide supply and the resulting fortification of 
benzylMD 1c activity might be indicative of increased drug bioactivation in NADPH 
dependent reactions. Moreover, in a recent study nicotinamide was shown to inhibit the 
histone deacetylase activity of the P. falciparum Sir2 protein (stands for silent information 
regulator 2), which was recently identified as essential for epigenetic regulation of 
virulence genes (Prusty et al, 2008). In support of the observed synergy with nicotinamide, 
a strong antagonistic effect was observed in combination with the hG6PD inhibitor CB83 
that targets the NADPH regeneration in erythrocyte. In addition, the latter result suggests 
that the host-cell cytosol is involved in benzylMD bioactivation and / or benzylMD action. 
In contrast, combining benzylMD 1c with the PfGluPho inhibitor ML276 resulted in a 
clear indifferent interaction.  
As emphasized before, it can be difficult to verify conclusions drawn from in vitro 
interaction studies. This is particularly important for compounds that target single 
components of complex intracellular networks. In the cases of NADPH or GSH balance, 
the regulatory mechanism and the complex interactions between host cell and parasite are 
not fully understood. Nevertheless, it might be interesting to point out that parasite’s NAD+ 
and glucose-6-phosphate metabolisms are of interest for the development of new 
antimalarial drugs (Preuss et al, 2012b; O'Hara et al, 2014). With this in mind, both 
synergistic and indifferent interactions between benzylMD 1c and compounds targeting 
these pathways could be further exploited as potential drug combinations.  
Iron complexation is crucially involved in benzylMD 1c’s activity 
BenzylMD 1c-derived metabolites are thought to act as metal chelators, which could play a 
critical role in global drug activity (Müller et al, 2011). The chelation of ferric iron (Fe
3+
) 
might catalyze key bioactivation steps or assist in drug transport within different 
compartments of the infected erythrocyte (siderophore-like transport). Recent biochemical 
studies identified the reduced benzoylMD 3c metabolite as effective Fe
3+
 chelator, while 
benzoylMD 2c only ineffectively bound to Fe
3+ 
species (Bielitza et al, submitted, 2014.). 
These results prompted further investigations to explore the importance of iron 
complexation for benzylMD 1c’s antiparasitic activity. Therefore, benzylMD 1c was tested 
in combination with the iron chelator DFO (section 3.3.3.3).  
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The role of iron complexation for benzylMD 1c’s global activity was discussed in detail in 
an article that was recently submitted (Bielitza et al, submitted, 2014.).  
“Regarding iron complexation, we propose that the metal binding properties of reduced 
benzylMD-derived metabolites, as benzoylMD 3c, play a critical role in the global activity 
of the lead benzylMD 1c. This was evidenced by the antagonistic interaction between 
benzylMD 1c and a powerful Fe
3+
 chelator from Streptomyces, DFO. Interestingly, the 
observed antagonist effect mediated by DFO on the antimalarial activity of the lead 
benzylMD 1c is the highest among all compound combinations to benzylMD 1c tested. As 
suggested in our previous study (Müller et al, 2011), the benzoylMD 3c was proposed to 
cycle in and out of the acidic vesicles, upon iron complexation / release and drug oxido-
reduction by GR. It is noteworthy to mention the strong antagonistic effect exerted by DFO 
with semisynthetic and synthetic endoperoxide antimalarial drugs (Stocks et al, 2007). The 
study suggested a common non-heme chelatable iron-dependent activation mechanism for 
endoperoxide drugs via Fe
3+
-Fe
2+
 redox cycling. Taking into account the central role of 
DFO as an iron chelator in fungi, we expected that DFO might inhibit the transport of 
drug metabolites:iron complexes in and out the parasite compartments, similarly to 
microbial siderophores upon iron complexation..” (Bielitza et al, submitted, 2014.) 
In addition, DFO exerts antioxidative effects by scavenging free iron sources and 
consequently preventing Fenton reactions (Reeder et al, 2008). These reactions can be 
considered to counteract the oxidative stress induced by benzylMD 1c. Most importantly, 
DFO was reported to reduce ferrylhemoglobin to methemoglobin and thereby prevents the 
denaturation of hemoglobin, in forms of a cross-linking of the protein structure and 
formation of hemichromes (Reeder et al, 2008). Interestingly, this reaction was observed at 
physiological conditions of pH 7.4 and moreover at acidic conditions of pH 5, as found in 
acidic vesicles and the digestive vacuole of the parasite. In line with Reeder et al, the 
reactions employed by DFO (i.e reduction of ferrylhemoglobin to methemoglobin and 
prevention of Fenton reactions) can be expected to counteract the over-oxidation and 
denaturation of hemoglobin species induced by continuous redox-cycling of benzylMD 1c-
derived metabolites. This hypothesis is currently investigated in the prolonged 
methemoglobin reduction assay (UV-Vis spectrophotometric assay), which was formerly 
used to evidence the formation of ferrylhemoglobin and precipitation of hemichrome by 
metabolite benzoylMD 2c in the presence of the NADPH-based GR system and 
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methemoglobin (as described before, Introduction, section 1.4.1). In conclusion, the strong 
in vitro antagonism between DFO and benzylMD 1c provides valuable support for the 
postulated mode of action. Based on the evidence of hemichrome formation in biochemical 
assays and furthermore in P. falciparum-infected benzylMD 1c-treated erythrocytes, this 
result strongly indicates that the oxidation and denaturation of hemoglobin species, 
together with increase of ROS-formation upon drug treatment, accounts, at least in parts, 
for the intracellular mechanism of action of benzylMD 1c. 
Redox homeostasis of the parasite reflected in levels of reduced GSH  
BenzylMD 1c are proposed to lead to the disruption of intracellular redox homeostasis. 
The redox homeostasis in infected erythrocytes largely depends on the glutathione systems 
of both, host and parasite, with reduced GSH as a major component of those systems.  
In vitro interaction studies with compounds affecting either GSH de novo synthesis (BSO 
or acetylcysteine) or levels of reduced GSH (acetaminophen, amodiaquine) have been 
inconclusive (section 3.3.3.5). In contrast, both the GSH-depleting agent acetaminophen 
and GSH precursor acetylcysteine behaved antagonistically in combination with 
benzylMD 1c.  
More convincing insight into benzylMD 1c’s effect on the glutathione-dependent redox 
potential of living P. falciparum blood-stage parasites was recently acquired when the 
genetically encoded real-time redox sensitive GFP biosensor hGrx1-roGFP2 was used 
(developed by Kasozi et al, 2013). Microscopical analysis of the cytosolic expression of 
hGrx1-roGFP2 in trophozoites detected a change of the GSH:GSSG equilibrium towards 
GSSG, indicative of a shift towards a more oxidizing redox potential in the cytosol 
(Bielitza et al, submitted, 2014.). This finding is a first evidence for the perturbation of 
intracellular redox homeostasis upon treatment with benzylMD 1c and provides important 
support for the proposed mechanism of action. Further studies aimed at investigating the 
perturbation of the redox homeostasis in other parasite’s compartments are currently 
ongoing. Given the demonstrated binding of hemichromes to the membrane of infected 
erythrocytes upon treatment with benzylMD 1c, it would be of particular interest to 
investigate the perturbation of the redox homeostasis in the cytosol of the host cell. This 
could be realized using a roGFP2-tagged protein that will be exported into the erythrocyte 
cytosol.   
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4.3.2 Lead 1c is not an inhibitor of the mitochondrial electron transport chain 
One antimalarial drug apparently related to benzylMD 1c is atovaquone, that shares the 
common 1,4-naphthoquinone core.  In this work, it was shown that lead benzylMD 1c is 
not an inhibitor of the mETC, in contrast to atovaquone, by using a transgenic 
P. falciparum strain (section 3.3.1) (Ehrhardt et al, 2013). This strain expresses a cytosolic 
bypass of the mETC, in form of the yDHODH, which confers resistance to atovaquone and 
other inhibitors of the mETC (Ke et al, 2011).  
Apart from structural differences, further biochemical or physicochemical compound 
properties seem to be important to explain the different modes of action of these two  
1,4-naphthoquinones: first the enzymatic substrate capacities and secondly the redox 
potential. Both aspects were discussed in detail in our previous publication (Ehrhardt et al, 
2013). “When we recently studied the ability of human and P. falciparum GR to reduce 
either atovaquone or 2-hydroxy-1,4-naphthoquinone at substrate concentrations of up to 
25 µM or 100 µM, respectively, no NADPH consumption was observed (Davioud-Charvet 
& Lanfranchi, 2011; Lanfranchi et al, 2012a). By contrast, methylene blue and predicted 
benzylMD metabolites were shown to be effective substrates with catalytic efficiencies - 
i.e., the kcat/Km values - as high as 13.7 mM
-1
s
-1
 for the blue dye and 12.5 mM
-1
s
-1
 for the 
predicted 3-[4-(substituted)benzoyl]-menadione metabolites (Morin et al, 2008; Müller et 
al, 2011; Blank et al, 2012). […] Another important property seems to be the redox 
potential. The low redox potential of atovaquone (-0.51 V) indicates that, under 
physiological conditions, atovaquone reduction is considerably less favored compared to 
menadione reduction (-0.14 V) (Lopez-Shirley et al, 1994). Even under highly reducing 
intracellular conditions with an estimated half-cell redox potential for NADPH around  
-0.34 V (Deponte, 2013), the redox potential for atovaquone will be too low for efficient 
reduction by two-electron reduced GRs, which have redox potentials around -0.24 V at pH 
7 (Veine et al, 1998). In contrast, the two-electron reduction potentials for methylene blue 
and menadione at pH 7 are +0.01 V (Impert et al, 2003) and -0.23 V (Patriarche & 
Lingane, 1970), respectively, and cyclic voltammetry measurements show that one-electron 
and two-electron-transfer reactions are kinetically reversible (Morin et al, 2008). These 
properties allow a continuous reduction and oxidation under physiological conditions, 
which is a prerequisite for a subversive substrate-driven redox cycle.” (Ehrhardt et al, 
2013) 
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5 CONCLUSIONS AND OUTLOOK 
The presented work on the in vitro activity of lead compound 1c represents a part of the 
lead evaluation stage of the benzylMD drug-development process. Overall, the presented 
findings demonstrate the promising in vitro potency of lead benzylMD 1c and furthermore 
emphasize its very attractive in vitro antimalarial activity profile. This work highly 
supports the further development of the benzylMD series as antimalarial drug candidates.  
In accordance with TCPs postulated by MMV (Burrows et al, 2013), benzylMD 1c would 
be a suitable drug candidate for first-line treatment mainly owing to its fast speed of action. 
Preliminary studies in the mouse model indicated that lead benzylMD might have a poor 
bioavailability or be rapidly eliminated from the bloodstream (Müller et al, 2011). 
Consequently, detailed pharmacological and pharmacokinetic studies are essential to 
determine the oral bioavailability and plasma half-life of lead compound 1c in order to 
assure that those fulfill the according requirements. At the same time, it would be of 
interest to assess the pharmacokinetic properties of benzylMD derivatives with similar in 
vitro antiparasitic potency. A short plasma half-life of benzylMD compounds would 
exclude their use as a combination partner for fast-acting compounds (TCP 2), their use as 
chemoprotection (TCP 4) and possibly also for blocking parasite transmission to the 
mosquito vector (Burrows et al, 2013).  
So far, the benzylMD drug design project focused mainly on the intraerythrocytic stages of 
P. falciparum. This is partly based on the relative accessibility and ease of using of blood-
stage cultures for standardized in vitro studies. Now, it would be timely to test selected 
benzylMD derivatives against other P. falciparum stages from the vertebrate host or 
mosquito vector. Alice-Anne Goetz, a PhD student under Dr. Stephanie Blandin’s 
supervision, is currently performing a detailed characterization of lead benzylMD 1c’s 
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activity in the Anopheles vector and the P. berghei mouse model. Prof. Katja Becker 
13
 
could preliminarily show that lead benzylMD 1c inhibits the development of P. falciparum 
gametocytes, which should be confirmed soon. Conversely, lead compound 1c and a panel 
of eight derivatives were recently shown to have no impact on the motility of P. berghei 
sporozoites, as investigated in the laboratory of Prof. Freddy Frischknecht 
14
. Another 
interesting aspect would be to test the activity of benzylMDs against P. vivax and P. ovale 
blood stages and dormant liver stages (hypnozoites), though respective in vitro cultures are 
not easy to establish (Burrows et al, 2013; Dembele et al, 2014).  
To provide further support of benzylMDs as drug candidates, it is of clear importance to 
test the activity of selected derivatives in P. berghei-infected mice and moreover in the 
humanized P. falciparum mouse model. A previous study using P. berghei-infected mice 
demonstrated a moderate antiparasitic activity of lead compound 1c and four analogues 
following intraperitoneal or oral administration (Müller et al, 2011). This observation 
might be explained by poor pharmacokinetic properties of benzylMDs, as mentioned 
before, but could also stem from a low antiparasitic drug activity against P. berghei 
parasites. The latter possibility will be addressed by Alice-Anne Goetz by assessing the 
activity of benzylMD 1c against P. berghei blood-stage development ex vivo.  
The second part of this work was dedicated to exploring the mechanism of action of lead 
benzylMD 1c. Most importantly, the possibility that benzylMD 1c inhibits the mETC, as 
suggested based on its structural similarities to atovaquone, can be clearly excluded 
(Ehrhardt et al, 2013). One important shortcoming of our work on the mode of action of 
benzylMDs is the lack of direct evidence that the proposed redox-cycling occurs in situ in 
the parasite or likewise any evidence that the proposed metabolites are formed 
intracellularly. The in vitro drug interaction studies conducted in this work provided 
interesting insights into different aspects of benzylMD 1c’s redox-cycling and antimalarial 
activity. In spite of this work, future attempts are necessary to provide a proof of concept 
for the proposed intracellular benzylMD 1c redox-cycling.  
Hopefully, the findings of this work could not only highlight the potential of benzylMDs as 
antimalarial drug candidates, but moreover emphasize the innovative approach of targeting 
P. falciparum parasites with redox-cycling agents.  
                                                          
13
 Prof. Katja Becker, Interdisciplinary Research Centre (IFZ), Justus Liebig University, Giessen, Germany. 
14
 Prof. Freddy Frischknecht, Department of Parasitology, University Hospital Heidelberg, Germany 
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Table A1  Definitions of hemoglobin catabolites and heme-containing molecules cited in this work 
Heme compound Oxidation state Definition 
Hemoglobin ferrous – Fe
2+
 
Oxygen-carrying Fe
2+
 hemoprotein of erythrocytes made 
up of four different polypeptide globin chains that 
contain between 141 and 146 amino acids and a 
prosthetic group that consists of an iron atom contained 
in the center of a heterocyclic porphyrin ring, namely 
the protoporphyrin-IX (PPIX).  
Oxyhemoglobin  ferrous – Fe
2+
 
Hemoglobin protein containing an oxygen molecule in 
its Fe
2+ 
PPIX site  
Methemoglobin ferric – Fe
3+
 
Methemoglobin is formed from hemoglobin by 
oxidation of the iron atom from the ferrous to the ferric 
state. A small amount is found in the blood normally, 
but injury or toxic agents convert a larger proportion of 
hemoglobin into methemoglobin, which does not 
function as an oxygen carrier.  
Heme  
or Fe
3+
-protoporphyrin-IX 
or Fe
3+
-PPIX 
ferric - Fe
3+
 
Heme corresponds to the active protein-free unit of 
hemoglobin molecule, or the prosthetic group of 
hemoglobin that consists of an iron atom contained in 
the center of a heterocyclic porphyrin ring, namely the 
protoporphyrin-IX.  
α-hematin or:  
Fe
3+
-PPIX(OH2) 
Fe
3+
-PPIX(OH) 
ferric - Fe
3+
 
Heme containing a water or and hydroxide molecule 
axially bound in the fifth position of the iron(Fe
3+
) 
porphyrinic system.  
-hematin ferric - Fe
3+
 
Synthetic hematin crystal standing for hemozoin 
pigment equivalent 
Hemozoin or  
malarial pigment 
ferric - Fe
3+
 
Disposal pigment – biocrystals which result from self-
association of Fe
3+
-protoporphyrin-IX - formed during 
the digestion of methemoglobin in several blood-
feeding parasites (the Fe
3+
-PPIX are held together 
mainly through - and µ-Pr interactions). 
Ferrylhemoglobin ferryl – Fe
4+
 
Oxidation product of hemoglobin following hydrogen 
peroxide treatment. Oxidation of the iron atom from 
the ferric to the ferryl state. Ferryl iron is reactive and 
unstable and can return to the ferric state by reacting 
with specific amino acids of the globin chains. 
Hemichrome ferric - Fe
3+
 
Hemichromes are low-spin Fe
3+
 species closely related 
to methemoglobin. Hemichromes mainly result from 
denaturation processes of hemoglobin. Hemichromes 
are characterized by the strong axial binding of two 
histidine residues to the ferric center, which prevent 
dioxygen or ligand binding. Hemichromes are 
considered as markers of the erythrocyte’s senescence. 
 
  
Table A2  Characterisation of lead benzylMD 1c and predicted benzylMD 1c-derived metabolites regarding their antimalarial activities against P. falciparum blood-stage 
parasites and physicochemical and biochemical parameters (unpublished data from Laboratory of Medicinal Chemistry, ECPM, Strasbourg and references cited below) 
 
 
P. falciparum strain  
IC50 (nM) ± SD 
a 1
 
Heme binding 
b
 
-Hematin 
 inhibition 
c
 
Enzymatic properties 
(hGR vs. PfGR/NADPH) 
d
 
metHb(Fe
3+
) reduction 
 (hGR/NADPH) 
e
 
Redox potentials
  f
 
Agent: 3D7 (nM) Dd2 (nM) 
[Heme]/KD 
(µM) 
IC50 (%max inhib.) 
Km (µM)/kcat (× 10
-3
 s
-1
)/ 
kcat/Km (mM
-1
 s
-1
) 
kmetHb (× 10
-2
 s
-1
) 
E1/2 (mV) 
[E (mV)] 
benzylMD 1c 49.2 ± 6.1 69.2 ± 2.8 [1:1]/0.15 No inhibition No substrate No reduction 
-0.61[84] 
 -1.35[88] 
benzylMD  2c >1,000 >1,000 [1:1]/2.0 2.8 (52%) 
16.6/44/2.7 vs. 
42.4/56/1.3 
0.12(3) 
-0.43[80] 
-1.12[84] 
-1.62[60] 
benzylMD 3c* 1,159 ± 136 1,290 ± 177 [1:1]/0.8 2.7 (57%) No substrate 1.3(2) ** nd 
benzylMD  4c 431 ± 120 613 ± 79 [1:1]/3.2 2.3 (70%) No substrate 0.22(2) *** 
E1pa = -0.05[irr] 
E2pa = 0.208[irr] 
-2.05[153] 
-1.71[146] 
CQ 7.9 ± 1.5 134.0 ± 11.3 [2:1]/1.3 1.6 (86%) 
2
  No substrate No reduction nd 
AQ 10.2 ± 0.2 * nd [4:1]/10.7 
3
 0.5 (86%) 
3
 No substrate No reduction nd 
MD 16,000 
2
 nd nd - 
31.2/160/5.1 vs. 
82.2/160/2.0 
4
 
Red at 100 µM 
5
 
-0.60[102] 
/-1.33[108] 
Experimental conditions: a) 3H-hypoxanthine incorporation assay (ref 1). * Dr. C. Deregnaucourt, MNHN, Paris, unpublished. b) 0.2 M sodium hepes buffer pH 7.5, the dimerization constant KDim of Fe
3+PPIX 
was fixed at 106.82 (ref 3). c) c12.9 M sodium acetate buffer pH 4.5, 60 °C, 1 h then 0.2 M + 0.02 M sodium hepes buffer pH 7.5 containing 5% pyridine (v/v) as reporting reagent (ref 3). d) 100 mM phosphate 
buffer pH 6.9, 1 mM EDTA, 200 mM KCl; T = 25.0 °C, [hGR]0 = 1.3-2.6 µM; [NADPH]0 = 100 µM. e) 47 mM phosphate buffer pH 6.9, 1 mM EDTA, 200 mM KCl; T = 25.0 °C, [hGR]0 = 81 nM; [NADPH]0 = 121 µM; 
[metHb]tot = 7.96 µM; [S]0 = 40 µM; **
 Direct reduction of metHb(FeIII) by the benzoyldihydroMD 3c* performed in the absence of hGR and NADPH. *** For 4c (40 µM), T = 37.0 °C (to increase the solubility), 
[hGR]0 = 133 nM; [NADPH]0 = 53 µM; [metHb]tot = 7.96 µM. e) Cyclic voltammetry (CV) and square wave voltammetry (SWV), DMSO (0.1 M NBu4PF6), v = 200 mV s
-1. References: (1) (Bielitza et al, submitted, 
2014.) (2) (Friebolin et al, 2008) (3) (Johann et al, 2012) (4) (Müller et al, 2011) (5) (Winterbourn et al, 1979). Abbreviations: AQ, amodiaquine; CQ, chloroquine; GR, glutathione reductase; metHb, 
methemoglobin; MD, menadione; nd = not determined 
  
Table A3  In vitro susceptibility profiles of Plasmodium falciparum strains to antimalarial agents 
P. falciparum  
strains and origin 
Susceptibility to antimalarial agents 
PPQ CQ QN MFQ MDAQ LMF DHA AS ATO PY DOX 
3D7 Sierra Leone S S S R S S S S S S S 
W2 Indochina S R I I R S S S S R S 
D6 Africa S S S R S S S S S S S 
FCM29 Cameroon S R I I R S S S S R S 
FCR3 The Gambia S R I I S S S S S S S 
PA Uganda S R I I R S S S S S S 
Bres 
a
 Brazil S R I I R S S S S S S 
8425 
a
 Senegal S S S R S S S S S S S 
K14 
a
 Cambodia S R RS I R S S S S R S 
K2 
a
 Cambodia S R I I R S S S S R S 
L1 
a
 Niger S R I I R S S S S S S 
Vol 
a
 Djibouti S R S I R S S S S S S 
Dd2 
b
 Indochina (W2) - R - R - - - - - R - 
Resistance cut-off values R > 150 nM > 100 nM 
I: 500-800 nM,  
RS > 800 nM 
I: 30-40 nM  
R > 40 nM 
R > 80 nM RS > 150 nM  RS > 10.5 nM 
I: 30-390 nM 
R > 390 nM 
I: 200-1000 nM 
R > 1000 nM 
RS> 35 nM 
Chemosusceptibility profiles were kindly provided by Dr. Bruno Pradines, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France. a strains were isolated at the Institut de Médecine 
Tropicale du Service de Santé des Armées, b chemosusceptibility according to (Ding et al, 2012). Antimalarial agents: PPQ, piperaquine; CQ, chloroquine; QN, quinine; MFQ, mefloquine; MDAQ, 
monodesethylamodiaquine; LMF, lumefantrine; AS, artesunate; ATO, atovaquone; DHA, dihydroartemisinin; PY, pyrimethamine and DOX, doxycycline. Resistance cut-off values: I, intermediate; RS, reduced 
susceptibility; R, resistance.  
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Table A4  In vitro antimalarial activity of benzylMD 1c and antimalarial agents against twelve drug-
sensitive and resistant P. falciparum strains originating from Asia, Africa or South America 
P. falciparum 
strains 
Agents: benzylMD 1c CQ
 
 QN
 
 MDAQ MQ 
3D7 IC50 
[CI95%] 
94.2 
[80-111] 
21.3 
[17.9-25.3] 
103.8 
[73-148] 
19.5 
[14.1-26.9] 
52.1 
[47.0-57.8] 
IC90 
[CI95%] 
246.6 
[216-281] 
40.4 
[33.2-49.0] 
597.0 
[512-696] 
31.4 
[23.4-42.1] 
119.4 
[103-138] 
D6 IC50 
[CI95%] 
138.0 
[101-189] 
23.0 
[18.8-28.0] 
61.8 
[44.5-85.9] 
17.5 
[11.2-27.3] 
62.1 
[52.5-73.4] 
IC90 
[CI95%] 
248.3 
[172-358] 
44.4 
[37.2-52.9] 
464.5 
[337-640] 
37.0 
[24.3-56.3] 
111.9 
[97-129] 
8425 IC50 
[CI95%] 
54.3 
[46.2-63.9] 
25.5 
[19.6-33.1] 
130.3 
[87-195] 
26.4 
[20.9-33.2] 
44.1 
[38.7-50.2] 
IC90 
[CI95%] 
135.8 
[135-137] 
59.2 
[45.5-76.9] 
389.9 
[272-560] 
41.4 
[29.9-57.3] 
85.3 
[74.2-98.1] 
Voll IC50 
[CI95%] 
68.6 
[44-107] 
262.4 
[236-292] 
421.7 
[377-472] 
77.5 
[71.1-84.4] 
32.5 
[25.8-40.9] 
IC90 
[CI95%] 
143.6 
[75-276] 
316.2 
[241-415] 
843.3 
[753-944] 
113.0 
[102-125] 
53.7 
[42.3-68.2] 
L1 IC50 
[CI95%] 
104.0 
[82-133] 
273.5 
[235-319] 
530.9 
[441-639] 
86.1 
[72-103] 
38.0 
[32.3-44.7] 
IC90 
[CI95%] 
201.4 
[124-328] 
417.8 
[355-492] 
995.4 
[809-1225] 
125.0 
[96-162] 
78.5 
[68.0-90.7] 
PA IC50 
[CI95%] 
70.8 
[59.1-84.8] 
330.4 
[275-398] 
626.6 
[505-778] 
72.8 
[56.5-93.7] 
36.9 
[31.5-43.2] 
IC90 
[CI95%] 
195.0 
[162-235] 
483.1 
[377-619] 
1106.6 
[871-1406] 
106.4 
[82-138] 
63.2 
[53.3-75.1] 
Bres IC50 
[CI95%] 
191.4 
[177-207] 
442.6 
[392-500] 
604.9 
[488-736] 
100.2 
[85-119] 
30.2 
[23.4-39.1] 
IC90 
[CI95%] 
328.1 
[297-362] 
613.8 
[561-672] 
1112.5 
[957-1281] 
143.2 
[116-176] 
51.5 
[40.0-65.1] 
FCR3 IC50 
[CI95%] 
73.5 
[48-112] 
477.5 
[376-607] 
665.3 
[546-811] 
79.1 
[66.3-94.3] 
35.9 
[28.5-45.2] 
IC90 
[CI95%] 
160.7 
[91-284] 
685.5 
[555-848] 
1111.7 
[928-1332] 
129.7 
[110-153] 
59.2 
[47.0-74.5] 
W2 IC50 
[CI95%] 
215.3 
[198-235] 
485.3 
[377-625] 
683.9 
[576-812] 
146.2 
[113-189] 
32.0 
[27.4-37.3] 
IC90 
[CI95%] 
368.1 
[349-389] 
693.4 
[598-805] 
1247.4 
[1109-1403] 
201.8 
[170-240] 
49.2 
[41.5-58.4] 
K2 IC50 
[CI95%] 
163.3 
[134-199] 
493.2 
[388-626] 
619.4 
[558-687] 
91.2 
[81-103] 
33.3 
[28.2-39.3] 
IC90 
[CI95%] 
310.5 
[272-354] 
912.0 
[659-1262] 
1510.1 
[1278-1785] 
143.6 
[102-202] 
97.3 
[82-116] 
K14 IC50 
[CI95%] 
57.2 
[41.5-78.7] 
648.6 
[529-795] 
495.5 
[421-583] 
160.3 
[134-192] 
30.7 
[26.6-35.5] 
IC90 
[CI95%] 
92.3 
[82-104] 
1129.8 
[1042-1225] 
1636.8 
[1404-1908] 
220.3 
[180-270] 
94.2 
[83-107] 
FCM29 IC50 
[CI95%] 
41.0 
[36.2-46.6] 
879.0 
[771-1002] 
543.3 
[416-709] 
317.7 
[278-369] 
27.5 
[21.1-36.0] 
IC90 
[CI95%] 
107.4 
[85-135] 
1241.7 
[1129-1365] 
1199.5 
[1024-1405] 
407.4 
[349-475] 
49.1 
[32.9-73.4] 
Antimalarial activity (presented as IC50 and IC90 values) was determined on P. falciparum blood-stage parasites using the  
3H-hypoxanthine incorporation assay. The chemosusceptibility profiles and multi-drug resistance phenotypes of the strains are 
given in Table A3, Appendix. Results are presented as mean values ± 95% confidence interval from 3 - 5 independent growth-
inhibition assays. Results were kindly provided by Dr. Bruno Pradines, Institut de Médecine Tropicale du Service de Santé des 
Armées, Marseille, France. CI95%, 95% confidence interval; CQ, chloroquine; MF, Mefloquine; MDAQ, monodesethyl-
amodiaquine;  QN, quinine.  
  
Table A5  Susceptibility of P. falciparum Dd2 parasites to benzylMD 1c and chloroquine prior to selection and after 1
st
 (Dd2MD1) and 2
nd
 selection cycles (Dd2MD2 parasites) 
Selection step       
Pre-selection benzylMD 1c chloroquine    
Culture IC50 (nM) IC90 (nM)  IC50 (nM) 
    
Dd2 51 ± 1 (2) 138 ± 13 (2) 105 ± 20 (2)  
 
 
 
 
    
 
 
 
1
st
 selection cycle (125 nM) weeks 1-3 after drug removal 
 
weeks 4-6 after drug removal 
 benzylMD 1c chloroquine 
 
benzylMD 1c chloroquine 
Culture IC50 (nM) IC90 (nM)  IC50 (nM) 
 IC50 (nM) IC90 (nM)  IC50 (nM) 
Dd2
MD1
 F2 162 ± 15 (3) 703 ± 250 (3) 101 ± 23 (3)  52 ± 9 (2) 105 ± 21 (2) 105 ± 30 (2) 
Dd2
MD1
 F3 208 ± 17 (3) 983 ± 125 (3) 97 ± 10 (3)  57 ± 0,4 (2) 110 ± 14 (2) 103 ± 20 (2) 
Dd2 55 ± 20 (3) 180 ± 52 (3) 123 ± 13 (3)  - - - 
 
    
 
 
 
2
nd
 selection cycle (500 nM) weeks 1-6 after drug removal 
 
weeks 7-10 after drug removal 
 benzylMD 1c chloroquine 
 
benzylMD 1c chloroquine 
Culture IC50 (nM) IC90 (nM)  IC50 (nM) 
 IC50 (nM) IC90 (nM)  IC50 (nM) 
Dd2
MD2
 F1 178 ± 68 (4) 495 ± 306 (4) 73 ± 8 (4)  74 (1) 170 (1) 80 (1) 
Dd2
MD2
 F2 250 ± 30 (3) 917 ± 76 (3) 81 ± 13 (2)  90 ± 22 (3) 213 ± 40 (3) 74 ± 3 (3) 
Dd2
MD2
 F3 197 ± 58 (5) 586 ± 176 (5) 87 ± 14 (5)  67 ± 18 (3) 145 ± 40  (3) 96 ± 22 (3) 
Dd2
MD2
 F4 259 ± 63 (5) 812 ± 250 (5) 96 ± 10 (4)  86 ± 9 (3) 183 ± 42 (3) 105 ± 30 (3) 
Dd2 63 ± 17 (8) 176 ± 45 (8) 95 ± 20 (3)  - - - 
Susceptibility to benzylMD 1c and chloroquine was assessed on drug-adapted parasites after removal of drug pressure. Susceptibility of progenitor Dd2 parasites was assessed in parallel. IC50 and IC90 
values are presented as mean ± standard deviation (SD) determined from (n) independent experiments using the SYBR® green technique. 
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Table A6  Susceptibility of drug-adapted parasites to benzylMD 1c after the 1
st
 selection 
cycle (independent repetition) 
1
st
 selection cycle benzylMD 1c chloroquine 
Culture IC50 (nM) IC90 (nM)  IC50 (nM) 
Dd2
MD1
 F1 163 ± 70 (3) 475 ± 301 (3) 136 ± 46 (3) 
Dd2
MD1
 F2 223 ± 169 (3) 783 ± 883 (3) 137 ± 39 (3) 
Dd2
MD1
 F3 178 ± 125 (3) 630 ± 754 (3) 128 ± 37 (3) 
Dd2
MD1
 F4 211 ± 115 (3) 947 ± 732 (3) 118 ± 34 (3) 
Dd2
MD1
 F5 104 ± 35 (3) 227 ± 95 (5) 99 ± 13 (3) 
Dd2
MD1
 F6 158 ± 85 (3) 425 ± 289 (3) 103 ± 6 (3) 
Dd2 57 ± 11 (3) 173 ± 15 (3) 108 ± 19 (3) 
Susceptibility to benzylMD 1c was assessed on Dd2MD2 parasites after removal of drug pressure and over a total 
period of 10 weeks. Susceptibility of progenitor Dd2 parasites was assessed in parallel. IC50 and IC90 values are 
presented as mean ± standard deviation (SD) determined from (n) independent experiments using the 
SYBR® green technique.  
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Table A7  Compounds selected for in vitro drug interaction studies (Results, section 3.3.3) 
Compound Structure IC50 (mM) ± SD (n)  
Acetaminophen 
 
1.2 ± 0.4 (3) 
Amodiaquine 
 
0.01 × 10
-3
 (3) 
Ascorbic acid 
 
6.8 ± 2.1 (3) 
BenzylMD 7a 
a
 
 
0.013 ± 0.004 (3) 
BSO 
 
0.21 ± 0.03 (3) 
CB83 
a
 
 
0.015 ± 0.0003 (2) 
DFO 
a
 
 
0.012 ± 0.0008 (3) 
Ferroquine 
 
0.02 × 10
-3
 
ML276 
a
 
 
0.002 ± 0.0004 (3) 
N-acetyl-cysteine 
 
16.9 ± 3.5 (3) 
IC50 values of single compounds were assessed in the frame of in vitro drug interactions studies on P. falciparum 3D7 strain 
according to the fixed-ratio isobologram method.  Results are presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments. Results of according in vitro drug-drug interactions are presented in Table 12, 
section 3.3.3.  a Results are presented in modified form in Bielitza et al. (Bielitza et al, submitted, 2014.). BSO, Buthionine 
sulfoximine; DFO, desferrioxamine B.  
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Table A8  In vitro antimalarial activity of methyl-substituted benzylMD derivatives 
Compound name            Structure 
P. falciparum Dd2 strain 
 IC50 (nM) ± SD (n) 
EC124 
 
1820 ± 71 (3) 
EC122 
 
3638 ± 193 (2) 
EC019 
 
171 ± 66 (3) 
EC021 
 
215 ± 68 (3) 
EC146 
 
992 ± 107 (3) 
EC145 
 
439 ± 205 (5) 
EC148 
 
3761 ± 972 (3) 
EC147 
 
3004 ± 941 (2) 
EC157 
 
2706 ± 26 (2) 
EC156 
 
3243 ± 260 (3) 
Controls compounds   
First hit 
benzylMD 1a 
            
82 ± 20 (7) 
Lead compound 
benzylMD 1c 
 
58 ± 11 (9) 
Chloroquine 
         
99 ± 19 (6) 
Activity against cultured parasites of P. falciparum Dd2 strain is presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments using the SYBR® green technique. Results will be published in Cesar-Rodo 
et al. (in preparation).   
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Table A9  In vitro antimalarial activity of fluorine- or diethylphosphate-substituted benzylMD derivatives  
Compound name            Structure 
P. falciparum Dd2 strain 
 IC50 (nM) ± SD (n) 
EC061 
 
74 ± 32 (4) 
EC060 
 
83 ± 12 (4) 
DAL53 
 
83 ± 23 (3) 
DAL54 
 
59 ± 11 (3) 
JB006 
 
157 ± 49 (2) 
JB008 
 
518 ± 231 (3) 
Control compounds   
First hit 
benzylMD 1a 
            
82 ± 20 (7) 
Lead compound 
benzylMD 1c 
 
58 ± 11 (9) 
Chloroquine 
          
99 ± 19 (6) 
Activity against cultured parasites of P. falciparum Dd2 strain is presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments using the SYBR® green technique. Results will be published in Cesar-Rodo 
et al. (in preparation).  
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Table A10  In vitro antimalarial activity of halogen- or methoxy-substituted benzylMD derivatives  
Compound name Structure 
P. falciparum Dd2 strain 
 IC50 (nM) ± SD (n) 
KU036 
 
64 ± 17 (3) 
KU040 
 
99 ± 17 (3) 
KU060 
 
168 ± 30 (3) 
KU062 
 
118 ± 36 (3) 
KU065 
 
132 ± 29 (3) 
KU066 
 
245 ± 80 (3) 
Control compounds   
First hit 
benzylMD 1a 
            
82 ± 20 (7) 
Lead compound 
benzylMD 1c 
 
58 ± 11 (9) 
Chloroquine 
         
99 ± 19 (6) 
Activity against cultured parasites of P. falciparum Dd2 strain is presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments using the SYBR® green technique. Results will be published in Cesar-Rodo 
et al. (in preparation). 
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Table A11  In vitro antimalarial activity of methoxy-substituted benzylMD derivatives  
Compound name Structure 
P. falciparum Dd2 strain 
 IC50 (nM) ± SD (n) 
EC005 
 
3230 (1) 
EC006 
 
3187 (1) 
DAL48 
 
171 ± 69 (3) 
DAL50 
 
186 ± 58 (3) 
EC050 
 
242 ± 60 (4) 
EC055 
 
881 ± 129 (4) 
EC054 
 
3685 (1) 
EC067 
 
778 ± 89 (4) 
EC069 
 
2187 (1) 
EC125 
 
104 ± 58 (4) 
EC057 
 
2704 (1) 
EC058 
 
1365 ± 521 (4) 
Control compounds:    
First hit 
benzylMD 1a             
82 ± 20 (7) 
Lead compound 
benzylMD 1c 
 
58 ± 11 (9) 
Chloroquine 
         
99 ± 19 (6) 
Activity against cultured parasites of P. falciparum Dd2 strain is presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments using the SYBR® green technique. Results will be published in Cesar-Rodo 
et al. (in preparation).  
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Table A12  In vitro antimalarial activity of benzylMD derivatives with a N-dimethyl or N-diethyl group 
Compound name Structure 
P. falciparum Dd2 strain 
 IC50 (nM) ± SD (n) 
KU097 
 
303 ± 138 (3) 
KU230 
 
411± 220 (3) 
KU234 
 
567 ± 217 (3) 
KU244 
 
310 ± 134 (3) 
KU249 
 
1198 ± 1651 (3) 
Precipitates in DMSO 
KU250 F1 
 
418 ± 166 (3) 
KU250 F2 
 
2056 ± 1073 (3) 
KU266 
 
282 ± 86 (3) 
KU271 
 
386 ± 151 (3) 
KU272 
 
236 ± 97 (3) 
P_TM87 
 
777 ± 248 (3) 
Control compounds   
First hit 
benzylMD 1a 
            
82 ± 20 (7) 
Lead compound 
benzylMD 1c  
58 ± 11 (9) 
P_TM45 
 
109 ± 46 (3) 
Activity against cultured parasites of P. falciparum Dd2 strain is presented as mean IC50 values ± standard deviation (SD) 
determined from (n) independent experiments using the SYBR® green technique. Results will be published in Cesar-Rodo 
et al. (in preparation).  
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